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ABSTRACT	  	  
C-­‐peptide	  improves	  hyperglycemia-­‐induced	  endothelial	  redox	  
balance	  by	  preventing	  mitochondrial	  oxidative	  stress	  and	  
enhancing	  NADPH	  synthesis	  
Himani	  Vejandla	  
	  C-­‐peptide,	   a	   by-­‐product	   of	   insulin	   biosynthesis,	   has	   been	   shown	   to	   ameliorate	  
diabetes-­‐induced	  renal	  impairment.	  Yet,	  the	  mechanisms	  underlying	  this	  protective	  
benefit	   remain	   unclear.	   Our	   studies	   have	   shown	   that	   C-­‐peptide	   improved	   renal	  
peritubular	   capillary	   blood	   flow	   and	   reduced	   vascular	   oxidants.	   NADPH	   (reduced	  
nicotinamide	  adenine	  dinucleotide	  phosphate),	   appears	   to	  be	   critical	   to	   this	   effect	  
via	   the	   actions	   of	   numerous	   vasoprotective	   systems.	   Further,	   our	   experiments	   in	  
type	  I	  diabetic	  mice	  resulted	   in	  a	  significant	  reduction	   in	  renal	  endothelial	  NADPH	  
that	   is	   subsequently	   restored	   with	   C-­‐peptide.	   We	   hypothesized	   that	   C-­‐peptide	  
provides	   protection	   to	   renal	   cortical	   endothelial	   cells	   during	   type	   I	   diabetes	   by	  
restoring	   the	  activity	  of	  glucose-­‐6-­‐phosphate	  dehydrogenase	  (G6PD),	   the	  principal	  
source	  of	  NADPH	  synthesis.	  Our	  data	  show	  that	  renal	  cortical	  endothelial	  cells	  (RCE)	  
from	   diabetic	   mice	   have	   diminished	   G6PD	   activity	   and	   their	   treatment	   with	   C-­‐
peptide	  restores	   its	  activity	  back	   to	  control	   levels.	  These	  changes	   in	  G6PD	  activity	  
occurred	  with	  concomitant	  alterations	   in	  NADPH.	  Using	  2-­‐D	  gel	  electrophoresis	  of	  
RCE	   lysate	   coupled	  with	   immunoblotting	   for	   G6PD,	  we	   demonstrate	   that	   diabetic	  
RCEs	  have	  a	  significant	   increase	   in	  G6PD	  post-­‐translational	  modification	  (PTM).	  C-­‐
peptide	   treatment	   reduced	   the	   magnitude	   of	   this	   PTM	   in	   diabetic	   RCEs,	   which	  
occurred	   concomitant	   to	   restored	   G6PD	   activity.	   These	   results	   suggest	   that	  
improving	   the	   activity	   of	   endothelial	   G6PD,	   by	   preventing	   its	   PTM,	   may	   be	   a	  
potential	   mechanism	   by	   which	   C-­‐peptide	   confers	   protection	   to	   renal	   cortical	  
endothelial	   cells	   during	   type	   I	   diabetes.	   Hyperglycemia-­‐mediated	   microvascular	  
damage	  has	  been	  proposed	  to	  originate	  from	  excessive	  generation	  of	  mitochondrial	  
	  
	  
superoxide	   in	   endothelial	   cells	   and	   is	   the	   suggested	   mechanism	   by	   which	   the	  
pathogenesis	   of	   diabetes-­‐induced	   renal	   damage	   occurs.	   To	   determine	   whether	   C-­‐
peptide	   affords	   protection	   to	   renal	   microvascular	   endothelial	   cell	   mitochondria	  
during	   hyperglycemia	   we	   exposed	   conditionally	   immortalized	   murine	   renal	  
microvascular	  endothelial	  cells	   (MEC)	   to	   low	  or	  high	  glucose	  (25	  mM)	  media	  with	  
either	  C-­‐peptide	  (6.6	  nM)	  or	  its	  scrambled	  sequence	  control	  peptide	  for	  24-­‐	  or	  48-­‐
hours.	   Respiratory	   control	   ratio,	   a	   measure	   of	   mitochondrial	   electrochemical	  
coupling,	  was	  significantly	  higher	  in	  high	  glucose	  treated	  renal	  MECs	  treated	  with	  C-­‐
peptide	   than	   those	   of	   high	   glucose	   alone.	   C-­‐peptide	   also	   restored	   high	   glucose-­‐
induced	  renal	  MEC	  mitochondrial	  membrane	  potential	  changes	  back	  to	   their	  basal	  
low	   glucose	   state.	   Moreover,	   C-­‐peptide	   prevented	   the	   excessive	   mitochondrial	  
superoxide	   generation	   and	   concomitant	   reductions	   in	   mitochondrial	   complex	   I	  
activity	   that	   are	   mediated	   by	   the	   exposure	   of	   the	   renal	   MECs	   to	   high	   glucose.	  
Together,	   these	   data	   demonstrate	   that	   C-­‐peptide	   protects	   against	   high	   glucose-­‐
induced	   generation	   of	   mitochondrial	   superoxide	   in	   renal	   MECs	   via	   restoration	   of	  
basal	   mitochondrial	   function.	   Although	   interest	   in	   the	   physiologic	   benefits	   of	   C-­‐
peptide	  has	  persisted	  for	  more	  than	  two	  decades,	  C-­‐peptide	  has	  yet	  to	  make	  its	  way	  
into	   standard	   treatment	   regimens	   for	  various	  diabetic	   complications.	  The	   findings	  
from	  our	  work	  have	  provide	  proof-­‐of-­‐principle	  evidence	  in	  support	  of	  the	  inclusion	  
of	   C-­‐peptide	   to	   the	   existing	   therapeutic	   regimen	   for	   treatment	   of	   diabetic	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SPECIFIC	  AIMS	  
Diabetes	  mellitus	   (DM)	   is	   the	   leading	   cause	   of	   chronic	   kidney	   disease	   and	  
kidney	   failure,	  with	  nearly	  25-­‐40%	  of	  patients	  with	  diabetes	  developing	  end-­‐stage	  
renal	   failure	   (21).	   Even	   after	   intensive	   insulin	   treatment	   for	   optimal	   glycemic	  
control,	   patients	   continue	   to	   develop	   microvascular	   complications,	   which	   are	   the	  
principal	   cause	   of	   diabetes-­‐induced	   renal	   dysfunction	   (1).	   	   Although	   diabetic	  
nephropathy	  (DN)	   is	  characterized	  by	  glomerulosclerosis	  (4),	   recent	  evidence	  also	  
indicates	   that	  glomerular	  damage	  causes	   stagnation	  of	  peritubular	  blood	   flow	  and	  
thus	   development	   of	   tubulointerstitial	   injury	   and	   ultimately	   peritubular	   capillary	  
loss	  (15,	  16).	  It	  has	  long	  been	  accepted	  that	  the	  peptide	  that	  connects	  the	  A-­‐	  and	  B-­‐
chains	  of	   insulin,	  known	  as	  C-­‐peptide,	   is	  biologically	   inert.	  However,	  many	  studies	  
have	   demonstrated	   that	   replacement	   doses	   of	   C-­‐peptide	   can	   ameliorate	   diabetes-­‐
induced	  renal	  dysfunction	  (8-­‐11,	  13,	  17,	  18,	  23-­‐25).	  Yet,	  the	  mechanisms	  underlying	  
the	  benefits	  of	  C-­‐peptide	  during	  diabetes	  are	  still	  unclear.	  	  
DM	  has	  been	  widely	  recognized	  as	  a	  state	  of	  imbalance	  between	  oxidants	  and	  
antioxidant	   protective	   systems	   (2,	   5,	   6).	   Moreover,	   chronic	   hyperlgycemia	  
associated	   with	   diabetes	   elevates	   oxidative	   stress	   in	   renal	   microvasculature	   (22,	  
26),	  directly	  damages	  the	  microcirculation	  leading	  to	  small	  vessel	  dysfunction	  (14),	  
and	  ultimately	  manifests	  as	  kidney	  dysfunction	  (6,	  19).	  Our	  central	  hypothesis	  is	  
that	  C-­peptide	  prevents	  diabetes	  induced	  renal	  microvascular	  dysfunction	  by	  
ameliorating	  oxidative	  imbalance	  created	  within	  endothelial	  cells.	  	  
	   xii	  
NADPH,	   a	   critical	   cofactor	   in	   preserving	   normal	   microvascular	   function	  
through	   actions	   of	   multiple	   vasoprotective	   systems	   like	   heme	   oxygenase	   -­‐1	   and	  
nitric	   oxide	   synthase	   (NOS),	   is	   depleted	   in	   microcirculation	   owing	   to	   increased	  
consumption	   in	   multiple	   pathways	   including	   glucose	   metabolism	   (7,	   20)	   and	  
NADPH	   oxidase	   (NOX)	   (2,	   3).	   G6PD,	   the	   first	   rate-­‐limiting	   enzyme	   of	   the	   pentose	  
phosphate	  pathway,	  is	  the	  major	  source	  of	  NADPH	  (12,	  27).	  	  	  
Our	  first	  working	  hypothesis	  is	  that	  microvascular	  dysfunction	  in	  type	  I	  diabetic	  
kidney	   involves	   loss	   of	   NADPH,	   due	   to	   inhibition	   of	   G6PD	   activity,	   in	   renal	   cortical	  
endothelial	  cells.	  	  
Specific	  Aim	  1:	  To	  determine	  whether	  C-­‐peptide	   confers	  microvascular	  protection	  
by	   enhancing	   renal	   endothelial	   antioxidative	   capacity.	   	   To	   address	   Aim	   1,	   we	  
characterized	  renal	  dysfunction	   in	  a	  streptozotocin	  (STZ)-­‐induced	  mouse	  model	  of	  
type	  I	  diabetes.	  
1.1:	   We	   examined	   the	   effect	   of	   C-­‐peptide	   on	   peritubular	   capillary	   perfusion	   in	  
kidney	  cortices	  from	  STZ-­‐	  induced	  type	  I	  diabetic	  mice.	  	  
1.2:	  We	  examined	  whether	  the	  alterations	  in	  microvascular	  function	  are	  reflected	  as	  
biochemical	  changes	  in	  freshly	  isolated	  diabetic	  RCEs.	  	  
1.3:	   We	   evaluated	   the	   mechanisms	   responsible	   for	   impaired	   endogenous	  
vasoprotection,	  NADPH	  levels,	  G6PD	  activity,	  and	  phosphorylation	  of	  G6PD	  in	  RCEs,	  
in	  the	  presence	  and	  absence	  of	  C-­‐peptide.	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Our	   second	   working	   hypothesis	   is	   that	   C-­peptide	   independently	   affords	  
protection	   to	   high-­glucose	   exposed	   renal	   MECs	   by	   diminishing	   mitochondrial	  
superoxide	  generation	  via	  restoration	  of	  basal	  mitochondrial	  complex	  I	  activity	  
Specific	  Aim	  2:	  To	  determine	  whether	  C-­‐peptide	  ameliorates	  high-­‐glucose	   induced	  
microvascular	   dysfunction	   by	   preventing	   mitochondrial	   superoxide.	   To	   examine	  
this	  we	  employed	  conditionally	   immortalized	  renal	  MECs,	  exposed	   to	  both	  normal	  
and	  high	  glucose	  conditions,	  to	  investigate	  the	  effects	  of	  C-­‐peptide	  on	  mitochondrial	  
parameters.	  
2.1:	  We	   evaluated	   the	   effects	   of	   C-­‐peptide	   treatment	   on	   renal	  MEC	  mitochondrial	  
respiration,	   membrane	   potential	   changes,	   superoxide	   production	   and	   complex	  
activity	  under	  exposure	  to	  a	  high	  glucose	  environment.	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1.1	  Diabetes	  Mellitus	  
DM	  represents	  a	  heterogeneous	  group	  of	  metabolic	  diseases	  characterized	  by	  
chronic	   hyperglycemia	   resulting	   from	   deficiencies	   in	   the	   actions	   of	   insulin,	   either	  
through	  a	   lack	  of	  production	  or	  an	   insensitivity	  of	   its	  receptors.	  Depending	  on	   the	  
severity,	   DM	  may	   present	   itself	   with	   overt	   symptoms	   of	   hyperglycemia	   including	  
polydipsia,	   polyuria,	   weight	   loss,	   sometimes	   with	   polyphagia,	   and	   vision	  
disturbances.	   If	   left	   uncontrolled,	   hyperglycemia	   often	   leads	   to	   biochemical	  
imbalances	   that	   progress	   to	   acute	   life-­‐threatening	   events,	   such	   as	   ketoacidosis,	  
coma	  and	  even	  death	  (2)	  Based	  on	  the	  pathogenesis,	  DM	  is	  broadly	  classified	  into	  1)	  
type	  I,	  with	  an	  absolute	  deficiency	  of	  insulin	  secretion,	  2)	  type	  II,	  with	  a	  combination	  
of	   resistance	   to	   insulin	   action	   and	   an	   inadequate	   compensatory	   insulin	   secretory	  
response,	   and	   3)	   gestational	   DM,	   any	   glucose	   intolerance	   developed	   or	   detected	  
during	   pregnancy	   (2).	   Ultimately,	   the	  major	   causes	   of	  morbidity	   and	  mortality	   in	  
diabetic	  patients	  are	  the	  long-­‐term	  complications,	  mainly	  involving	  microcirculation	  
of	  the	  eyes,	  kidneys,	  nerves	  and	  heart.	  	  
The	  Diabetes	  Control	  and	  Complications	  Trial	  (DCCT)	  study	  demonstrated	  a	  
decreased	   occurrence	   of	   complications	   in	   the	   group	   of	   type	   I	   DM	   patients	   that	  
received	  intensive	  insulin	  therapy	  and	  achieved	  improved	  blood	  glucose	  control	  (4).	  
This	   is	   all	   in	   keeping	   with	   the	   view	   that	   hyperglycemia	   is	   a	   major	   culprit	   in	   the	  
pathogenesis	   of	  microvascular	   complications.	   Even	  with	   strict	   glycemic	   control,	   a	  
large	   proportion	   of	   these	   patients	   developed	   complications	   (3).	   Microvascular	  
complications	   are	   devastating;	   they	   greatly	   reduce	   life	   expectancy,	   and	   adversely	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affect	  the	  quality	  of	  life	  amongst	  those	  affected	  (98).	  	  DM	  is	  also	  associated	  with	  an	  
increased	   incidence	   of	   macrovascular	   diseases	   (i.e.,	   peripheral	   arterial	   and	  
cerebrovascular	  diseases).	  	  
1.1a	  Global	  Health	  Perspective	  
Widely	   recognized	   as	   one	   of	   the	   leading	   causes	   of	   death	   and	   disability	  
worldwide,	  DM	   imposes	  a	   large	  economic	  burden	  on	  national	  health	   care	   systems	  
(187).	   In	   2006,	   DM	  was	   the	   seventh	   leading	   cause	   of	   death.	   In	  most	   cases	   DM	   is	  
reported	   only	   as	   the	   underlying	   cause	   of	   death,	   with	   heart	   disease,	   stroke	   and	  
kidney	  failure	  as	  the	  attributing	  causes	  of	  death.	  Accounting	  for	  more	  than	  10%	  of	  
total	  health	  care	  expenditure,	  DM	  is	  emerging	  as	  a	  global	  health	  crisis	  (25).	  In	  the	  US	  
alone,	  the	  total	  costs	  incurred	  on	  diabetes	  was	  $174	  billion	  in	  2007	  (1).	  	  
1.1b	  Type	  I	  Diabetes	  Mellitus	  
Previously	   called	   insulin-­‐dependent	   or	   juvenile-­‐onset,	   this	   form	   of	   DM	  
develops	   most	   often	   in	   children	   but	   can	   occur	   at	   any	   age.	   Resulting	   from	  
autoimmune-­‐mediated	  pancreatic	  β-­‐cell	  destruction	  type	  I	  DM	  accounts	   for	  5-­‐10%	  
of	   the	   diabetic	   population.	   Individuals	   suffering	   from	   this	   form	   of	   DM	   exhibit	  
varying	   degrees	   of	   insulin	   dependency	   and	   deficiency	   as	   well	   as	   a	   risk	   for	  
ketoacidosis.	   In	   the	   latter	   stages	   of	   disease,	  many	   patients	   encounter	   an	   absolute	  
requirement	  for	  insulin	  replacement	  therapy.	  
1.1c	  Type	  II	  Diabetes	  Mellitus	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This	   form	  of	  DM	  accounts	   for	  90-­‐95%	  of	   those	  with	  diabetes	   and	  develops	  
typically	  after	  middle	  age,	  but	  may	  occur	   in	  young	  people.	   Individuals	  with	   type	   II	  
DM	   have	   insulin	   resistance	   [with	   normal	   or	   elevated	   insulin	   levels]	   followed	   by	  
relative	  insulin	  deficiency	  [due	  to	  defective	  insulin	  secretion].	  The	  risk	  of	  developing	  
type	  II	  DM	  increases	  with	  age,	  obesity	  and	  lack	  of	  physical	  activity.	  It	  frequently	  goes	  
undiagnosed	  for	  many	  years	  as	  the	  hyperglycemia	  develops	  gradually.	  At	  its	  earlier	  
stages	   it	   is	   not	   often	   severe	   enough	   for	   the	   patient	   to	   notice	   any	   of	   the	   classic	  
symptoms	  of	  diabetes.	  
1.	  2	  Diabetic	  Kidney	  Disease	  
Considered	  the	  leading	  cause	  of	  end-­‐stage	  renal	  disease,	  DN	  manifests	  within	  
20-­‐25	  yrs	  of	  onset	  of	  the	  disease	  (56).	  One	  out	  of	  three	  diabetics	  worldwide	  develop	  
DN	   (129).	   With	   recent	   advances	   in	   the	   management	   of	   DM	   and	   the	   consequent	  
decrease	  in	  diabetes-­‐associated	  mortality,	  patients	  are	  living	  longer	  and	  more	  likely	  
to	  develop	  microvascular	  complications.	  DN	  bears	  a	  significant	  burden	  to	  the	  society	  
and	   this	   is	   illustrated	   by	   the	   fact	   that	   in	   2009	   ~6.5%	   of	   US	   Medicare	   budget	   is	  
directed	  to	  the	  end-­‐stage	  renal	  disease	  population	  (5).	  The	  earliest	  clinical	  evidence	  
of	  incipient	  DN	  is	  the	  development	  and	  progression	  of	  persistent	  microalbuminuria	  
(urinary	   albumin	  excretion	   rates	  between	  20-­‐200	  µg/min),	  which	   is	   also	   a	   strong	  
predictor	   for	   the	   future	   development	   of	   end-­‐stage	   renal	   disease	   (115-­‐118).	   The	  
majority	  of	  the	  type	  I	  diabetics	  progress	  to	  overt	  albuminuria	  (>200	  µg/min)	  more	  
rapidly	  than	  that	  of	  rate	  compared	  to	  type	  II	  diabetics	  (56).	  Other	  hallmark	  features	  
of	   DN	   include	   glomerular	   hyperfiltration,	   basement	   membrane	   thickening,	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mesangial	   extracellular	   matrix	   expansion	   and	   ultimately	   glomerulosclerosis	   with	  
renal	  dysfunction	  (50).	  
Major	   clinical	   treatments	   for	   DN	   continue	   to	   target	   hyperglycemia	   and	  
hypertension	   (105).	   Importantly,	   inhibition	   of	   renin-­‐angiotensin-­‐aldosterone	   axis,	  
and	   in	   particular	   angiotensin	   II	   (AngII)	   has	   a	   major	   impact	   on	   slowing	   the	  
progression	   of	   kidney	   damage.	   Currently	   the	   best	   approach	   to	   treatment	   of	   DN	  
includes	  achievement	  of	  optimal	  glycemic	  control	  in	  combination	  with	  tight	  control	  
of	   blood	   pressure	   (174).	   Nevertheless,	   the	   incidence	   of	   DN	   continues	   to	   rise	   and	  
underscores	  the	  compelling	  need	  for	  new	  treatments.	  	  
1.2a	  	  Pathophysiology	  –	  Structural	  alterations	  
Persistent	   hyperglycemia	   initiates	   several	   complex	   reactions	   in	   the	   renal	  
vasculature	  that	  culminate	  in	  DN.	  Structurally;	  the	  kidney	  is	  comprised	  of	  filter	  units	  
-­‐	   nephrons,	   blood	   vessels	   and	   interstitial	   tissue.	   Diabetic	   kidney	   damage	   mainly	  
occurs	   due	   to	   changes	   in	   the	   blood	   flow	   through	   the	   microcirculation	   of	   the	  
glomerular	   capsule	   (157).	  Within	   the	   capsule,	   oxidative	   remodeling	   of	   the	   vessel	  
walls	   lead	   to	   reduced	   flow	   of	   oxygenated	   blood	   and	   impairment	   of	   vessel	   wall	  
integrity.	   These	   changes	   ultimately	   lead	   to	   irreversible	   loss	   of	   glomerular	  
capillaries,	  and	  eventually	  kidney	  function	  (123).	  	  
Many	   studies	   have	   shown	   that	   hyperglycemia	   also	   affects	   glomerular	  
mesangial	  cells	  (66,	  158,	  170).	  However,	  there	  is	  a	  recent	  shift	  in	  the	  focus	  to	  other	  
glomerular	  cell	  types	  and	  tubulo-­‐interstitial	  cells	  (45,	  106,	  125).	  Initially,	  glomerular	  
damage	   results	   in	   post-­‐glomerular	   ischemia	   and	   is	   associated	   with	   downstream	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hypoxia,	   subsequent	   oxidative	   stress,	   tubular	   injury,	   and	   eventually	   nephron	   loss.	  	  
These	  events,	   in	  turn,	   impose	  hemodynamic	  stress	   in	  the	  remaining	  nephron	  units	  
(149).	   Finally,	   tubulo-­‐interstitial	   damage	   results	   in	   the	   loss	   and	   distortion	   of	  
peritubular	   capillary	   plexus	   (123,	   124),	   a	   network	   of	   capillaries	   that	   are	   fed	   by	  
glomerular	   efferent	   arterioles	   and	   supply	   nutrients	   and	   oxygen	   to	   tubular	   and	  
interstitial	  cells.	  	  
1.2	  b	  Pathophysiology	  –	  Renal	  hemodynamic	  alterations	  
Several	   lines	   of	   evidence	   indicate	   that	   renal	   hemodynamics	   are	   altered	   in	  
clinical	  and	  experimental	  DM,	  and	  that	  changes	  in	  renal	  hemodynamics	  play	  a	  role	  
in	  the	  pathogenesis	  of	  the	  DN	  (12,	  32,	  79,	  130).	  Moreover,	  studies	  have	  documented	  
a	  consistent	  increase	  in	  glomerular	  filtration	  rate	  (GFR)	  in	  type	  I	  DM	  during	  periods	  
of	   poor	   metabolic	   control(12,	   23,	   38).	   Conversely,	   when	   hyperglycemia	   is	   more	  
severe,	  as	  in	  diabetic	  keto-­‐acidosis,	  hyperfiltration	  no	  longer	  occurs.	  Thus,	  because	  
of	   the	   potential	   importance	   of	   alterations	   in	   renal	   microcirculatory	   dynamics	   to	  
these	   functional	   responses	  of	   the	  glomerulus	   in	  DM,	   it	   is	   important	   to	  understand	  
the	  hemodynamic	  determinants	  of	  GFR	  under	  normal	  and	  diabetic	  conditions.	  	  
The	  balance	  of	  vascular	  tone	  of	  the	  afferent	  and	  efferent	  arteriole	  is	  a	  crucial	  
determinant	   of	   glomerular	   haemodynamics.	   Despite	   their	   intimate	   anatomical	  
relationship	   in	   the	   juxtaglomerular	   apparatus,	   the	   mechanisms	   that	   regulate	  
afferent	  and	  efferent	  arteriolar	  tone	  are	  different	  (8).	   In	  the	  afferent	  arteriole,	   two	  
intrinsic	   mechanisms,	   the	   myogenic	   response	   and	   macula	   densa-­‐mediated	  
tubuloglomerular	   feedback	   (TGF)	   play	   a	   dominant	   role,	  maintaining	   the	   GFR	   at	   a	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constant	   level	   over	   a	  wide	   range	  of	   renal	   perfusion	  pressure.	   Studies	  have	   shown	  
that	   these	   two	   mechanisms	   are	   modulated	   by	   nitric	   oxide	   (NO)	   (90,	   172).	   	   In	  
addition,	  an	  interaction	  between	  TGF	  and	  AngII	  seems	  to	  be	  essential	  to	  maintaining	  
GFR	  despite	  large	  variations	  in	  daily	  intake	  of	  salt	  and	  water	  (172).	  In	  the	  efferent	  
arteriole,	  neither	  myogenic	  response	  nor	  TGF	  seems	  to	  be	  important,	  while	  AngII	  is	  
one	  major	   factor	   involved	   in	   the	  control	  of	  vascular	   resistance.	   In	  addition,	   recent	  
studies	   have	   provided	   evidence	   that	   NO	   and	   prostaglandins	   produced	   by	   the	  
glomerulus	  may	  control	  resistance	  of	   the	  downstream	  efferent	  arteriole	  (144).	   	  As	  
the	   early	   segment	   of	   the	   efferent	   arteriole	   resides	  within	   the	   glomerulus,	   various	  
autacoid	  hormones	  produced	  by	  the	  glomerulus	  may	  reach	  and	  directly	  act	  on	  this	  
segment,	  thereby	  controlling	  the	  glomerular	  capillary	  pressure	  (144).	  	  
Decreased	   renal	   vascular	   resistance	   and	   diminished	   responsiveness	   to	  
numerous	   vasoconstrictor	   stimuli	   are	   evident	   during	   the	   early	   stage	   of	   DM	   (78).	  
Indeed,	   DM	   impairs	   afferent	   arteriolar	   myogenic	   and	   tubuloglomerular	   feedback	  
responses	   as	   well	   as	   autoregulation	   of	   renal	   blood	   flow	   (78).	   In	   rats	   with	   STZ-­‐
induced	   DM,	   the	   renal	   vasodilation	   is	   localized	   to	   the	   preglomerular	   vasculature	  
whereas	   efferent	   arteriolar	   resistance	   is	   either	   normal	   or	  minimally	   decreased,	   a	  
situation	   that	   promotes	   glomerular	   hypertension	   and	   hyperfiltration	   (7,	   12).	  
Further,	  studies	  have	  confirmed	  that	   juxtamedullary	  afferent	  arterioles	  are	  dilated	  
and	   exhibit	   reduced	   constrictor	   responsiveness	   to	   noradrenaline	   during	   diabetic	  
hyperfiltration,	   while	   these	   parameters	   of	   efferent	   arteriolar	   function	   remain	  
unaltered	  (130).	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1.3	  Endothelial	  Dysfunction	  in	  Diabetes	  
Endothelial	   dysfunction	   is	   the	   inability	   of	   the	   endothelium	   to	   properly	  
maintain	  vascular	  homeostasis	  and	  results	  mainly	  from	  the	  reduced	  bioavailability	  
of	   NO.	   The	   main	   functional	   manifestation	   of	   this	   loss	   of	   NO	   bioavailability	   is	  
impairment	   of	   endothelium	   dependent	   vasorelaxation	   (30).	   Although	   the	  
underlying	   mechanisms	   responsible	   for	   enhanced	   degradation	   of	   NO	   seem	   to	   be	  
diverse,	  during	   the	  manifestation	  and	  pathogenesis	  of	  DM	   they	  originate	   from	   the	  
effects	   of	   hyperglycemia	   (24),	   advanced	   glycation	   end	   products	   (AGE)	   (28)	   and	  
oxidative	  stress	  (34,	  72).	  	  
Impaired	   endothelial	   function	   is	   a	   fundamental	   component	   in	   the	  
development	  of	  diabetic	  microvascular	  and	  macrovascular	  complications	  (167).	  The	  
delicate	   balance	   between	   endothelium	   dependent	   relaxation	   and	   contraction	   is	  
altered	  in	  diabetes.	  In	  addition,	  DM	  is	  associated	  with	  increased	  levels	  of	  circulating	  
endothelium-­‐derived	   adhesion	   molecules	   and	   plasminogen	   activator	   inhibitor-­‐I,	  
reflecting	   a	   pro-­‐inflammatory	   and	   pro-­‐thrombotic	   endothelial	   phenotype	   (114).	  
Onset	  of	  endothelial	  dysfunction	  is	  coincident	  with	  impaired	  glucose	  tolerance,	  and	  
worsens	  with	  the	  progression	  of	  diabetes.	  Jensen	  et	  al.,	  were	  the	  first	  to	  describe	  the	  
presence	  of	  endothelial	  injury	  in	  type	  I	  diabetic	  patients	  with	  incipient	  nephropahty,	  
as	  evidenced	  by	  an	  increase	  in	  their	  plasma	  levels	  of	  Von	  Willebrand	  factor	  (83,	  84)	  
DN,	   a	   serious	   complication	   of	  DM,	   can	  progress	   to	   end-­‐stage	   renal	   disease.	  
However,	   the	   incidence	   of	   nephropathy	   in	   diabetic	   patients	   is	   variable,	   with	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epidemiological	  studies	  showing	  that	  only	  30%	  of	  patients	  develop	  overt	  symptoms	  
(20,	  80).	   Importantly,	  endothelial	   function	  was	  more	  severely	   impaired	  in	  patients	  
with	  overt	  than	  incipient	  nephropathy	  (83,	  84).	  Similarly,	  advanced	  renal	  lesions	  do	  
not	   consistently	   develop	   in	   diabetic	   animals	   and	   require	   factors	   in	   addition	   to	  
hyperglycemia,	   with	   endothelial	   NO	   deficiency	   and	   subsequent	   endothelial	  
dysfunction	  as	   important	  contributors	  (120,	  121).	  Endothelial	   injury	   in	  diabetes	   is	  
accompanied	   by	   structural	   abnormalities,	   mainly	   the	   loss	   of	   endothelial	  
fenestrations	  (170).	  	  	  
Brodsky	   and	   colleagues	   found	   that	   high	   levels	   of	   glucose	   induce	   the	  
uncoupling	   of	   endothelial	   NOS	   (eNOS),	   which	   causes	   a	   reduction	   in	   NO	  
bioavailability	  and	  a	  concurrent	  increase	  in	  superoxide	  production	  (24).	  In	  brief,	  the	  
generation	  of	  NO	   from	  L-­‐arginine	  by	  eNOS	   requires	   the	  presence	  of	   cofactors	   that	  
can	  be	  inactivated	  by	  oxidants;	  when	  eNOS	  is	  uncoupled,	  superoxide	  as	  opposed	  to	  
nitric	  oxide	  will	  be	  generated	  (69,	  162).	  Even	  though	  several	  studies	  examined	  eNOS	  
polymorphisms	   (40,	   102,	   147,	   160),	   only	   some	   reported	   positive	   association	   of	  
specific	  eNOS	  polymorphisms	  with	  DN	  (103,	  126,	  127,	  161,	  185).	  	  Some	  studies	  even	  
reported	   increases	   in	   eNOS	   enzyme	   associated	   with	   diabetes	   (77,	   166),	   but	   it	   is	  
likely	  that	  the	  increased	  level	  of	  eNOS	  might	  be	  an	  inactivated	  form	  of	  the	  enzyme	  
(24,	   97).	   Further,	   diabetic	   eNOS	   knockout	   mice	   exhibit	   higher	   mortality	   from	  
progressive	   renal	   disease	   (120),	   adding	   strength	   to	   the	   hypothesis	   that	   a	   lack	   of	  
endothelial	  NO	  could	  be	  a	  key	  factor	  in	  the	  development	  of	  advanced	  DN.	  Even	  the	  
failure	   of	   rennin-­‐angiotensin	   system	   inhibitors	   to	   prevent	   the	   progression	   of	   DN	  
might	  be	  accounted	  for	  by	  endothelial	  dysfunction	  (18,	  113).	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   The	  association	  between	  diabetes	  and	  endothelial	  dysfunction	  is	  particularly	  
true	   in	   patients	  with	   type	   I	  DM	  who	  have	   either	   early	   (microalbuminuria)	   or	   late	  
(macroalbuminuria)	   nephropathy	   (122).	   What	   remains	   a	   debate	   is	   whether	  
endothelial	  dysfunction	  is	  a	  cause	  or	  a	  consequence	  of	  microvascular	  injury	  in	  type	  I	  
DM.	  	  
1.4	  Oxidative	  Stress	  and	  Diabetes	  	  
1.4a	  Sources	  of	  ROS	  in	  Diabetes	  
A	   wealth	   of	   evidence	   largely	   from	   the	   last	   15	   years	   suggests	   increased	  
oxidative	   stress	   in	  diabetes	   (19,	  33,	  135,	  150).	  There	  are	  a	  number	  of	   sources	   for	  
generation	  of	  ROS	  in	  diabetes	   including	  auto-­‐oxidation	  of	  glucose,	   transition	  metal	  
catalyzed	   Fenton	   reactions,	   mitochondrial	   respiratory	   chain	   deficiencies,	  
augmented	  xanthine	  oxidase	  activity	  and	  activation	  of	  enzymes	  such	  as	  peroxidases,	  
NOS	  and	  NOX	  (39).	  	  In	  DM,	  many	  studies	  have	  shown	  that	  NOX	  is	  the	  major	  source	  of	  
reactive	   oxygen	   species	   (ROS)	   in	   cardiac,	   vascular	   and	   renal	   tissue	   (58,	   134,	   159,	  
164)	   with	   the	   expression	   of	   NOX	   subunits	   elevated	   in	   micro-­‐	   and	  macrovascular	  
tissues	  of	  diabetic	  animals	  (43,	  48).	  Endothelial	  dysfunction	  linked	  to	  NOX-­‐induced	  
ROS	   generation	   has	   been	   observed	   in	   animal	   models,	   as	   well	   as	   in	   patients	   with	  
diabetes	   (6,	   70).	   Importantly,	   sustained	   increases	   in	   NOX	   activity	   deplete	   cellular	  
NADPH	  an	  essential	   cofactor	   for	   the	  proper	   function	  of	  major	  antioxidant	  enzyme	  
systems	  (159).	  Glucose	  auto-­‐oxidation	  generates	  OH	  radicals	  (135)	  and	  is	  the	  major	  
non-­‐enzymatic	  source	  of	  ROS	  generation.	  In	  its	  enediol	  form,	  glucose	  is	  oxidized	  in	  a	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transition	  metal-­‐dependent	   reaction	   to	   an	   enediol	   radical	   anion	   that	   is	   converted	  
into	   reactive	   ketoaldehydes	   and	   to	   superoxide	   anion	   radicals.	   Further,	   glucose	  
oxidation	   can	   also	   lead	   to	   NOX	   activation	   via	   accumulation	   of	   AGEs	   and	   their	  
receptor	  activation	  (61,	  156,	  177).	  Overproduction	  of	  ROS	  leads	  to	  the	  oxidation	  of	  
tetrahydrobiopterin,	  a	  cofactor	   for	  NOS	  (162).	   If	  NOS	   lacks	   its	  substrate	  L-­‐arginine	  
or	  one	  its	  cofactors,	  it	  may	  produce	  superoxide	  instead	  of	  NO	  and	  this	  is	  referred	  to	  
as	  NOS	  uncoupling	  (69,	  162).	  	  
1.4b	  Deficiency	  in	  Antioxidant	  Protective	  Systems	  	  
Data	   implicating	   changes	   in	   antioxidant	   enzyme	   systems	   in	   diabetes	   are	  
conflicting	   (13,	   19).	   These	   differences	   likely	   reflect	   heterogeneity	   of	   models	  
(including	  cell	   type	  studied,	  animal	  model	  used,	  and	   time	   tissues	  were	  examined).	  
The	  following	  studies	  indicate	  reductions	  in	  antioxidant	  capacity	  in	  diabetic	  settings.	  
a)	   The	   activity	   and	   expression	   of	   catalase	   (CAT),	   glutathione	   reductase	   (GR),	  
glutathione	   peroxidase	   (GPx)	   and	   superoxide	   dismutase	   (SOD)	   are	   decreased	   in	  
various	  tissues	  (13)	  with	  long-­‐term	  DM,	  as	  well	  as	  in	  a	  transgenic	  mouse	  model	  of	  
DN	  (55).	  	  
b)	   Reduced	   glutathione	   (GSH)	   concentration	   is	   decreased	   in	   the	   liver,	   kidney	   and	  
pancreas	  of	  chemically	  induced	  diabetic	  animals	  (111).	  	  
c)	  Elevated	  oxidative	  stress	  is	  linked	  to	  decreased	  GSH	  and	  NADPH	  levels	  (37,	  63)	  in	  
diabetic	  rodent	  tissues.	  	  
1.4c	  Oxidative	  Stress	  and	  Diabetic	  Kidney	  Disease	  
Of	  particular	  interest	  in	  diabetic	  kidney	  disease	  is	  the	  superoxide	  production	  
from	   mitochondria	   (159)	   and	   NOX	   (53,	   159).	   It	   has	   been	   suggested	   that	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mitochondrial	   superoxide	   is	   the	   initiating	   event	   in	   diabetes	   that	   turns	   oxidative	  
stress	   into	   an	   evolving	   cascade	   of	   subsequent	   insults	   by	   stimulating	   more	   ROS	  
production	  via	  downstream	  activation	  of	  nuclear	   factor-­‐kappaB	  mediated	  cytokine	  
production,	  protein-­‐kinase	  C	  (PKC)	  activation	  and	  NOX	  (42,	  43,	  58,	  85)	  
Elevated	  glucose	  levels	  associated	  with	  DM	  increased	  the	  expression	  and/or	  
activation	  of	  NOX	   (77,	   166).	  Renal	   expression	  of	  NOX	   is	   enhanced	   in	   STZ-­‐induced	  
diabetic	   rats	   (10,	   48,	   131).	   In	   vitro	   high	   glucose	   has	   been	   shown	   to	   activate	  NOX	  
subunits	  in	  mesangial	  cells	  through	  PKC	  activation	  (71,	  81).	  The	  inhibition	  of	  a	  NOX	  
subunit,	  gp91phox,	  retarded	  mesangial	  matrix	  expansion	  in	  rats	  with	  DN	  and	  NOX-­‐
dependent	   ROS	   generation	   in	   renal	   cortical	   and	   glomerular	   homogenates,	   with	  
concomitant	  reductions	  in	  whole	  kidney	  glomerular	  hypertrophy	  (10).	  Particularly,	  
elevated	   levels	   of	   nitrotyrosine	   were	   observed	   with	   increases	   in	   gp91phox	  
expression	  (52).	  Either	  direct	   inhibition	  of	  the	  assembly	  of	  NOX	  by	  treatment	  with	  
apocynin	   (10)	   or	   indirect	   inhibition	   of	   NOX	   activity	   by	   angiotensin	   converting	  
enzyme	   inhibition	  and	  angiotensin	  receptor	  blockade	  (52)	  resulted	   in	  significantly	  
less	  diabetes-­‐induced	  renal	  damage.	  These	  reports	  highlight	  the	  importance	  of	  NOX	  
as	  a	  major	  source	  of	  oxidative	  stress	  in	  diabetic	  kidney.	  
	  1.5	  NADPH	  and	  G6PD	  
1.5a	  Significance	  of	  NADPH	  	  
Several	   enzymes	   that	   catalyze	   substrate	   reduction	   generate	   nicotinamide	  
adenine	  dinucleotide	  phosphate	  (NADP+).	  As	  such	  NADP	  and	  NADPH	  are	  the	  classic	  
molecules	   involved	   in	   energy	   metabolism,	   antioxidant	   potential,	   and	   reductive	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biosynthesis	  (15-­‐17).	  The	  major	  biological	  impact	  of	  NADPH	  are	  three-­‐fold:	  the	  first	  
is	  to	  act	  as	  a	  key	  component	  in	  cellular	  antioxidant	  systems	  (184);	  the	  second	  is	  to	  
act	   as	   an	   electron	   source	   for	   reductive	   synthesis	   of	   fatty	   acids,	   steroids	   and	  DNA	  
(136);	   and	   the	   third	   is	   to	   act	   as	   the	   substrate	   for	  NOX,	  which	   plays	   a	   key	   role	   in	  
many	  biological	  and	  pathological	  processes	  by	  generating	  ROS	  (184).	  	  
1.5b	  Sources	  of	  NADPH	  
	  	   The	   NADPH	   generated	   via	   mitochondrial	   enzymes	   likely	   contributes	   to	  
mitochondrial	   antioxidant	   potential	   and	   biosynthesis	   (100,	   175),	   while	   NADPH	  
generated	   by	   cytosolic	   sources	   not	   only	   permit	   it	   to	   serve	   as	   an	   intracellular	  
reductant,	   but	   also	   as	   a	   substrate	   for	  NOX-­‐dependent	   ROS	   generation.	   	   There	   are	  
four	   known	   enzymes	   that	   catalyze	   the	   formation	   of	   NADPH	   from	   NADP+	   in	   cells.	  
Firstly,	  there	  is	  G6PD	  and	  6-­‐phosphogluconate	  dehydrogenase	  -­‐	  two	  enzymes	  in	  the	  
pentose	   phosphate	   pathway;	   secondly,	   there	   are	   the	   cytosolic	   and	   mitochondrial	  
NADP+	   dependent	   isocitrate	   dehyrogenases;	   thirdly,	   there	   are	   the	   cytosolic	   and	  
mitochondrial	   NADP+	   dependent	   malic	   enzymes;	   and	   lastly,	   the	   mitochondrial	  
transhydrogenase.	   However,	   the	   majority	   of	   these	   enzymes	   do	   not	   appear	   to	   be	  
adequate	   sources	   of	   NADPH	   as	   much	   as	   G6PD	   (184).	   6-­‐phoshogluconate	  
dehydrogenase	  produces	  as	  much	  NADPH	  as	  G6PD,	  but	  the	  NADPH	  produced	  by	  the	  
former	  is	  entirely	  dependent	  on	  G6PD	  activity	  (184).	  	  
1.5c	  Role	  of	  NADPH	  in	  Cellular	  Antioxidant	  Potential	  	  
NADPH	  plays	  an	  important	  role	  in	  cellular	  antioxidant	  protection.	  To	  begin,	  NADPH	  
is	   required	   for	   generation	   of	   GSH	   from	   GSSG	   (oxidized	   glutathione)	   through	   the	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action	  of	  GR.	  GSH	  is	  the	  principal	  intracellular	  antioxidant	  in	  most	  mammalian	  cells,	  
participates	  in	  the	  removal	  of	  H2O2	  and	  toxic	  end-­‐products	  of	  lipid	  peroxides	  (184);	  
its	  depletion	  renders	  cells	  susceptible	  to	  oxidative	  damage.	  Secondly,	  a	  large	  portion	  
of	   NADPH	   binds	   to	   the	   important	   allosteric	   binding	   site	   of	   CAT	   (93),	   which	  
reactivates	   CAT	   when	   it	   is	   inactivated	   by	   H2O2	   and	   maintains	   its	   most	   active	  
tetrameric	  form	  (93).	  In	  red	  blood	  cells,	  NADPH	  plays	  a	  significantly	  more	  important	  
role	   than	   GSH	   in	   defending	   oxidative	   insults,	   owing	   to	   its	   capacity	   in	   reactivating	  
catalase	   (57).	   Moreover,	   NADPH	   is	   an	   essential	   component	   in	   the	   thioredoxin	  
system	   (9).	   It	   also	   binds	   directly	   to	   the	   reductase	   domain	   of	   eNOS	   (186)	   and	   is	  
required	   to	   maintain	   tetrahydrobiopterin	   stores	   via	   de	   novo	   synthesis.	   Another	  	  
important	  antioxidant	  enzyme,	  heme	  oxygenase	  is	  also	  dependent	  on	  NADPH.	  It	  acts	  
as	   a	   backbone	   for	   generation	   of	   antioxidants,	   such	   as	   biliverdin	   and	   bilirubin,	  
through	   degradation	   of	   the	   highly	   oxidative	   heme.	   Biliverdin	   and	   bilirubin	   are	  
considered	  potent	  antioxidants	  because	  of	  their	  ability	  to	  directly	  scavenge	  ROS	  and	  
peroxynitrite	   (108-­‐110).	   In	   addition,	   bilirubin	   has	   been	   shown	   to	   act	   as	   a	   potent	  
suppressor	   of	   NOX,	   through	   unknown	   mechanisms,	   independent	   of	   its	   ROS	  
scavenging	  effect	  (109).	  	  
Seemingly	  paradoxical,	  increasing	  evidence	  has	  suggested	  that	  NADPH	  could	  
also	  significantly	  contribute	  to	  generation	  of	  oxidative	  stress	  through	  the	  activity	  of	  
NOX	   (58,	   67,	   68,	   134).	   Since	   NADPH	   has	   been	   shown	   to	   play	   both	   beneficial	   and	  
detrimental	   roles	   in	   maintaining	   cellular	   oxidant	   status,	   one	   could	   speculate	   the	  
importance	  of	  maintaining	  NADPH	  as	  a	  favorable	  endeavor.	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1.5d	  NADPH	  Depletion	  During	  Diabetes	  
	  	   DN	   involves	   a	   state	   of	   imbalance	   between	   the	   increased	   production	   of	  
oxidants	   and	  decreased	   antioxidant	  defenses.	  An	   important,	   but	   often	  overlooked,	  
consequence	  of	  type	  I	  DM	  is	  the	  net	  depletion	  of	  NADPH	  (11).	  This	  net	  loss	  is	  owed	  
to	   its	   increased	   consumption	   in	   multiple	   pathways	   including	   glucose	  metabolism	  
(76,	   142)	   and	   NOX	   (14,	   31).	   With	   moderate-­‐to-­‐	   severe	   hyperglycemia,	   the	  
	  
Figure	   1.1:	   Schematic	   depicting	   the	   effects	   of	   NADPH	   on	   cellular	   antioxidation	   capacity.	   Adapted	  
from	  Ying	  W,	  2008	  (184).	  NADPH	  can	  be	  generated	  by	  G6PD,	  6GPDH,	  NADP+	  dependent	  isocitrate	  
dehydrogenases(IDPs),	   NADP+-­‐dependent	   malic	   enzymes(MEPs)	   and	   transhydrogenase	   (TH).	  
NADPH	   can	   increase	   cellular	   antioxidation	   capacity	   by	   acting	   as	   a	   substrate	   for	   glutathione	  
reductase	   (GR)	   to	   reduce	  GSSG	   to	  GSH	   that	   is	   required	   for	   activities	  of	   the	  antioxidation	  enzymes	  
glutathione	   peroxidase	   (GPx)	   and	   glutathione-­‐S-­‐transferases	   (GST).	   NADPH	   can	   also	   increase	  
antioxdiation	   capacity	   by	   reactivating	   H2O2-­‐inactivated	   catalase	   (CAT)	   and	   by	   promoting	  
thioredoxin	   reductase	   (TrxR)-­‐mediated	   generation	   of	   thioredoxin.	   Adapted	   from	  Ying	   et	   al.,	  2008	  
(185)	  
}	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NADPH/NADP+	   ratio,	   GSH	   concentration	   and	   G6PD	   activity	   are	   diminished	   in	   the	  
liver	   and	   pancreas	   of	   diabetic	   rats	   (41)	   with	   concomitant	   increases	   NADP	  
concentration.	  	   	  
1.6	  Glucose-­6-­Phosphate	  dehydrogenase	  	  
1.6a	  Siginificance	  of	  G6PD	  
	  	   	   G6PD,	   a	   key	   enzyme	   for	   NADPH	   generation	   (96),	   has	   long	   been	  
recognized	   as	   the	   only	   antioxidant	   enzyme	   in	   erythrocytes,	   the	   cell	   type	   with	   no	  
alternative	  source	  of	  NADPH.	  G6PD	  is	  also	  the	  most	  studied	  among	  the	  enzymes	  that	  
synthesize	  NADPH	  and	  is	  the	  main	  source	  of	  mammalian	  NADPH	  (101,	  182).	  More	  
importantly,	   G6PD	   is	   critical	   for	   cell	   survival	   via	   its	   essential	   role	   in	   normal	   cell	  
growth	  and	  in	  preventing	  cell	  death	  (168).	  	  
G6PD	   was	   shown	   to	   be	   critically	   essential	   for	   defense	   against	   oxidative	  
stress,	   although	   its	   role	   was	   found	   to	   be	   dispensable	   for	   pentose	   phosphate	  
synthesis	  (133).	   	  For	  example,	  when	  fibroblasts	  are	  exposed	  to	  an	  oxidative	  insult,	  
G6PD	   deficiency	   has	   been	   shown	   to	   manifest	   as	   premature	   senescence	   and	  
diminished	   cell	   viability	   (75).	   Not	   surprisingly,	   G6PD	   deficient	   mice	   exhibit	  
increased	  oxidative	  stress,	  reduced	  NADPH	  and	  GSH	  levels,	  and	  elevated	  markers	  of	  
lipid	  peroxidation	   (182).	  Attempts	   to	  produce	  G6PD	  knockouts	  were	  unsuccessful	  
mainly	   because	   complete	   knock-­‐outs	   were	   embryonically	   lethal	   (104,	   133).	   In	  
vascular	  endothelium,	  G6PD	  is	   the	  principal	  source	  of	  NADPH	  (101)	  and	  regulates	  
the	  activity	  of	  enzymes	  requiring	  NADPH	  as	  a	  cofactor,	  including	  eNOS	  (101).	  	  Thus,	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in	  endothelial	  cells,	  G6PD	  is	  the	  critical	  determinant	  of	  intracellular	  redox	  state	  and	  
creates	   an	   environment	   that	   favors	   the	   generation	  of	  NO.	   In	   response	   to	   agonists,	  
G6PD-­‐deficient	   endothelial	   cells	   produce	   less	   NO,	   as	   a	   result	   of	   eNOS	   uncoupling	  
(179,	   180).	   Further,	   G6PD	   over-­‐expression	   results	   in	   lower	   endothelial	   oxidative	  
stress	  and	  elevated	  NO	  levels	  (101,	  112).	  	  
1.6b	  	  G6PD	  in	  Diabetes	  	  
Several	   studies	   have	   shown	   that	   G6PD	   activity	   is	   decreased	   in	   the	   liver,	  
pancreas	   and	   other	   tissues	   of	   diabetic	   animals	   and	   patients	   (140,	   141,	   152,	   171,	  
178).	   In	   addition	   to	   deficient	   G6PD	   activity,	   reductions	   in	   NADPH	   and	   GSH	   have	  
been	   reported	   in	   diabetic	   conditions	   both	   in	   vivo	   and	   in	   vitro	   (171,	   181).	   This	  
inhibition	   of	   G6PD	   activity	   was	   attributed	   to	   cyclic	   Adenosine	   Mono	   Phosphate	  
(cAMP)-­‐mediated	   phosphorylation	   in	   high	   glucose	   exposed	   cultured	   endothelial	  
cells,	   as	   well	   as	   in	   diabetic	   rat	   kidney	   cortex	   (181,	   188).	   Interestingly,	   G6PD	  
deficient	   mice	   exhibit	   renal	   damage	   as	   evidenced	   by	   increased	   urinary	   albumin,	  
similar	   to	   those	   seen	   in	   experimental	   diabetic	   animals	   (182).	  Many	   even	   contend	  
that	   diabetes	   is	   an	   acquired	   form	   of	   G6PD	   deficiency	   leading	   to	   decreased	   G6PD	  
activity,	   NADPH	   levels	   and	   damage	   to	   kidney	   tissue	   and	   endothelium	   (164,	   178,	  
182).	  
1.7	  C-­Peptide	  	  
1.7a	  History	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In	   their	   quest	   to	   understand	   insulin	   biosynthesis,	   Steiner	   and	   colleagues	  
(165)	   discovered	   pro-­‐insulin.	   Pro-­‐insulin	   is	   the	   intact	   parent	   molecule	   of	   insulin	  
with	   the	  connecting	  peptide,	  C-­‐peptide,	  serving	  the	  structural	  role	  of	   folding	  the	  A	  
and	   B	   chains	   of	   insulin	   into	   a	   favorable	   conformation.	   C-­‐peptide	   is	   subsequently	  
cleaved	   from	   the	   pro-­‐insulin	   molecule	   and	   released	   in	   an	   equimolar	   ratio	   with	  
insulin.	   The	   functional	   impact	   of	   the	   action	   of	   C-­‐peptide	   was	   confined	   to	   only	   a	  
structural/stereometric	  role	  owing	  to	  data	  demonstrating	  the	  failure	  of	  C-­‐peptide	  to	  
have	  any	  influence	  on	  glucose	  metabolism	  or	  the	  lipolysis	  of	  isolated	  fat	  cells	  (95).	  	  
With	   the	   advent	   of	   advanced	   immunological	   methods,	   in	   the	   early-­‐to-­‐mid	  
1970s,	   a	   growing	   number	   of	   studies	   were	   aimed	   at	   measuring	   C-­‐peptide	  





levels	  (95,	  137,	  151,	  169).	  	  C-­‐peptide,	  unlike	  insulin,	  undergoes	  negligible	  first-­‐pass	  
metabolism	  (151).	  This	  led	  to	  the	  journey	  of	  C-­‐peptide	  as	  a	  diagnostic	  marker	  in	  DM	  
(151).	   Therefore,	   peripheral	   C-­‐peptide	   concentrations	   are	   now	  used	   as	   a	   valuable	  
semi-­‐quantitative	   marker	   of	   beta-­‐cell	   function	   as	   well	   as	   insulin	   secretion	   under	  
normal	  and	  diabetic	  conditions	  (137,	  138,	  169).	  Very	  careful	  studies	  by	  Kitabchi	  et	  
	  
	  
Figure	  1.2:	  	  	  	  	  	  	  	  Schematic	  
representation	  of	  human	  
proinsulin,.	   Adapted	  
from	   Brandenburg,	  
2008.	  (22)	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al.,	   demonstrated	   that	   C-­‐peptide	   possessed	   no	   insulin-­‐like	   physiological	   activity	  
(94).	  
Chance	  et	  al.,	  were	  the	  first	  to	  unravel	  the	  amino	  acid	  sequence	  of	  C-­‐peptide	  
in	   the	   process	   of	   isolating	   and	   characterizing	   proinsulin	   from	   crystalline	   porcine	  
insulin	  (35).	  Intensive	  protein-­‐chemical	  work	  conducted	  by	  several	  other	  groups	  on	  
pro-­‐insulin	  and	  C-­‐peptide	  across	  several	  species	  helped	  determine	  and	  confirm	  the	  
sequence	  of	  C-­‐peptide	   (62,	   183).	   Surprisingly,	   this	  work	  demonstrated	   the	   lack	  of	  
structural	   homogeneity/	   conservation	   among	   C-­‐peptides	   isolated	   from	   different	  
species,	   and	   further	   corroborated	   the	   previous	   work	   showing	   lack	   of	   functional	  
significance.	  The	  highly	  conserved	  region	  amongst	  mammalian	  sequence	  patterns	  of	  
C-­‐peptide	  is	  only	  four	  amino	  acids	  long	  and	  includes	  four	  non-­‐consecutive	  positions	  
with	   glutamic	   acid,	   an	   interspaced	   glycine-­‐rich	   segment	   and	   some	   other	   residues	  
(62,	  183).	  	  
The	  question	  as	  to	  whether	  C-­‐peptide	  had	  a	  physiological	  role	  was	  re-­‐visited	  
by	   John	  Wahren’s	   group	   from	   the	   Karolinska	   Institute	   in	   the	   early	   1990’s	   (176).	  
Since	   then,	   interest	   into	   the	   physiological	   impact	   of	   C-­‐peptide	   has	   persisted,	   and	  
garnered	  significant	  support	  from	  the	  clinical	  observations	  that	  patients	  with	  type	  I	  
DM,	  with	   a	   small	   level	   of	   endogenous	   beta	   cell	   activity,	   are	   less	   prone	   to	   develop	  
long	   term	   complications	   (176).	   Replacement	   of	   physiological	   concentrations	   of	   C-­‐
peptide	   in	   type	   I	   diabetic	   patients	   that	   lack	   C-­‐peptide	   resulted	   in	   significant	  
amelioration	   of	   diabetes-­‐induced	   abnormalities	   of	   regional	   blood	   flow,	   as	   well	   as	  
improvements	  in	  peripheral	  nerve	  conduction	  velocity	  and	  kidney	  function	  (46,	  86,	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88,	  89)	  Further,	   combined	   replacement	  of	   insulin	   and	  C-­‐peptide	  was	  also	  deemed	  
beneficial	   (87).	   These	   findings	   prompted	   the	   general	   hypothesis	   that	   C-­‐peptide	  
deficiency	   in	   type	   I	   DM	   may	   contribute	   to	   the	   development	   of	   microvascular	  
complications,	  and	  ultimately	  its	  associated	  complications.	  	  
1.7b	  C-­peptide	  and	  kidney	  dysfunction	  
The	   work	   of	   Johansson	   et	   al.,	   demonstrated	   that	   the	   administration	   of	   C-­‐
peptide	   for	   short	   term	  as	  well	   as	   long-­‐term	  (3	  months)	   to	   type	   I	  diabetic	  patients	  
receiving	  insulin,	  reduced	  glomerular	  filtration	  rate	  and	  urinary	  albumin	  excretion	  
(87).	  Net	  dilation	  of	  the	  efferent	  arteriole,	  as	  well	  as	  prevention	  of	  mesangial	  matrix	  
expansion,	   were	   proposed	   as	   the	   underlying	  mechanisms	   in	   this	   3-­‐month	   double	  
blind	   study	   (87).	   However	   the	   patients	   in	   these	   studies	   also	   exhibited	   better	  
glycemic	  control,	  hence	  their	  claims	  suggesting	  the	  specific	  C-­‐peptide	  related	  effects	  
lacked	  support	  and	  warranted	  further	  studies.	  	  
The	   hypothesis	   that	   C-­‐peptide	   has	   a	   renal	   protective	   effect	   started	   gaining	  
more	   strength	   due	   to	   the	   data	   obtained	   from	   animal	   models	   of	   experimental	  
diabetes.	   	   These	   studies	   exhibited	   similar	   beneficial	   renal	   outcomes,	   such	   as	  
decreased	  GFR	  and	  proteinuria	  (107,	  154,	  155).	  The	  glomerular	  microcirculation	  is	  
regulated,	   to	   a	   great	   extent,	   through	   alterations	   in	   the	   vascular	   resistance	   of	   the	  
afferent	  and	  efferent	  arterioles	  (145).	  The	  constriction	  of	  afferent	  arterioles	  lowers	  
glomerular	  filtration	  pressure,	  and	  thus	  decreases	  GFR.	  C-­‐peptide	  constricts	  isolated	  
renal	  afferent	  arterioles	  from	  diabetic	  mice,	  but	  not	  from	  normoglycemic	  mice	  with	  
no	  changes	  in	  renal	  blood	  flow	  (155).	  However,	  the	  afferent	  constriction	  caused	  by	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C-­‐peptide	  was	  demonstrated	  in	  isolated	  arterioles,	  where	  the	  arteriole	  is	  not	  set	  up	  
with	  an	   intact	   tubulus	  and	  thus	   is	   independent	  of	  TGF.	   In	  addition,	   it	  was	  recently	  
shown	   by	   Sallstrom	   et	   al	   that	   TGF	   does	   not	   mediate	   diabetes-­‐induced	  
hyperfiltration,	   since	   diabetes-­‐induced	   glomerular	   hyperfiltration	   occurs	   in	  
adenosine	  A1-­‐receptor-­‐defi	   cient	  mice	  known	   to	   lack	  a	   functional	  TGF	  mechanism	  
(153).	   If	   TGF	   is	   not	   the	  mediator	   of	   diabetic	   hyperfiltration,	   it	   is	   unlikely	   that	   C-­‐
peptide	   would	   exert	   its	   effect	   on	   filtration	   via	   a	   TGF-­‐dependent	   mechanism.	  
Therefore,	   a	   possible	   conclusion	   is	   that	   C-­‐peptide	   exerts	   its	   effect	   directly	   on	   the	  
glomerular	  afferent	  arterioles.	  Yet	  another	  study	  reported	  that	  acute	  administration	  
of	  C-­‐peptide	  reduced	  GFR	  in	  diabetic	  rats	  via	  seemingly	  two	  different	  mechanisms,	  
by	   causing	   a	   net	   dilation	   of	   efferent	   arteriole	   and	  by	   inhibition	   of	   tubular	   sodium	  
reabsorption	   (128).	   	   Taken	   together,	   these	   studies	   suggest	   that	  C-­‐peptide	   reduces	  
diabetes-­‐induced	  glomerular	  hyperfiltration	  via	  constriction	  of	  glomerular	  afferent	  
arteriole,	   but	   with	   a	   simultaneous	   dilation	   of	   the	   efferent	   arteriole	   that	  
counterbalances	  the	  effect	  of	  renal	  blood	  flow.	  
	  1.7c	  C-­peptide	  -­	  Cellular	  and	  Molecular	  effects	  	  
The	   cell	   signaling	   elicited	   by	   C-­‐peptide,	   and	   its	   subsequent	   transduction	  
pathways,	   were	   the	   subject	   of	   research	   mainly	   because	   C-­‐peptide	   exhibited	  
beneficial	  renal,	  neural	  and	  microvascular	  effects.	  	  Due	  to	  the	  behavior	  of	  c-­‐	  terminal	  
pentapeptide	  (akin	  to	  a	  peptide	  ligand	  interacting	  with	  its	  specific	  receptor),	  some	  
studies	  postulated	  the	  existence	  of	  a	  C-­‐peptide	  receptor	  (139,	  146).	  Indeed,	  specific	  
and	  displaceable	  binding	  of	   125I-­‐labelled	  C-­‐peptide	  was	   first	  demonstrated	  by	  Flatt	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et	  al.	  (51)	  who	  derived	  a	  curvilinear	  Scatchard	  plot	  of	  specific	  C-­‐peptide	  binding	  to	  
pancreatic	   islet	   beta-­‐cells.	   	   Surprisingly,	   the	  mid-­‐region	   segment	  was	   reported	   to	  
mediate	   non-­‐specific	   interactions	   by	   Ido’s	   group	   (82).	   However,	   the	   balance	   of	  
activity	  provided	  by	  these	  two	  regions	  of	  the	  C-­‐peptide	  molecule	  in	  vivo	  is	  not	  well	  
understood.	   The	   general	   consensus	   about	   the	   structure-­‐activity	   relationship	   of	   C-­‐
peptide	   suggests	   that	   it	   exists	   as	   a	   tripartite	   structure	   with	   its	   terminal	   sections	  
responsible	   for	   functional	   interactions	   and	   the	   mid-­‐portion	   forming	   a	   joining	  
segment	   (189).	   Interactions	   of	   human	   C-­‐peptide	   with	   plasma	   membranes	   were	  
reported,	  with	  the	  following	  binding	  characteristics	  (139,	  146):	  high	  affinity	  specific	  
binding	  with	   an	   association	   rate	   constant	   of	   ~	   3	   nM;	   half	  maximal	   occupation	   of	  
binding	   sites	   at	   ~0.3	   nM	   C-­‐peptide;	   and	   full	   occupation	   at	   ~0.9	   nM	   C-­‐peptide.	  
Importantly,	  the	  same	  study	  reported	  that	  the	  binding	  of	  C-­‐peptide	  was	  inhibited	  by	  
pertussis	   toxin.	   Overall,	   these	   results	   strongly	   support	   the	   existence	   of	   a	   specific	  
GTP-­‐binding	  protein-­‐coupled	  receptor	  (GPCR)	  for	  C-­‐peptide,	  linked	  either	  to	  the	  G-­‐
protein	   α-­‐subunit	   Gαi	   or	   Gαo,	   which	   interacts	   with	   the	   C-­‐terminal	   pentapeptide	  
region	  of	  the	  C-­‐peptide	  molecule.	  	  
C-­‐peptide	  has	  salutary	  effects	  on	  organ	  physiology	  and	  microvasculature	  of	  
type	   I	   diabetic	   animals	   as	   well	   as	   diabetic	   animals.	   Consequently	   there	   is	   a	   clear	  
need	   for	   molecular	   studies	   evaluating	   the	   effects	   of	   C-­‐peptide	   in	   various	  
microvascular	  cell	  types	  to	  delineate	  mechanisms	  that	  are	  the	  basis	  for	  the	  observed	  
clinical	  effects.	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1.8	  Mitochondrial	  Oxidative	  Stress	  and	  Complex	  I	  
	  
1.8a	  Mitochondrial	  	  Oxidative	  Stress	  
Both	   insulin-­‐deficient	   and	   insulin-­‐resistant	   diabetic	   states	   have	   been	  
associated	   with	   mitochondrial	   dysfunction	   since	   the	   1950s.	   There	   is	   an	   ongoing	  
controversy	  as	  to	  whether	  mitochondrial	  dysfunction	  is	  a	  cause	  or	  consequence	  of	  
diabetes	   and/or	   its	   complications.	   Despite	   several	   studies	   using	   the	   phrase	  
“mitochondrial	   dysfunction”,	   it	   must	   be	   acknowledged	   that	   beyond	   dysfunction,	  
evidence	  also	   exists	   for	  defects	   in	  mitochondrial	  biogenesis,	   number,	  morphology,	  
and	  dynamics	  (29,	  36,	  92).	  Reductions	  in	  mitochondrial	  respiration	  were	  found	  for	  
the	   skeletal	  muscle	  mitochondria	  of	   type	   II	  diabetic	  patients	   (92,	  148).	  Conflicting	  
reports	  also	  exist	  reporting	  a	  lack	  of	  change	  to	  heart	  and	  brain	  mitochondria,	  with	  
apparent	   increases	   in	   renal	   mitochondrial	   respiration	   on	   succinate	   or	   complex	   I	  
substrates	  from	  STZ	  diabetic	  rats	  (91).	  	  
Much	  of	  the	  work	  linking	  mitochondria	  to	  long-­‐term	  diabetic	  complications	  is	  
focused	   in	   cells	   that	   are	   insulin-­‐independent,	   such	   as	   kidney	   podocytes	   and	  
mesangial	  cells,	  capillary	  endothelial	  cells	  of	  the	  retina	  and	  neurons/Schwann	  cells	  
of	   peripheral	   nerves,	   and	   vascular	   endothelial	   cells	   (27).	   DM,	   and	   therefore	  
hyperglycemia,	   results	   in	   a	   constant	   exposure	   of	   this	   particular	   subset	   of	   cells	  
exposed	  to	  excess	  glucose.	  This	  causes	  selective	  damage	  because	  of	  their	  inability	  to	  
regulate	   glucose	   transport.	   The	   excess	   glucose	   entering	   these	   cells	   is	   fed	   into	   the	  
tricarboxylic	  acid	  cycle	   leading	   to	   increased	  generation	  and	  channeling	  of	  electron	  
donors	   (NADH2	   and	   FADH2)	   into	   the	   electron	   transport	   chain.	   As	   a	   consequence,	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voltage	  across	  the	  mitochondrial	  membrane	  increases	  and	  electrons	  are	  transferred	  
to	   molecular	   oxygen	   leading	   to	   the	   production	   of	   superoxide.	   	   Brownlee	   et	   al.,	  
proposed	   this	   superoxide	   generation	   as	   a	   common	   element	   linking	   the	   damage	  
pathways	  underlying	  the	  pathogenesis	  of	  diabetic	  complications	  (27).	  As	   indicated	  
previously,	  superoxide	  reacts	  with	  NO	  to	   form	  peroxynitrite.	  This	  will	   induce	   lipid	  
peroxidation	   and	   consume	   NO,	   which	   can	   impair	   endothelium-­‐mediated	  
vasodilation	   (74).	   Superoxide	   can	   also	   damage	   iron–sulfur	   centers,	   reducing	  
catalysis	   by	   enzymes	   such	   as	   aconitase	   (173).	   Moreover,	   hydrogen	   peroxide,	  
produced	  from	  superoxide	  by	  MnSOD,	  can	  react	  with	  iron	  to	  form	  the	  very	  reactive	  
OH.	  	  
	  
Figure 1.3: Mitochondrial overproduction of superoxide activates four major pathways of 
hyperglycemic damage by inhibiting GAPDH. Adapted from  Brownlee et al., 2001 (26) 
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Several	   reports	   suggest	   that	   the	   diabetic	   state	   increases	   mitochondrial	  
superoxide	  generation	  both	  in	   in	  vitro	  high	  glucose	  conditions	  (44,	  49,	  64,	  143),	  as	  
well	   as	   in	   diabetic	   animal	   models	   (29,	   73).	   Furthermore,	   this	   excessive	  
mitochondrial	  superoxide	  generation	  leads	  to	  the	  subsequent	  accumulation	  of	  other	  
free	  radicals,	  thereby	  imparting	  diffuse	  damage	  to	  proteins	  and	  mitochondrial	  DNA,	  
and	   ultimately	   leading	   to	   mitochondrial	   dysfunction	   (132,	   163).	   Finally,	  
mitochondrial	  damage	  and	  consequent	  dysfunction	  will	  disrupt	  calcium	  transit	  and	  
induce	  the	  mitochondrial	  permeability	  transition,	  leading	  to	  apoptosis	  (54).	  	  
1.8b	  Complex	  I	  	  
Although	  all	  of	  the	  complexes	  of	  the	  mitochondrial	  electron	  transport	  chain	  
contribute	   to	   total	   mitochondrial	   superoxide	   generation,	   growing	   evidence	   now	  
suggests	   that	   complex	   I	   produces	  most	   of	   the	   superoxide	   generated	  within	   intact	  	  	  
mammalian	  mitochondria	  (21).	  It	  is	  well	  known	  that	  complex	  II	  also	  has	  the	  capacity	  
to	   produce	   superoxide,	   but	   this	   only	   occurs	   while	   in	   the	   presence	   of	   specific	  
inhibitors	  and	  is	  not	  a	  physiologically	  relevant	  site	  of	  generation	  (65).	  Complex	  III,	  
on	  the	  other	  hand,	  has	  been	  shown	  to	  produce	  large	  amounts	  of	  superoxide,	  at	  least	  
in	   the	   presence	   of	   antimycin	   (65).	   Complex	   I	   is	   the	   first	   member	   of	   the	  
mitochondrial	   membrane-­‐bound	   electron	   transport	   chain	   and	   its	   substrates/co-­‐
factors	   have	   the	   lowest	   potentials	   in	   the	   chain	   (47).	   	   Inhibition	   of	   the	   electron	  
transport	   chain	  during	  pathological	   conditions	   and/or	   the	  build-­‐up	  of	  NADH	   (and	  
subsequent	   elevation	   in	   the	   NADH/NAD+	   ratio)	   have	   been	   shown	   to	   contribute	  
significantly	   to	   superoxide	   generation	   by	   complex	   I	   (99).	   Under	   physiological	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conditions,	  mitochondrial	  superoxide	  originates	  predominantly	  from	  complex	  I	  and	  
complex	   III	   (59,	   60),	   yet	   growing	   evidence	   suggests	   that	   complex	   I	   alone	   is	  
responsible	   for	   the	  majority	  of	   the	   superoxide	  produced	  within	   intact	  mammalian	  
mitochondria	   (119).	   	   Further,	   Lambert	   and	   Brand	   (99)	   have	   shown	   that	   high	  
superoxide	  generation	  by	  the	  mitochondria	  requires	  inhibition	  of	  complex	  I	  activity.	  
In	   conclusion,	   complex	   I	   appears	   to	   be	   the	  major	   source	   and	   site	   for	   superoxide	  
generation.	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Chapter	  2:	  	  
C-­peptide	  Confers	  Anti-­oxidative	  Protection	  in	  	  
Renal	  Cortical	  Endothelial	  Cells	  during	  	  
Type	  I	  diabetes	  by	  Restoring	  	  
Glucose-­6-­Phosphate	  Dehydrogenase	  Activity	  
Himani	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  ,	  Robert	  W.	  Brock1,2.	  	  
1Physiology	  &	  Pharmacology,	  2Center	  for	  Cardiovascular	  &	  Respiratory	  Sciences,	  	  





	   47	  
ABSTRACT	  	  
Previously	   we	   have	   shown	   that	   C-­‐peptide,	   a	   by-­‐product	   of	   insulin	  
biosynthesis,	  improves	  renal	  peritubular	  capillary	  blood	  flow	  and	  reduces	  vascular	  
oxidants.	   NADPH	   appears	   to	   be	   critical	   to	   this	   effect	   via	   the	   actions	   of	   numerous	  
vasoprotective	   systems.	   We	   have	   found	   that	   diabetes	   results	   in	   a	   significant	  
reduction	   in	   endothelial	  NADPH	   that	   is	   subsequently	   restored	  with	  C-­‐peptide.	  We	  
hypothesize	   that	   C-­‐peptide	   provides	   protection	   to	  RCEs	   during	   type	   I	   diabetes	   by	  
restoring	   the	   activity	   of	  G6PD,	   the	  principal	   source	   of	  NADPH	   synthesis.	  Our	  data	  
show	   that	   RCEs	   from	   diabetic	   mice	   have	   diminished	   G6PD	   activity	   (p<0.05)	   and	  
their	  treatment	  with	  C-­‐peptide	  restores	   its	  activity	  back	  to	  control	   levels	  (p<0.05).	  
These	   changes	   in	   G6PD	   activity	   occurred	  with	   concomitant	   alterations	   in	  NADPH.	  
Using	  2-­‐D	  gel	  electrophoresis	  of	  RCE	  lysate	  coupled	  with	  immunoblotting	  for	  G6PD,	  
we	   demonstrate	   that	   diabetic	   RCEs	   have	   a	   significant	   increase	   in	   G6PD	   PTM.	   C-­‐
peptide	   treatment	   reduced	   the	   magnitude	   of	   this	   PTM	   in	   diabetic	   RCEs,	   which	  
occurred	   concomitant	   to	   restored	   G6PD	   activity.	   These	   results	   suggest	   that	  
improving	   the	   activity	   of	   endothelial	   G6PD,	   by	   preventing	   its	   PTM,	   may	   be	   a	  
potential	  mechanism	  by	  which	  C-­‐peptide	  confers	  protection	   to	  RCEs	  during	   type	   I	  
diabetes.	  	  
Keywords:	   C-­‐peptide,	   Glucose-­‐6-­‐Phosphate	   Dehydrogenase	   (G6PD),	   Endothelial	  
cells,	  Diabetic	  Nephropathy.	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INTRODUCTION	  
DN	  is	  the	  leading	  cause	  of	  chronic	  kidney	  disease	  and	  end-­‐stage	  renal	  failure	  
in	  type	  I	  diabetic	  patients.	  Even	  with	  optimal	  glucose	  control,	  many	  type	  I	  diabetic	  
patients	   develop	   end-­‐stage	   renal	   failure.	   Although	   DN	   is	   characterized	   by	  
glomerulosclerosis	   (14),	   recent	   evidence	   also	   indicates	   that	   glomerular	   damage	  
causes	   stagnation	   of	   peritubular	   blood	   flow	   and	   thus	   development	   of	   tubulo-­‐
interstitial	  injury	  and	  ultimately	  peritubular	  capillary	  loss	  (36,	  37).	  	  
DN	  involves	  a	  state	  of	   imbalance	  with	  increased	  production	  of	  oxidants	  and	  
decreased	   antioxidant	   defenses	   (57).	   An	   important,	   but	   often	   overlooked,	  
consequence	   of	   type	   I	   diabetes	   is	   the	   net	   depletion	   of	   NADPH	   (3),	   the	   principal	  
intracellular	   reductant	   for	   all	   cells.	   Moreover,	   NADPH	   is	   a	   critical	   cofactor	   in	  
preserving	   normal	   microvascular	   function	   through	   actions	   of	   multiple	  
vasoprotective	   systems	   like	   heme	   oxygenase	   -­‐1	   and	   NOS.	   There	   is	   a	   net	   loss	   of	  
NADPH	   in	  microcirculation	  owing	   to	   increased	  consumption	   in	  multiple	  pathways	  
including	  glucose	  metabolism	  (17,	  42)	  and	  NOX	  (5,	  8).	  G6PD,	  the	  first	  rate-­‐limiting	  
enzyme	  of	  the	  pentose	  phosphate	  pathway,	  is	  the	  major	  source	  of	  NADPH	  (30,	  58).	  
In	   fact,	   when	   G6PD	   activity	   is	   reduced	   to	   10%	   of	   normal,	   the	   pentose	   phosphate	  
pathway	  fails	  to	  generate	  any	  NADPH	  (1).	  Recent	  reports	  show	  that	  hyperglycemia	  
causes	   inhibition	   of	   G6PD	   activity,	   thus	   NADPH	   depletion,	   in	   diabetic	   rat	   kidney	  
cortex	   and	   bovine	   aortic	   endothelial	   cells	   (57,	   60).	   Further,	   in	   endothelial	   cells,	  
hyperglycemia-­‐induced	   inhibition	   of	   G6PD	   appeared	   to	   occur	   via	   PKA	   mediated	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phosphorylation	   (60).	   We	   hypothesize	   that	   microvascular	   dysfunction	   in	   type	   I	  
diabetic	  kidney	  involves	  loss	  of	  NADPH,	  due	  to	  inhibition	  of	  G6PD	  activity,	  in	  RCEs.	  
C-­‐peptide,	  a	  by-­‐product	  of	  insulin	  biosynthesis	  (50),	  had	  long	  been	  thought	  to	  
be	   physiologically	   inert	   (26).	   However,	   several	   studies	   have	   reported	   beneficial	  
effects	  of	  exogenous	  C-­‐peptide	  on	  renal	  function	  in	  type	  I	  diabetic	  patients	  (11,	  22-­‐
24).	  In	  experimental	  diabetes,	  short-­‐term	  infusions	  of	  C-­‐peptide	  have	  been	  shown	  to	  
improve	   glomerular	   hyper-­‐filtration,	   reduce	   albuminuria	   whereas	   long-­‐term	  
substitution	   improved	   overall	   renal	   function	   in	   diabetic	   patients	   (18,	   21,	   46-­‐48).	  
Despite	  numerous	  reports	  indicating	  that	  C-­‐peptide	  replacement	  is	  beneficial	  to	  the	  
state	   of	   renal	   function	   in	   type	   I	   DM,	   the	   exact	   nature	   of	   its	   bioactivity	   and	  
physiological	  effect	  on	  the	  renal	  microcirculation	  requires	  further	  clarity.	  
We	   examined	   the	   effect	   of	   C-­‐peptide	   on	   peritubular	   capillary	   perfusion	   in	  
kidney	   cortices	   from	   experimental	   diabetic	   animals.	   Further	   we	   correlated	   the	  
alterations	   in	   microvascular	   function	   with	   changes	   in	   biochemistry	   of	   freshly	  
isolated	   diabetic	   RCEs.	   To	   evaluate	   the	   mechanisms	   responsible	   for	   impaired	  
endogenous	   vasoprotection,	   NADPH	   levels,	   G6PD	   activity,	   and	   phosphorylation	   of	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MATERIALS	  AND	  METHODS	  
Murine	  Model	  of	  Type	  1	  diabetes:	  	  
Male	   C57BL/6	   mice	   (Jackson	   Laboratories)	   were	   maintained	   on	   standard	  
rodent	   chow	   with	   free	   access	   to	   water.	   	   Mice	   weighing	   20-­‐25	   g	   were	   randomly	  
assigned	  to	  control	  and	  diabetic	  groups.	  Type	  I	  diabetes	  was	  induced	  using	  NIDDK-­‐
sponsored	  Animal	  Models	  of	  Diabetic	  Complications	  Consortium	  (AMDCC)	  low-­‐dose	  
STZ	  regimen.	  Briefly,	  mice	  received	  daily	  STZ	  (Sigma,	  St..	  Louis,	  MO)	  at	  a	  dose	  of	  50	  
mg/kg	  BW,	   freshly	  made	   in	  0.1	  M	  sodium-­‐citrate	  buffer,	  pH	  4.5,	   for	  5	   consecutive	  
days	  whereas	  control	  mice	  received	  only	  the	  vehicle.	  Body	  weight	  and	  fasting	  blood	  
glucose	   level	   (AccuSoft	   Advantage(R)	   glucose	   meter,	   Roche	   Diagnostics,	  
Indianapolis,	   IN,	   USA)	   were	   examined	   weekly	   in	   all	   animals	   (19).	   Mice	   were	  
considered	   diabetic	   if	   their	   fasting	   blood	   glucose	   exceeded	   200	  mg/dL	   after	   four	  
weeks.	  	  
Biosynthetic	  Rat	  C-­peptide	  II:	  	  
Rat	   C-­‐peptide	   II	   (NH2	   EVEDPQVAQLELGGGPGAGDLQTLALQVARQ-­‐COOH)	  
with	   purity	   greater	   than	  90%	  was	   obtained	   from	  Primm	  biotech,	   Inc.,	   Cambridge,	  
MA,	   USA).	   	   Briefly,	   the	   peptide	   was	   dissolved	   in	   0.5	   M	   acetic	   acid	   and	   further	  
dilutions	   made	   with	   saline.	   After	   5-­‐weeks	   of	   untreated	   diabetes,	   mice	   were	  
anesthetized	   with	   inhalational	   isoflurane	   and	   an	   Alzet	   micro-­‐osmotic	   pump	  
(DURECT	   Corporation,	   Cupertino,	   CA,	   USA)	   was	   implanted	   subcutaneously.	   The	  
pump	  was	   filled	  with	   rat	  C-­‐peptide	   II	   and	  delivered	  50	  pmol/kg/min	  of	  C-­‐peptide	  
	   51	  
for	  24	  hours.	  At	  the	  end	  of	  24	  hr,	  animals	  were	  anesthetized	  for	  either	  in	  vivo	  digital	  
microscopy	  or	  for	  tissue	  harvest	  and	  processing.	  
Urinary	  Albumin	  and	  Creatinine	  Excretion:	   	  
The	   excretion	   of	   urinary	   albumin	   was	   determined	   using	   the	   albumin-­‐to-­‐
creatinine	   ratio	   on	   morning	   spot	   urine	   as	   endorsed	   by	   the	   AMDCC.	   Spot	   urine	  
collection	  was	   conducted	  using	   a	   custom-­‐made	   collection	   cage	   that	   is	   constructed	  
with	  a	  96-­‐well	  assay	  plate	  as	  the	  floor.	  Mice	  were	  permitted	  to	  roam	  over	  the	  plate	  
until	   spontaneous	   urination.	   Only	   the	   urine	   without	   contamination	   was	   used	   for	  
assay.	   The	   urinary	   albumin	   and	   creatinine	   concentrations	  were	   determined	   using	  
commercially	   available	   immunoassay	   kits	   (Albuwell	   M	   and	   The	   Creatinine	  
Companion,	  Exocell)(43)	  
In	  Vivo	  Digital	  Microscopy:	  
To	   properly	   visualize	   the	   microcirculation	   for	   perfusion	   analysis,	   prior	   to	  
microscopy,	   a	   Fluorescein	   isothiocyanate-­‐conjugated,	   high	  molecular	   weight	   (500	  
kDa;	   Invitrogen)	   neutral	   dextran	   was	   injected	   via	   tail	   vein.	  With	   an	   anesthetized	  
mouse	  (isoflurane;	  5%	  induction,	  2%	  maintenance)	  lying	  on	  the	  stage	  of	  an	  inverted	  
microscope	  (Axiovert	  200;	  Zeiss),	  the	  left	  kidney	  was	  exposed	  and	  imaged	  through	  a	  
retro-­‐peritoneal	   left	   flank	   incision(51,	   54).	   The	   left	   kidney	   surface	  was	  moistened	  
with	  warmed	  saline;	  heat	  lamps	  were	  used	  to	  preserve	  body	  and	  bath	  temperatures	  
at	   37o	   C.	   Following	   preparation	   of	   the	   kidney	   for	   imaging,	   10	   random	   high	  
magnification	  fields	  of	  view	  (Plan-­‐Neo	  20x/0.5	  and	  40x/0.75;	  Zeiss)	  were	  projected	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onto	  a	  1/2”	  CCD	  video	  camera	  (C2400-­‐75E;	  Hamamatsu)	  and	  digitally	  recorded	  for	  
later	  analyses.	  
Peritubular	  Perfusion:	  	  
To	  determine	  peritubular	  perfusion,	  a	  stereological	  point-­‐counting	  grid	  was	  
used	  to	  provide	  a	  greater	  than	  95%	  confidence	  that	  the	  density	  of	  points	  counted	  is	  
proportional	   to	   the	  density	  of	  peritubular	  capillaries	  within	   the	  area	  of	   interest.	  A	  
capillary	  was	  only	  counted	  if	  a	  point	  from	  the	  pre-­‐determined	  array	  lands	  within	  its	  
dimensions.	   Continuously	   perfused	   capillaries	   are	   defined	   as	   vessels	   that	   possess	  
continuous	   red	   cell	   perfusion	   throughout	   the	   entire	   1-­‐minute	   observation	   period.	  
Intermittently	   perfused	   capillaries	   are	   vessels	   that	   possess	   red	   cell	   perfusion	   that	  
stopped	  at	   least	  once	  during	  the	  observation	  period.	  A	  non-­‐perfused	  capillary	  was	  
defined	  as	  any	  vessel	  that	  is	  devoid	  of	  red	  cell	  perfusion	  throughout	  the	  observation	  
period.	  Peritubular	  perfusion	  was	  expressed	  as	  a	  proportion	  of	  the	  total	  number	  of	  
capillaries	  (%).	  
Immunomagnetic	  Separation	  of	  Renal	  Cortical	  Endothelial	  Cells:	  
For	  sufficient	  yields,	  a	  pool	  of	  15	  kidney	  cortices	  (5	  mice)	  was	  used.	  Briefly,	  
the	  cortices	  were	  pressed	  through	  a	  250	  µm	  stainless	  steel	  sieve	  using	  a	   flattened	  
pestle	   and	   the	   slurry	   transferred	   for	   digestion	   in	   liberase	   (1	   mg/ml	   liberase	  
blendzyme	   3,	   Roche	   corporation,	   Indianapolia,	   IN,	   USA,	   in	   HBSS)	   at	   37°C	   for	   45	  
minutes	  with	  gentle	  agitation	  (15,	  52).	  The	  liberase-­‐digested	  slurry	  was	  then	  filtered	  
through	   a	   100	   µm	   cell	   strainer	   and	   washed	   with	   5	   ml	   of	   ice-­‐cold	   HBSS.	   The	  
remaining	   cell	   suspension	  was	   centrifuged	  at	  600	  g	   for	  10	  minutes.	   Subsequently,	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the	  supernatant	  was	  discarded	  and	  the	  pellet	  resuspended.	  RCEs	  were	  isolated	  and	  
purified	  from	  this	  cell	  suspension	  using	  immunomagnetic	  beads	  coated	  with	  sheep	  
anti-­‐rat	  IgG	  (Dynabeads	  M-­‐450)(13,	  35).	  The	  endothelial	  cell-­‐specific	  rat	  anti-­‐mouse	  
CD31	   antibody	   (Pharmingen)	   was	   bound	   to	   the	   beads	   as	   per	   manufacturer’s	  
instructions.	  After	  incubation	  of	  the	  cortical	  cell	  suspension	  with	  the	  magnetic	  beads	  
at	  4°C.	  CD31-­‐positive	  cells	  were	  captured	  with	  the	  aid	  of	  a	  magnet	  and	  washed.	  The	  
identity	   and	   purity	   of	   the	   CD31-­‐positive	   cells	   was	   initially	   verified	   by	  
immunocytochemistry	  for	  endothelial-­‐specific	  Factor	  VIII	  and	  Flk-­‐1	  (Pharmingen).	  
Assay	  for	  G6PD	  Activity	  
RCE	   lysates	  were	   used	   for	   the	   quantitative	   determination	   of	   G6PD	   activity	  
using	  a	  spectrophotometric	  assay	  from	  Oxis	  Research.	  In	  principle,	  the	  assay	  would	  
measure	   the	  production	  of	  NADPH	  by	  detecting	   the	   increase	   in	  absorbance	  at	  340	  
nm	   (from	   the	   reduction	   of	   NADP+).	   The	   minimal	   detectable	   limit	   was	   0.024	   mU	  
enzyme/cuvette.	  One	  unit	  of	  activity	  was	  defined	  as	  the	  quantity	  of	  enzyme	  needed	  
to	  produce	  1	  µM	  NADPH	  per	  minute	  (U/mg	  protein).	  
Assay	  for	  NADPH	  
NADPH	  levels	  in	  RCEs	  were	  determined	  spectrophotometrically	  based	  on	  the	  
absorbance	  of	   the	   reduced	  coenzyme	  at	  340	  nm,	  as	  described	  previously	   (61).	  An	  
initial	   reading	   was	   taken	   from	   lysates,	   representing	   the	   total	   amount	   of	   pyridine	  
nucleotides	   in	   the	   sample	   (A1=NADPH	   and	   NADH).	   A	   second	   sample	   (50	   μl)	  was	  
incubated	   with	   glutathione	   reductase	   (5	   U)	   for	   5	   minutes	   to	   convert	   all	   of	   the	  
NADPH	  to	  NADP+.	  Glutathione	  (0.005	  M)	  was	  added	  for	  an	  additional	  5	  minutes	  to	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initiate	   the	   reaction.	   Because	   the	   oxidized	   nucleotide	   NADP+	   does	   not	   have	  
absorbance	   at	   340	   nm,	   the	   absorbance	   that	   occurs	   strictly	   represents	   NADH	  
(A2=NADH).	  As	  such,	  subtraction	  of	  A2	  from	  A1	  equals	  the	  total	  amount	  of	  NADPH	  
(M).	  
Two-­Dimensional	  Gel	  Electrophoresis:	  	  
Sample	   Preparation:	   The	   RCEs	   obtained	   after	   immunomagnetic	   separation	  
were	  washed	  with	  cell	  wash	  buffer	  (10	  mM	  Tris	  pH	  8.0,	  5	  mM	  magnesium	  acetate)	  
followed	  by	  suspension	  in	  cell	  lysis	  buffer	  (30	  mM	  Tris,	  2	  M	  thiourea,	  7	  M	  urea,	  4%	  
CHAPS	  (w/v)	  at	  pH	  8.5).	  	  RCE	  lysates	  were	  prepared	  by	  brief	  sonication	  followed	  by	  
centrifugation	   at	   5000	   rpm	   for	   5	   min.	   Protein	   content	   was	   determined	   using	   2D	  
quant	  assay	  kit	  (GE	  Health	  Care	  Ltd).	  
Two-­‐dimensional	  gel	  electrophoresis	  was	  performed	  using	  Zoom	  IPG	  Runner	  
system	   (Invitrogen,	   Carlsbad,	   CA).	   Briefly	   RCE	   lysates	   (equivalent	   to	   50	   µg	   of	  
protein)	   were	   solubilized	   in	   rehydration	   buffer	   (100	   mM	   DTT,	   Zoom	   carrier	  
ampholytes	  0.5%	  and	  a	  trace	  of	  bromophenol	  blue)	  to	  a	  total	  of	  140	  µl	  and	  loaded	  
on	   Zoom	   Narrow	   range	   strips	   (6.1	   -­‐	   7.1).	   	   After	   1.5	   hr	   rehydration,	   strips	   were	  
loaded	   onto	   mini-­‐cell	   chamber	   of	   the	   Zoom	   IPG	   runner.	   Isoelectric	   focusing	   was	  
carried	  out	  using	  voltage	  ramp	  protocol	  (175	  V	  for	  15	  min,	  175-­‐2000	  V	  ramp	  for	  45	  
min	  and	  2000	  V	  for	  120	  min)	  followed	  by	  equilibration	  by	  reduction	  (using	  Nupage	  
sample	   reducing	   agent)	   and	   alkylation	   (using	   125	  mM	   Iodoacetamide)	   in	   Nupage	  
sample	  buffer.	  Equilibrated	  strips	  were	  loaded	  into	  Nupage	  4-­‐12%	  Bis-­‐Tris	  gels	  and	  
electrophoresis	  was	  performed	  for	  ~1	  hr	  at	  200	  V.	  	  Focused	  and	  separated	  proteins	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were	   transferred	   onto	   nitrocellulose	  membrane	   followed	   by	   blocking	   (5%	  Nonfat	  
dry	   milk	   (NFDM)	   in	   0.1%	   Tween	   in	   PBS),	   overnight	   incubation	   with	   primary	  
antibody	  to	  G6PD	  (Bethyl	  research	  labs)	  (1:2500	  in	  5%	  NFDM	  in	  0.1%	  Tween/PBS),	  
1	  hr	  incubation	  with	  Protein	  A	  conjugated	  HRP	  (Amersham	  Biosciences)	  (1:2500	  in	  
5%	   NFDM	   in	   0.1%	   Tween/PBS).	   Blots	   were	   developed	   using	   ECL	   advance	  
(Amersham	  Biosciences)	   and	   chemiluminiscence	  was	  visualized	  and	  quantified	  by	  
using	  G-­‐Box	  (Syngene	  Ltd.)	  
	  
RESULTS	  
Animal	  Characteristics	  (Table	  1):	  
	  Compared	   to	   non-­‐diabetic	   groups,	   diabetic	   mice	   had	   significantly	   higher	   blood	  
glucose	   levels	   with	   concomitant	   siginificant	   reductions	   in	   serum	   C-­‐peptide	   levels	  
and	   elevations	   in	   urinary	   albumin	   excretion	   with	   no	   change	   in	   body	   weight.	   C-­‐
peptide	   administration	   did	   not	   show	   any	   siginificant	   effect	   on	   body	   weight	   and	  
blood	   glucose	   in	   diabetic	   mice	   with	   significant	   improvement	   in	   diabetes-­‐induced	  
reductions	  in	  ACR.	  
Renal	  Peritubular	  Capillary	  Perfusion	  :	  	  
As	  depicted	  in	  Figure.	  1,	  in	  control	  and	  diabetic	  mice	  treated	  with	  C-­‐peptide,	  
majority	  of	  the	  renal	  peritubular	  capillaries	  were	  continuously	  perfused.	  Compared	  
to	  non-­‐diabetic	  controls	  	  the	  number	  of	  continuously	  perfused	  renal	  capillaries	  was	  
significantly	  lower	  in	  diabetic	  mice	  whereas	  the	  number	  of	  intermittently	  and	  non-­‐
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perfused	   capillaries	   was	   significantly	   higher	   .	   C-­‐peptide	   treatment	   normalized	  
perfusion	  of	  peritubular	  capillaries.	  	  
NADPH	  Bioavailabilty:	  	  
We	  determined	  whether	  RCEs	   from	   type	  1	  diabetic	  mice	   exhibit	   decreased	  
NADPH	   levels.	   As	   shown	   in	   Figure	   2,	   	   RCEs	   isolated	   from	   diabetic	   mice	   have	  
significantly	   reduced	   NADPH	   levels	   compared	   to	   non-­‐diabetic	   RCEs.	   C-­‐peptide	  
treatment	   restored	   the	   NADPH	   to	   more	   than	   control	   levels.	   Notably,	   there	   was	  
significant	  elevation	  in	  endothelial	  NAPDH	  with	  C-­‐peptide.	  	  
G6PD	  activity:	  	  	  
Studies	  were	  performed	  to	  determine	  the	  G6PD	  activity	  in	  all	  the	  groups.	  As	  
shown	   in	   Figure	   3,	   G6PD	   activity	   was	   significantly	   reduced	   in	   diabetic	   RCEs	  
compared	   to	   their	   non-­‐diabetic	   counterparts.	   C-­‐peptide	   treatment	   augmented	   the	  
G6PD	  activity	  in	  RCEs	  of	  diabetic	  mice.	  	  
G6PD	  Post-­translational	  Modifications:	  	  	  
We	  examined	  the	  effect	  of	  C-­‐peptide	  treatment	  on	  phosphorylation	  status	  of	  
G6PD	  in	  type	  I	  diabetic	  mouse	  RCEs.	  The	  Figure	  4	  depicts	  that	  type	  I	  diabetes	  caused	  
PTMs	   of	   G6PD.	   RCEs	   isolated	   from	   type	   I	   diabetic	   treated	   with	   C-­‐peptide,	   have	  
shown	  reductions	  in	  number	  of	  trailing	  spots	  as	  well	  as	  decrease	  in	  spot	  intensity,	  
suggesting	  a	  decrease	  in	  PTMs	  of	  G6PD.	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DISCUSSION:	  
Many	   investigators	   have	   challenged	   the	   notion	   that	   C-­‐peptide	   is	  
physiologically	   inert	   (25,	   26).	   Both	   short	   and	   long	   term	   infusions	   of	   C-­‐peptide	   in	  
type	  I	  diabetic	  patients	  and	  experimental	  animals	  have	  proven	  beneficial	  not	  only	  in	  
terms	   of	   diabetes-­‐induced	   functional	   changes	   (i.e.,	   improved	   glomerular	   filtration	  
rate	   and	   decreased	   urinary	   albumin	   excretion	   (11,	   18,	   21-­‐24,	   46-­‐48)	   but	   also	   on	  
structural	   changes	   i.e.,	   glomerular	   hypertrophy	   and	   mesangial	   matrix	   expansion	  
(34).	   Since	   there	   has	   been	   a	   shift	   in	   focus	   from	   the	   glomerular	   to	   the	   tubular	  
segment	  during	   the	  progression	  of	  diabetic	  nephropathy,	   tubulointerestitial	   injury	  
has	  been	  broadly	  recognized	  as	  the	  final	  common	  pathway	  for	  kidney	  failure	  (10,	  37,	  
38).	   This	   injury	   is	   extensively	   associated	   with	   distortion	   and	   loss	   of	   peritubular	  
capillaries(6,	   9,	   33).	   Although	   numerous	   reports	   suggest	   that	   C-­‐peptide	   prevents	  
diabetes-­‐induced	  changes	  in	  vascular	  perfusion	  in	  peripheral	  vascular	  beds	  (11,	  24),	  
opposing	  or	  no	  effects	  have	  been	  reported	   in	   renal	  and	  retinal	  vessels	   (4,	  27,	  55).	  
Our	   results	   clearly	   indicate	   that	   C-­‐peptide	   improves	   peritubular	   perfusion	   in	   the	  
kidney	  cortices	  of	   type	   I	  diabetic	  mice.	  Yet,	  mechanisms	  underlying	   this	  biological	  
effect	  are	  not	  fully	  understood.	  
The	  role	  of	  the	  endothelium	  in	  micro-­‐vascular	  blood	  flow	  regulation	  has	  been	  
extensively	   investigated.	   Endothelial	   cells	   not	   only	   serve	   as	   a	   barrier	   between	  
circulating	  red	  blood	  cells	  and	  vascular	  smooth	  muscle	  cells	  but	  also	  play	  a	  central	  
role	  in	  maintaining	  vascular	  tone	  and	  remodeling.	  Therefore,	  it	  is	  not	  surprising	  that	  
early	  pathological	  changes	  induced	  by	  hyperglycemia	  are	  first	  evident	  in	  endothelial	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cells.	   	   It	   is	   commonly	   accepted	   that	   the	   imbalance	   between	   oxidants	   and	  
antioxidants	   caused	   by	   hyperglycemia	   leads	   to	   the	   pathogenesis	   of	  microvascular	  
complications	   (7,	   39).	   Disturbance	   in	   antioxidant	   status	   within	   endothelial	   cells	  
causes	   the	   redox	   imbalance	   (16).	   Importantly,	   NADPH	   is	   an	   essential	   cofactor	   for	  
the	   proper	   function	   of	   many	   antioxidative	   enzymes	   like	   GPx,	   glutathione-­‐s-­‐
transferase,	   CAT	   (56)	   as	   well	   as	   the	   vasoprotective	   systems	   involving	  	  
hemeoxygenase	  and	  NOS.	  Diabetes	  results	  in	  a	  net	  depletion	  of	  NADPH	  mainly	  due	  
to	   the	   increased	   flux	   through	   polyol	   pathway	   (17,	   42)	   in	   addition	   to	   increased	  
production	   of	   reactive	   oxygen	   species	   through	   NOX	   (5,	   8).	   Previous	   studies	   have	  
shown	  diabetes	  decreased	  NADPH	  levels	  in	  rat	  kidney	  cortices	  and	  in	  bovine	  aortic	  
endothelial	  cells	   (3,	  57,	  60).	   	  We	  have	  shown,	   for	   the	   first	   time,	   that	   there	   is	  a	  net	  
loss	  of	  NADPH	  in	  renal	  cortical	  endothelial	  cells	  of	   type	  I	  diabetic	  mice.	   	  C-­‐peptide	  
treatment	   restored	   the	   diabetic	  RCE	  NADPH	   to	  more	   than	   control	   levels.	  Notably,	  
there	   is	   significant	   elevation	   in	   endothelial	   NAPDH	   with	   C-­‐peptide.	   This	  
unanticipated	   rise	  may	   be	   a	   consequence	   of	   decline	   in	   NADPH	   consumption	   as	   a	  
result	  of	   reduced	  oxidant	   stress	  and/or	   increased	   synthesis	  due	   to	  elevated	  G6PD	  
activity.	  These	  results	  suggest	  that	  type	  I	  DM	  leads	  to	  a	  loss	  in	  endothelial	  NADPH	  in	  
mouse	  kidney	  cortex	  and	  provide	  the	  first	  indication	  that	  treatment	  of	  diabetic	  mice	  
with	  C-­‐peptide	  enhances	  endothelial	  NADPH.	  This	  suggests	  that	  loss	  of	  NADPH	  may	  
be	   an	   important	   factor	   by	   which	   endothelial	   dysfunction,	   and	   the	   consequent	  
impairment	  in	  vasoprotection,	  might	  occur.	  	  
Our	  results	  also	  demonstrate	   that	  C-­‐peptide	  may	  confer	  antioxidant	  benefit	  
by	   preventing	   the	   loss	   of	   NADPH	   during	   type	   I	   DM.	   Notably,	   with	   C-­‐peptide	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treatment,	  there	  is	  a	  significant	  increase	  in	  diabetic	  endothelial	  NADPH	  above	  non-­‐
diabetic	  levels.	  This	  interesting	  and	  unexpected	  finding	  demonstrates	  that	  C-­‐peptide	  
can	   be	   acting	   by	   enhancing	   the	   synthesis	   of	   NADPH	   and/or	   decreasing	   its	  
consumption.	  To	  explore	  the	  first	  possibility	  we	  examined	  the	  effect	  of	  C-­‐peptide	  on	  
the	  systems	  that	  synthesize	  NADPH,	  mainly	  G6PD.	  	  
G6PD	   is	   a	   critical	   participant	   antioxidant	   protection	   because	   it	   produces	  
NADPH,	   the	   essential	   intracellular	   reductant	   (53).	   Reductions	   in	   NADPH	  
biovailabilty,	   attributed	   to	   PKA	  mediated	   phosphorylation	   of	   G6PD	   activity,	   	   have	  
been	  reported	  both	  in	  in	  vitro	  and	  in	  vivo	  diabetic	  settings	  (57-­‐59).	  Previously,	  G6PD	  
is	   thought	   to	   be	   minimally	   effected	   by	   post-­‐translational	   modifications,	   and	   was	  
only	   thought	   to	  be	  regulated	  by	  specific	  signal	   transduction	  molecules	  (40,	  49,	  53,	  
57,	   58).	   Moreover,	   among	   all	   the	   enzymes	   that	   produce	   NADPH,	   only	   G6PD	   is	  
activated	   during	   oxidative	   stress	   (12).	   It	   has	   also	   been	   shown	   that	   deficiency	   in	  
G6PD	   activity	   increases	   the	   susceptibility	   of	   endothelial	   cells	   to	   oxidant	   (29,	   30).	  
Recent	  work	  from	  Stanton’s	  group	  (57,	  59)	  demonstrated	  that,	  in	  rat	  kidney	  cortices	  
and	  bovine	  aortic	  endothelial	  cells,	  hyperglycemia	  causes	  inhibition	  of	  G6PD	  activity	  
(by	  activating	  PKA	  via	  c-­‐AMP)	  with	  concomitant	  decreases	  in	  G6PD	  expression	  and	  
NADPH.	  	  	  
Previously	   other	   labs	  have	  demonstrated	   that	   diabetes	   causes	   inhibition	  of	  
G6PD	   activity	   in	   rat	   kidney	   cortex	   and	   this	   effect	   being	   mediated	   by	   serine	  
phosphorylation	   of	   G6PD	   via	   PKA	   activation	   (57).	   Our	   findings	   showing	   the	  
decrease	  in	  G6PD	  activity	  in	  RCEs	  of	  type	  I	  diabetic	  mice	  reinforced	  the	  reports	  from	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Robert	  Stanton’s	  group.	  	  Using	  antibodies	  against	  phosphoserine,	  they	  also	  reported	  
that	  the	  inhibition	  of	  G6PD	  activity	  is	  by	  PTMs,	  i.e.	  via	  phosphorylation	  of	  key	  serine	  
residue/s	   on	   G6PD.	   Our	   attempt	   to	   identify	   phosphorylation	   of	   G6PD	   using	  
phosphoserine	  specific	  antibodies	  (data	  not	  shown)	  produced	  ambiguous	  results.	  In	  
spite	  of	  advances	  in	  detecting	  phospho-­‐proteins	  by	  western	  blotting	  using	  phospho-­‐
specific	   antibodies,	   phospho-­‐serine	   and	   phospho-­‐threonine	   antibodies	   lack	  
considerable	   specificity.	   Moreover	   our	   focus	   on	   mouse	   renal	   cortical	   endothelial	  
cells,	   as	   opposed	   to	   Stanton	   et	   al.,	   study	   in	   diabetic	   rat	   kidney	   cortex,	   may	   have	  
contributed	  to	  differences	  in	  identification	  of	  G6PD	  phosphorylation	  using	  phospho-­‐
serine	  specific	  antibodies.	  Another	  recent	  study	  by	  Pan	  et	  al.,(40)	  demonstrated	  c-­‐
Src	  mediated	   tyrosine	   phosphorylation	   of	   G6PD	   in	   bovine	   aortic	   endothelial	   cells.	  
These	  seemingly	  contradictory	  results	  highlight	  the	  existence	  of	  a	  post-­‐translational	  
mechanism	   regulating	   G6PD	   at	   the	   tissue	   level,	   countering	   the	   popular	   notion	   of	  
G6PD	   as	   a	   “house-­‐keeping”	   enzyme	   (32,	   41).	   Hence	   further	  work	   is	  warranted	   to	  
delineate	   mechanisms	   by	   which	   G6PD	   is	   regulated	   under	   normal	   as	   well	   as	  
pathophysiological	  conditions.	  	  	  
Our	  work	  resorted	  to	  more	  sophisticated	  detection	  technique	  for	  pinpointing	  
post-­‐translational	   modifications,	   using	   two-­‐dimensional	   gel	   electrophoresis.	   Our	  
2D-­‐gel	  electrophoresis	  data	   indicates	   that	  G6PD	   is	  post-­‐translationally	  modified	   in	  
diabetic	   RCEs.	   Unique	   resolving	   power	   of	   2D-­‐gel	   electrophoresis	   allows	   for	  
separation	  of	  different	  modified	  forms	  of	  the	  same	  protein	  into	  distinct	  spots	  on	  the	  
gel	   (2).	   Heterogeneous	   phosphorylation	   of	   a	   protein	   gives	   a	   series	   of	   spots	   with	  
same	   molecular	   weight	   but	   different	   pI	   values	   (44).	   The	   shift	   of	   G6PD	   immuno-­‐
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reactive	  spots	  towards	  cathodic	  end	  denotes	  a	  change	  of	  the	  pI	  towards	  more	  acidic	  
values	   and	  may	   be	   an	   indication	   of	   the	   predominant	   PTM	   i.e.	   phosphorylation.	   In	  
addition	   to	   2D-­‐gel	   electrophoresis,	   further	   studies	   using	   mass-­‐spectrometry	   are	  
needed	  for	  confirming	  the	  phosphorylation	  of	  G6PD.	  
Treatment	   with	   C-­‐peptide	   ameliorated	   the	   diabetes-­‐induced	   reductions	   in	  
G6PD	   activity	   by	   preventing	   its	   PTM,	   potentially	   phosphorylation,	   in	   RCEs.	  
Preventing	  the	  PTMs	  of	  G6PD	  thereby	  enhancing	  the	  synthesis	  of	  NADPH	  may	  be	  a	  
major	   mechanism	   by	   which	   C-­‐peptide	   improves	   endogenous	   vasoprotection.	   The	  
exact	  intracellular	  mechanism	  underlying	  such	  an	  event	  needs	  to	  be	  investigated.	  In	  
fact,	  C-­‐peptide	  has	  been	  shown	  to	  interact	  (20)	  and	  attenuate	  the	  activity	  of	  protein	  
tyrosine	   phosphatase	   (31).	   Similar	   interactions	   with	   other	   phosphatases,	  
specifically	   serine/threonine	   phosphatases,	  may	   be	   occurring	   physiologically.	   One	  
such	  Ser/Thr	  phosphatases	   is	  protein	  phosphatase	  2A(PP2A)	  and	  has	  been	  widely	  
implicated	  in	  regulating	  the	  activity	  of	  several	  protein	  kinases.	  Specifically,	  PP2A	  has	  
been	  shown	  to	  dictate	  the	  functional	  status	  of	  the	  calcium	  channel	  protein	  in	  β-­‐cell	  
by	   fine-­‐tuning	   the	   balance	   between	   protein	   kinase	   A	   mediated	   phosphorylation	  
(thereby	  cAMP	  activation)	  and	  serine/threonine	  dephosphorylation	  (28).	  The	  exact	  
role	   of	   C-­‐peptide	   in	   modulating	   PP2A	   mediated	   dephosphorylation,	   and	   possibly	  
protein	  kinase	  A	  mediated	  phosphorylation,	  needs	  to	  be	  examined	  and	  is	  beyond	  the	  
scope	  of	  this	  paper.	  
In	   conclusion,	   C-­‐peptide	   has	   been	   shown	   to	   improve	   anti-­‐oxidant	   status	   of	  
the	  diabetic	  renal	  cortical	  endothelial	  cells	  by	  preventing	  the	  PTMs	  of	  anti-­‐oxidative	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enzyme	   G6PD,	   and	   thereby	   enhancing	   the	   synthesis	   of	   NADPH.	   This	   anti-­‐oxidant	  
benefit	   can	   complement	   the	   repertoire	   of	   other	   beneficial	   effects	   reported	   for	   C-­‐
peptide.	   This	   study	   adds	   more	   substantial	   evidence	   to	   include	   C-­‐peptide	   in	   the	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FIGURE	  LEGENDS:	  
Table	  1:	  Body	  weight,	  fasting	  blood	  glucose,	  serum	  C-­‐peptide,	  and	  urinary	  Albumin	  
Creatinine	   Ratio	   (ACR)	   levels	   of	   Non-­‐Diabetic,	   Diabetic,	   and	   Non-­‐Diabetic	   +	   C-­‐
peptide	  mice	  5	  weeks	  after	  STZ	  injections	  are	  shown	  in	  Table	  1.	  
Figure	  1:	  Perfusion	  of	  peritubular	  capillaries	  of	   type	  I	  diabetic	  mice	  was	   improved	  
by	   C-­‐peptide.	   Data	   were	   expressed	   as	   Mean±SEM.	   (n=5	   in	   each	   group).	   *,	  
significantly	   less	   than	   Non-­‐diabetic	   +	   C-­‐peptide	   (p<0.03);	   †,	   significantly	   greater	  
than	  Non-­‐Diabetic	  +	  C-­‐peptide	  (p<0.02).	  
Figure	  2:	  Reductions	  in	  NADPH	  of	  RCEs	  from	  STZ-­‐induced	  type	  I	  diabetic	  mice	  were	  
reversed	   by	   24	   h	   of	   C-­‐peptide	   treatment.	   Data	   expressed	   as	   mean±SEM	   (n=5	   in	  
each).	  *,	  significantly	   less	   than	  all	   groups	   (p<0.05);	  †,	   significant;y	  greater	   than	  all	  
groups	  (p<0.02).	  
Figure	  3:	  RCEs	  from	  type	  I	  diabetic	  mice	  have	  lower	  G6PD	  activity	  than	  non-­‐diabetic	  
mice.	  Treatment	  with	  C-­‐peptide	  restores	   its	  activity.	  Data	  expressed	  as	  mean±SEM	  
(n=5).	  *p<0.05	  less	  than	  all	  groups.	  
Figure	   4:	   	   Representative	  western	   blot	   images	   of	   2D	   gels	   probed	   for	   G6PD	   using	  
anti-­‐	   G6PD	   antibody	   as	   described	   in	   methods	   section.	   Notice	   the	   presence	   and	  
intensity	   of	   more	   G6PD-­‐immunoreactive	   spots	   in	   chemilumiscent	   G6PD	   signal	  
obtained	  from	  RCE	  cell	  lysate	  of	  type	  I	  diabetic	  mice,	  compared	  to	  non-­‐diabetic	  and	  
diabetic	  mice	  treated	  with	  C-­‐peptide	  for	  24	  h.	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ABSTRACT	  
Hyperglycemia-­‐mediated	   microvascular	   damage	   has	   been	   proposed	   to	  
originate	  from	  excessive	  generation	  of	  mitochondrial	  superoxide	  in	  endothelial	  cells	  
and	   is	   the	   suggested	   mechanism	   by	   which	   the	   pathogenesis	   of	   diabetes-­‐induced	  
renal	   damage	   occurs.	   C-­‐peptide	   has	   been	   shown	   to	   ameliorate	   diabetes-­‐induced	  
renal	   impairment.	   Yet,	   the	  mechanisms	   underlying	   this	   protective	   benefit	   remain	  
unclear.	   The	   objective	   of	   this	   study	   was	   to	   determine	   whether	   C-­‐peptide	   affords	  
protection	   to	   renal	   microvascular	   endothelial	   cell	   mitochondria	   during	  
hyperglycemia.	  Conditionally	  immortalized	  murine	  renal	  microvascular	  endothelial	  
cells	   (MEC)	  were	   exposed	   to	   low	   (5.5	  mM)	   or	   high	   glucose	   (25	  mM)	  media	  with	  
either	  C-­‐peptide	  (6.6	  nM)	  or	  its	  scrambled	  sequence	  control	  peptide	  for	  24-­‐	  or	  48-­‐
hours.	   Respiratory	   control	   ratio,	   a	   measure	   of	   mitochondrial	   electrochemical	  
coupling,	  was	  significantly	  higher	  in	  high	  glucose	  renal	  MECs	  treated	  with	  C-­‐peptide	  
than	  those	  of	  high	  glucose	  alone.	  C-­‐peptide	  also	  restored	  high	  glucose-­‐induced	  renal	  
MEC	   mitochondrial	   membrane	   potential	   changes	   back	   to	   their	   basal	   low	   glucose	  
state.	   Moreover,	   C-­‐peptide	   prevented	   the	   excessive	   mitochondrial	   superoxide	  
generation	  and	  concomitant	  reductions	  in	  mitochondrial	  complex	  I	  activity	  that	  are	  
mediated	  by	   the	  exposure	  of	   the	   renal	  MECs	   to	  high	  glucose.	  Together,	   these	  data	  
demonstrate	   that	   C-­‐peptide	   protects	   against	   high	   glucose-­‐induced	   generation	   of	  
mitochondrial	   superoxide	   in	   renal	   MECs	   via	   restoration	   of	   basal	   mitochondrial	  
function.	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INTRODUCTION:	  	  
Diabetic	  renal	  impairment,	  a	  serious	  and	  frequent	  complication	  of	  both	  type	  I	  
and	  type	  II	  diabetes	  (32,	  42),	  is	  a	  leading	  cause	  of	  chronic	  renal	  disease	  (34,	  35).	  The	  
pathobiology	  of	  diabetic	   renal	   impairment	   is	   founded	   in	   the	  microcirculation.	   It	   is	  
well	   established	   that	   the	   chronic	   hyperglycemia	   associated	  with	   diabetes	   directly	  
damages	   the	   microcirculation,	   leading	   to	   small	   vessel	   dysfunction	   (33).	   More	  
specifically,	  hyperglycemia	  has	  been	  shown	  to	  selectively	  damage	  endothelial	  cells	  
because	   their	   glucose	   transport	   rate	   is	   not	   diminished,	   leading	   to	   an	   excessive	  
accumulation	   of	   glucose	   within	   them	   (4,	   5).	   As	   a	   consequence,	   the	   elevated	  
intracellular	   glucose	   that	   ensues	   leads	   to	   increased	   generation	   of	   mitochondrial	  
superoxide,	   proposed	   as	   a	   central	   player	   in	   the	   pathogenesis	   of	   all	   diabetic	  
complications	   (4).	   Several	   reports	   contend	   that	   the	   diabetic	   state	   increases	  
mitochondrial	  superoxide	  generation	  both	  in	  in	  vitro	  high	  glucose	  conditions	  (8,	  10,	  
14,	   44),	   as	  well	   as	   in	   diabetic	   animal	  models	   (6,	   17).	  Furthermore,	   this	   excessive	  
superoxide	  generation	  leads	  to	  the	  subsequent	  accumulation	  of	  other	  free	  radicals,	  
thereby	   imparting	   diffuse	   damage	   to	   proteins	   and	   mitochondrial	   DNA,	   and	  
ultimately	  leading	  to	  mitochondrial	  dysfunction	  (43,	  51).	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Complex	   I	   is	   the	   first	   member	   of	   the	   mitochondrial	   membrane-­‐bound	  
electron	  transport	  chain	  and	  its	  substrates/co-­‐factors	  have	  the	  lowest	  potentials	  in	  
the	   chain	   (9).	   	   Inhibition	   of	   the	   electron	   transport	   chain	   during	   pathological	  
conditions	   and/or	   the	   build-­‐up	   of	   NADH	   (and	   subsequent	   elevation	   in	   the	  
NADH/NAD+	   ratio)	   has	   been	   shown	   to	   contribute	   significantly	   to	   superoxide	  
generation	   by	   complex	   I	   (29).	   Under	   physiological	   conditions,	   mitochondrial	  
superoxide	  originates	  predominantly	   from	  complex	   I	  and	  complex	   III	   (12,	  13),	  yet	  
growing	   evidence	   suggests	   that	   complex	   I	   alone	   is	   responsible	   for	   the	  majority	   of	  
the	  superoxide	  produced	  within	  intact	  mammalian	  mitochondria	  (39).	  	  	  
C-­‐peptide,	  a	  by-­‐product	  of	  insulin	  biosynthesis	  (52),	  had	  long	  been	  thought	  to	  
be	   physiologically	   inert.	   However,	   several	   studies	   have	   reported	   the	   beneficial	  
effects	  of	  exogenous	  C-­‐peptide	  on	  renal	  function	  in	  type	  I	  diabetes	  (22,	  23).	  In	  fact,	  
short-­‐term	   infusions	   of	   C-­‐peptide	   have	   been	   shown	   to	   improve	   glomerular	  
hyperfiltration	   and	   reduce	   albuminuria	   (19,	   40,	   41),	   whereas	   long-­‐term	  
administration	   improved	   overall	   renal	   function	   in	   diabetic	   patients	   (46,	   47).	   	   Not	  
surprisingly,	  many	  in	  vitro	  studies	  have	  been	  aimed	  at	  delineating	  the	  molecular	  and	  
cellular	  basis	  for	  the	  observed	  actions	  of	  C-­‐peptide	  (1,	  49,	  56).	  Despite	  these	  reports,	  
the	   exact	   nature	   of	   its	   bioactivity	   and	   physiologic	   impact	   on	   the	   renal	  
microcirculation	   during	   diabetes	   needs	   further	   clarification.	   Given	   that	   C-­‐peptide,	  
administered	   in	   the	   absence	   of	   insulin,	   provides	   benefits	   to	   general	   renal	   and	  
microvascular	  function	  during	  type	  I	  diabetes,	  our	  central	  hypothesis	  follows	  that	  C-­‐
peptide	   independently	   affords	   protection	   to	   high-­‐glucose	   exposed	   renal	   MECs	   by	  
diminishing	   mitochondrial	   superoxide	   generation	   via	   restoration	   of	   basal	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mitochondrial	   complex	   I	   activity.	   To	   examine	   this,	   we	   evaluated	   the	   effects	   of	   C-­‐
peptide	   treatment	   on	   renal	   MEC	   mitochondrial	   respiration,	   membrane	   potential	  
changes,	   superoxide	   production	   and	   complex	   activity	   while	   exposed	   to	   a	   high	  
glucose	  environment.	  	  
MATERIALS	  and	  METHODS:	  	  
Biosynthetic	   C-­‐peptide	   (NH2-­‐EVEDPQVAQLELGGGPGAGDLQTLALQVARQ-­‐COOH)	   and	  
its	   scrambled	   sequence	   peptide	   control	   (NH2-­‐
LGGGPQVGTLLAQVEQEAEDGLDVRLAQQPA-­‐	  COOH),	  both	  with	  a	  purity	  greater	   than	  
90%	   (HPLC),	   was	   synthesized	   by	   PrimmBiotech,	   Inc.	   (Cambridge,	   MA).	   The	  
scrambled	   sequence	   peptide	   control	   has	   the	   same	   composition	   as	   the	   native	   C-­‐
peptide,	  but	  with	  the	  amino	  acid	  residues	  in	  random	  order.	  Cell	  culture	  media	  was	  
supplied	  by	  Gibco	  (Invitrogen,	  Carlsbad,	  CA).	  All	  other	  chemicals	  were	   from	  Sigma	  
Chemical	   (St.	   Louis,	   MO),	   with	   the	   exception	   of	   MitoSOX	   Red	   [3,8-­‐
phenanthradinediamine,	   5-­‐(6’	   triphenylphosphoniumhexyl)-­‐5,6	   dihydro-­‐6-­‐phenyl],	  
which	  was	  purchased	  from	  Molecular	  Probes	  (Invitrogen,	  Carlsbad,	  CA).	  
Cell	   Culture:	   Conditionally	   immortalized	   MECs	   were	   obtained	   from	   Dr.	   Isaiah	   J.	  
Fidler	   (MD	   Anderson	   Cancer	   Center).	   Cells	   were	   derived	   from	   the	   kidneys	   of	  
transgenic	  mice	  harboring	  the	  temperature-­‐sensitive	  SV-­‐40	  large	  T	  antigen,	  referred	  
to	  as	  H-­2Kb-­tsA58	  mice(30).	  Cells	  were	  either	  grown	  in	  a	  T75	  flask	  or	  100	  mm	  plates	  
in	  a	  humidified	  incubator	  gassed	  with	  5%	  CO2	  and	  95	  %	  O2	  in	  DMEM	  containing	  5%	  
fetal	  bovine	  serum	  and	  supplemented	  with	  non-­‐essential	  amino	  acids,	  penicillin	  and	  
streptomycin.	  Cells	  were	  used	  between	  passages	  3-­‐10	  and	  renal	  MECs	  were	  grown	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and	   maintained	   at	   33°C.	   Once	   the	   cells	   reached	   50-­‐60%	   confluence,	   they	   were	  
shifted	   to	   37°C	   to	   permit	   activation	   of	   the	   temperature	   sensitive	   antigen	   and	  
retention	   of	   the	   original	   endothelial	   cell	   phenotype.	   After	   48-­‐hours	   at	   37°C,	   cells	  
were	  serum	  deprived	  for	  24-­‐hours	  to	  allow	  for	  synchronization	  of	  cell	  cycles	  prior	  
to	   treatments.	   Cells	   were	   subsequently	   divided	   into	   the	   following	   groups	   and	  
medium	  was	  supplemented	  with	   the	   following	  agents:	  A)	   low-­‐glucose	   -­‐	  5.5	  mM	  D-­‐
glucose	  (LG);	  B)	  low-­‐glucose	  with	  C-­‐peptide	  -­‐	  6.6	  nM	  (LG	  +	  C-­‐pep);	  C)	  high-­‐glucose	  -­‐	  
25	  mM	  D	  –glucose	   (HG);	  D)	  high-­‐glucose	  with	  C-­‐peptide	  –	  6.6nM	  (HG	  +	  C-­‐pep);	  E)	  
Low-­‐glucose	  with	   scrambled	   peptide,	   6.6	   nM	   and	   F)	   high-­‐glucose	  with	   scrambled	  
peptide	   for	   either	   24-­‐	   or	   48-­‐hours.	   Low	   glucose	   cells	  were	   also	   treated	  with	   19.5	  
mM	  raffinose	  to	  serve	  as	  an	  osmotic	  control.	  We	  chose	  to	  treat	  cells	  with	  6.6	  nM	  of	  
C-­‐peptide	  because	  that	  is	  the	  physiological	  postprandial	  concentration	  observed	  in	  
humans	   (18)	   and	   this	   concentration	   is	   comparable	   to	   the	   previous	   literature	  
involving	  in	  vitro	  C-­‐peptide	  studies	  (54).	  For	  the	  sake	  of	  clarity	  and	  brevity,	  we	  did	  
not	   present	   data	   on	   the	   high-­‐glucose/low-­‐glucose	   +	   scrambled	   peptide	   control	  
groups	  since	  they	  did	  not	  differ	  from	  their	  respective	  non-­‐treatment	  conditions	  for	  
any	   of	   the	   parameters	   assessed.	   Renal	   MECs	   treated	   with	   high-­‐glucose	   did	   not	  
exhibit	  any	  changes	  in	  cell	  viability	  (as	  assessed	  by	  trypan	  blue	  exclusion),	  nor	  did	  
they	  demonstrate	  changes	  in	  their	  characteristic	  cobblestone	  morphology	  (data	  not	  
shown).	  	  
Mitochondrial	   Respiration	   Assays:	   Mitochondrial	   respiration	   (a	   marker	   for	  
mitochondrial	   electrochemical	   coupling)	   was	   measured	   by	   oxygen	   consumption	  
rates	   in	   digitonin-­‐permeabilized	   renal	   MECs	   using	   a	   Clark-­‐type	   oxygen	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electrode(43).	   Cells	   were	   trypsinized,	   centrifuged	   at	   1000	   g	   for	   10	   min	   and	  
resuspended	   in	   10	  ml	   of	   respiration	   buffer	   containing	   (in	  mmol/l)	   20	   HEPES,	   10	  
MgCl2,	  and	  250	  sucrose	  with	  100-­‐150	  µg	  of	  digitonin.	  Cells	  were	  then	  incubated	  on	  
ice	   for	   10-­‐minutes,	   washed	   three	   times	   with	   respiration	   buffer	   containing	   0.5%	  
bovine	  serum	  albumin,	   followed	  by	  resuspension	  at	  5-­‐8	  million	  cells	  per	  1.5	  ml	  of	  
respiration	  buffer	  into	  a	  Gilson	  chamber	  (Gilson;	  Middleton,	  WI).	  The	  chamber	  was	  
maintained	  at	  30°C	  and	  attached	  to	  YSI	  5300	  Biological	  Oxygen	  Monitor	  (YSI;	  Yellow	  
Springs,	  OH)(7).	  After	  an	  initial	  period	  of	  stabilization,	  the	  substrates	  glutamate	  and	  
malate	   (100mM	   of	   each)	   were	   added	   followed	   by	   ADP.	   Protein	   content	   was	  
determined	  using	  the	  Bradford	  method	  (BCA	  Protein	  assay,	  Pierce),	  and	  values	  were	  
expressed	   as	   nmol	   O2	   consumed/min/mg	   protein.	   State	   3	   respiration	   is	   an	   active	  
state	  of	  maximal	  respiration	  with	  ADP	  and	  substrates,	  while	  state	  4	  respiration	  is	  a	  
slow	   respiration	   state	  with	   low	  ADP	   and	   substrates	   (11).	   The	   respiratory	   control	  
ratio	  (RCR),	  a	  ratio	  of	  the	  state	  3	  to	  state	  4	  respiration	  rates,	  is	  a	  measure	  coupling	  
the	   transfer	   of	   electrons	   driving	   oxygen	   consumption	   and	   proton	   transfer	   driving	  
ATP	  synthesis.	  
Mitochondrial	   Membrane	   Potential	   Measurements:	   Assessments	   of	  
mitochondrial	   membrane	   potential	   (ΔΨm)	   were	   performed	   using	   a	   previously	  
described	  method	  (38),	  which	  employs	  the	  J-­‐aggregate	   lipophilic	  cationic	  dye,	   JC-­‐1	  
(Molecular	  Probes;	  Eugene,	  OR).	  Briefly,	  renal	  MECs	  were	  incubated	  in	  the	  dark	  with	  
JC-­‐1	  (7.5	  µM,	  30	  min	  at	  37	  °C)	  following	  either	  the	  24-­‐	  or	  48-­‐hour	  treatments.	  After	  
incubation,	   renal	   MECs	   were	   measured	   for	   fluorescence	   emission	   at	   530	   nm	  
(monomer	  =	   green)	   and	  at	  590	  nm	   (J-­‐aggregates	  =	   red)	   in	   a	   F-­‐2500	  Fluorescence	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Spectrophotometer	  (Hitachi	  High	  Technologies	  America;	  Pleasanton,	  CA)	  equipped	  
with	   a	   cover	   slip	   holder	   and	   using	   an	   excitation	   wavelength	   of	   488	   nm.	   Relative	  
ΔΨm	  changes	  were	  calculated	  using	   the	  ratio	  of	   the	   J-­‐aggregate	   to	  monomer	  (590	  
nm/530	   nm).	   Values	   were	   expressed	   as	   fold	   increase	   in	   J-­‐aggregate/monomer	  
fluorescence	   over	   control	   cells.	   As	   a	   complement,	   cells	   were	   grown	   on	   six-­‐well	  
dishes	  and	  observed	  using	  an	  Eclipse	  800	  Fluorescence	  Microscope	  (Nikon;	  Melville,	  
NY)	  equipped	  with	  a	  dual	  filter	  for	  fluorescein	  and	  rhodamine.	  	  
Mitochondrial	   Superoxide	   Measurements:	   Mitochondrial	   superoxide	   was	  
measured	  using	   a	  previously	  described	   flow	   cytometry	  method	   (37).	  Briefly,	   after	  
the	   24-­‐	   or	   48-­‐hour	   treatments,	  MitoSOX	  Red	  was	   added	   to	   fresh	  media	   to	   a	   final	  
concentration	   of	   5	   µM	   according	   to	   manufacturer’s	   instructions.	   The	   renal	   MECs	  
were	   incubated	   with	   the	   MitoSOX	   for	   30-­‐minutes	   in	   the	   dark,	   washed	   two	   times	  
with	   PBS	   containing	   calcium	   and	  magnesium.	   Antimycin	   (100	   µM),	   a	   complex	   III	  
inhibitor,	  was	   used	   as	   a	   control.	   Flow	   cytometry	  measurements	  were	   carried	   out	  
using	   a	   FACScalibur	   (BD	   Biosciences;	   San	   Jose,	   CA).	   A	   laser	   at	   488	   nm	   excited	  
MitoSOX	  Red,	  and	  data	  was	  collected	  at	  forward	  and	  side	  scatter,	  582/42	  nm	  (FL2)	  
channels.	   Data	   were	   presented	   in	   the	   FL2	   channel.	   Cell	   debris,	   represented	   by	   a	  
distinct	  low	  forward	  scatter,	  was	  gated	  out	  of	  the	  analyses.	  	  
Mitochondrial	   Complex	   Activity	   Measurements:	   	   Mitochondrial	   complex	   I,	   III,	  
and	  IV	  activities	  were	  assessed	  using	  the	  previously	  described	  method	  of	  Trounce	  et	  
al.	  	  (53).	  Complex	  activities	  were	  expressed	  as	  nmol/min/mg	  protein.	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Western	  blotting:	  Cell	  supernatants	  were	  obtained	  from	  the	  renal	  MECs	  grown	  in	  
100	   mm	   plates	   and	   subjected	   to	   24-­‐hour	   treatments.	   While	   adherent,	   cells	   were	  
washed	  twice	  with	  ice-­‐cold	  PBS	  followed	  by	  treatment	  with	  ice-­‐cold	  1X	  RIPA	  Buffer	  
(20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  150	  mM	  NaCl,	  1	  mM	  Na2EDTA,	  1	  mM	  EGTA,	  1%	  NP-­‐40,	  
1%	   sodium	   deoxycholate,	   2.5	   mM	   sodium	   pyrophosphate,	   1	   mM	   beta-­‐
glycerophosphate,	   1	  mM	  Na3VO4,	   1	   µg/ml	   leupeptin)	   supplemented	  with	  protease	  
and	  phosphatase	  inhibitor	  cocktails,	  for	  5-­‐minutes	  on	  ice.	  Renal	  MECs	  were	  scraped	  
gently	   using	   a	   rubber	   policeman,	   collected	   into	   a	   1.5	   ml	   centrifuge	   tube	   and	  
sonicated	  briefly	  to	  ensure	  complete	  lysis	  of	  cells.	  The	  extract	  is	  then	  centrifuged	  for	  
10-­‐minutes	   at	   14,000	   g	   to	   obtain	   the	   supernatants.	   Protein	   concentration	   was	  
determined	   using	   Pierce	   BCA	   protein	   assay	   kit	   (Thermo	   Fisher	   Scientific	   Inc.,	  
Rockford,	  IL)	  
Cell	   supernatants	   (equivalent	   to	   40	   mg	   of	   protein)	   were	   separated	   on	   a	   4-­‐12%	  
Novex	  NuPAGE	  Bis-­‐Tris	  gels	  using	  Novex	  system	  (Invitrogen,	  Carlsbad,	  CA)	  and	  then	  
transferred	   on	   to	   nitrocellulose	   membrane.	   Membranes	   were	   then	   blotted	   for	  
Extracellular-­‐Signal	  Regulated	  Kinase	   (ERK)1/2	   (p44/p42	   [ERK1/2]	  137F5	  Rabbit	  
mAb),	   Phospho	   ERK1/2	   (p44/p42	   [ERK1/2]	   (Thr202/Tyr204)	   Rabbit	   mAb),	   p38	  
Mitogen-­‐Activated	   Protein	   Kinase	   (MAPK)	   mAb,	   and	   phospho	   p38	   MAPK	  
(Thr180/Tyr182)Rabbit	  mAb(	  Cell	  signaling,	  Danvers,	  MA),	  followed	  by	  incubation	  
with	   peroxidase	   conjugated	   anti-­‐rabbit	   secondary	   antibody.	   Membranes	   were	  
developed	   with	   ECL	   advance	   detection	   reagent	   (Amersham,	   GE	   Healthcare,	  
Piscataway,	  NJ)	   followed	  by	  detection	  of	   chemiluminiscent	   signal	   using	  G:Box,	  Gel	  
Imager	   (Syngene,	   Synoptics	   Ltd.,).	   Densitometric	   analysis	   was	   performed	   using	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Gene	   Tools	   (Syngene)	   software	   and	   data	   were	   calculated	   as	   arbritrary	   units.	  
Phosphorylated	  MAPK	  phosphorylations	  were	  normalized	  to	  total	  MAPK	  levels.	  
Statistical	   Analysis:	   Statistical	   siginificances	   were	   determined	   using	   standard	  
ANOVA	   procedures.	   If	   significance	   was	   found,	   the	   effects	   were	   tested	   further	   by	  
using	   the	   Student	  Newman-­‐Keuls	   post	   hoc	   comparison.	   A	   probability	   of	   0.05	  was	  
accepted	   as	   statistically	   significant,	   and	   the	   sample	   sizes	   for	   each	   experimental	  
group	   provided	   a	   statistical	   power	   of	   greater	   than	   80%.	   Data	   are	   expressed	   as	  
means	  ±	  SEM.	  
	  
RESULTS:	  	  
C-­peptide	  ameliorated	  defects	  in	  mitochondrial	  electrochemical	  coupling	  
during	  high	  glucose	  exposure	  of	  renal	  MECs.	  State	  3	  mitochondrial	  respiration	  is	  
the	  slope	  of	  measured	  oxygen	  consumption	  in	  the	  presence	  of	  glutamate-­‐malate	  and	  
ADP.	  State	  3	  respiration	  rates	  were	  significantly	  decreased	   in	  high	  glucose	  cells	  at	  
both	   24-­‐	   and	   48-­‐hours.	   C-­‐peptide	   treatment	   restored	   state	   3	   respiration	   to	   basal	  
levels	   (Figure	   1A;	   p<0.02).	   State	   4	   respiration	   is	   the	   slope	   of	   measured	   oxygen	  
consumption	  after	  ADP	  depletion.	  State	  4	  respiration	  was	  increased	  in	  high	  glucose	  
cells	   at	   both	   24-­‐	   and	   48-­‐hours	   while	   C-­‐peptide	   treatment	   restored	   state	   4	  
respiration	  (Figure	  1B).	  RCR,	  the	  ratio	  of	  state	  3-­‐to-­‐state	  4	  respiration,	  is	  a	  measure	  
coupling	  the	  transfer	  of	  electrons	  driving	  oxygen	  consumption	  and	  proton	  transfer	  
driving	   ATP	   synthesis.	   RCRs	   were	   significantly	   decreased	   in	   high	   glucose	   cells	   at	  
both	   24-­‐	   and	   48-­‐hours	   and	   were	   restored	   with	   C-­‐peptide	   (Figure	   1C;	   p<0.0001).	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These	  data	  demonstrate	  that	  C-­‐peptide	  abrogates	  mitochondrial	  respiratory	  defects	  
caused	  by	  high	  glucose.	  
C-­peptide	   restored	   the	   mitochondrial	   membrane	   potential	   (ΔΨm)	   of	  
renal	   MECs	   during	   high	   glucose	   exposure.	   Changes	   in	   ΔΨm	   were	   measured	   in	  
renal	   MECs	   using	   JC-­‐1	   staining.	   At	   24-­‐hours,	   high	   glucose	   exposure	   resulted	   in	  
significant	   hyperpolarization	   of	   the	  mitochondrial	  membrane	   (Figure	   2;	   p<0.009).	  
Subsequently,	   endothelial	  mitochondria	  were	  depolarized	  after	  48-­‐hour	   (Figure	  2;	  
p<0.002).	  Treatment	  with	  C-­‐peptide	  resulted	  in	  restoration	  of	  ΔΨm	  at	  both	  24-­‐	  and	  
48-­‐hours	  of	  exposure	  to	  a	  high	  glucose	  stress.	  
C-­peptide	  reduced	  the	  excessive	  mitochondrial	  superoxide	  levels	  observed	  
in	   high	   glucose	   exposed	   renal	   MECs.	   Using	   MitoSOX	   Red	   and	   measuring	  
fluorescence	   by	   flow	   cytometry,	   the	   exposure	   of	   renal	   MECs	   to	   high	   glucose	  
significantly	   elevated	  mitochondrial	   superoxide	   generation	   (Figure	   3b;	   p<0.0001)	  
compared	   to	   low	   glucose	   at	   both	   24-­‐	   and	   48-­‐hours.	   C-­‐peptide	   treatment	   restored	  
mitochondrial	  superoxide	  generation	  to	  basal	  levels	  at	  both	  time	  points.	  
C-­peptide	   improves	   mitochondrial	   complex	   I	   activity	   in	   high	   glucose	  
exposed	   renal	   MECs.	   Renal	   MECs	   exposed	   to	   high	   glucose	   exhibited	   significant	  
reductions	  in	  complex	  I	  activity	  at	  24-­‐	  and	  48-­‐hours	  (Figure	  4A;	  (p<0.002	  at	  24	  hr	  
and	  p<0.0009	  at	  48	  hr),	  with	  no	  change	  to	  complex	  III	  and	  IV	  (Figure	  4B	  and	  4C).	  C-­‐
peptide	  restored	  complex	  I	  activity	  back	  to	  levels	  observed	  with	  low	  glucose.	  
C-­peptide	   activates	   Extracellular	   Signal	   Regulated	   Kinase	   (ERK)	   1/2	   in	  
high	   glucose	   exposed	   renal	   MECs.	   C-­‐peptide	   treatment	   resulted	   in	   activation	   of	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ERK	  1/2	  (Fig	  4A;	  p<0.005)	   in	  high	  glucose	  exposed	  renal	  MECs,	  however	   failed	   to	  
induce	  phosphorylation	  of	  	  p38	  MAPK.	  
DISCUSSION:	  
Chronic	   hyperglycemia	   is	   the	   main	   trigger	   initiating	   diabetic	   renal	  
impairment.	  Although	  to	  varying	  degrees,	  chronic	  hyperglycemic	  injury	  affects	  all	  of	  
the	  cell	  types	  within	  the	  glomerular,	  vascular	  and	  tubulo-­‐interstitial	  compartments	  
of	   the	   kidney.	   	   	   However,	   the	   initial	   stages	   of	   diabetic	   renal	   impairment	   can	   be	  
ascribed	   to	   dysfunction	   of	   glomerular	   capillaries	   and	   barrier	   function,	   which	  
clinically	   manifest	   as	   hyperfiltration	   and	   microalbuminaria.	   The	   glomerulus	   is	  
composed	   of	   endothelial	   cells,	   podocytes	   and	  mesangial	   cells,	   all	   of	   which	   play	   a	  
crucial	   role	   in	   maintaining	   barrier	   function.	   Furthermore	   endothelial	   cells,	   both	  
from	   glomeruli	   and	   the	   tubulo-­‐interstitium,	   play	   an	   important	   role	   in	   the	   overt	  
hyperglycemic	  damage	  to	   the	  kidney	  due	  to	   the	  previously	  discussed	  deficiency	   in	  
glucose	  transport.	  The	  murine	  renal	  microvascular	  endothelial	  cells	  utilized	  in	  this	  
study	  are	  an	  ideal	  cell	  type	  to	  study	  the	  effects	  of	  high	  glucose-­‐induced	  deleterious	  
changes	  that	  ultimately	  lead	  to	  renal	  microvascular	  endothelial	  dysfunction.	  
This	  study	  demonstrates,	  for	  the	  first	  time,	  that	  C-­‐peptide	  confers	  protection	  
against	  hyperglycemia-­‐mediated	  mitochondrial	  dysfunction	  in	  endothelial	  cells.	  We	  
show	   that	   C-­‐peptide	   inhibits	   high	   glucose-­‐induced	   changes	   to	   mitochondrial	  
respiration,	   membrane	   potential,	   superoxide	   generation	   and	   complex	   I	   activity.	  
Several	   studies	   suggest	   that	   C-­‐peptide	   prevents	   diabetes-­‐induced	   renal	  
microvascular	  complications,	  and	  subsequently	  improves	  renal	  function	  (19,	  40,	  41,	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46,	  47).	  Although	  mitochondrial	  superoxide	  generation	  has	  been	  widely	  implicated	  
in	  the	  pathogenesis	  of	  diabetic	  microvascular	  complications	  (5,	  33),	  there	  is	  a	  dearth	  
of	  knowledge	  regarding	  the	  impact	  of	  C-­‐peptide	  on	  diabetes-­‐induced	  mitochondrial	  
dysfunction.	   This	   is	   the	   first	   investigation	   addressing	   whether	   the	   protection	  
rendered	  by	  C-­‐peptide	  during	  diabetes	  involves	  the	  mitochondria.	  	  
Our	   studies	   examining	   the	   effect	   of	   C-­‐peptide	   on	   hyperglycemia-­‐mediated	  
mitochondrial	   dysfunction	   suggest	   that	   C-­‐peptide	   improved	   mitochondrial	  
respiration	   in	   high	   glucose-­‐exposed	   renal	   MECs.	   Mitochondrial	   respiration	   is	   a	  
reflection	  of	   its	  capacity	  to	  synthesize	  ATP,	  which	  occurs	  by	  means	  of	   the	  electron	  
transport	  chain	  and	  oxidative	  phosphorylation.	  The	  process	  of	  electron	  transfer	  and	  
ATP	   generation	   are	   tightly	   coupled,	   with	   respiratory	   control	   ratio	   used	   as	   an	  
indicator	   of	   the	   extent	   of	   electrochemical	   coupling.	   Recent	   reports	   using	   the	  
mitochondria	   isolated	   from	   diabetic	   animals	   demonstrated	   compromised	  
mitochondrial	   respiration	   (6,	   17,	   50).	   Recently,	   Palmeira	   et	   al.	   (43),	   reported	  
impairment	   of	   mitochondrial	   respiration	   rates	   under	   similar	   high-­‐glucose	  
conditions	   in	   HepG2	   cells.	   	   Clearly,	   there	   is	   a	   need	   to	   delineate	   the	   mechanisms	  
underlying	   high	   glucose-­‐mediated	   damage	   to	   microvascular	   endothelial	   cells,	   the	  
main	  cell	  type	  associated	  with	  diabetic	  end-­‐organ	  complications.	  Since	  it	  has	  already	  
been	   shown	   that	   C-­‐peptide	   prevents	   diabetes-­‐induced	   renal	   microvascular	  
complications	  (40,	  41),	  restoration	  of	  mitochondrial	  respiration	  and	  attenuation	  of	  
mitochondrial	   superoxide	   generation	   in	   high	   glucose-­‐exposed	   renal	   MECs	   is	   a	  
legitimate	  channel	  by	  which	  C-­‐peptide	  can	  exert	  these	  beneficial	  renal	  effects	  during	  
diabetes.	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It	  is	  well	  recognized	  that	  the	  major	  pathways	  involved	  in	  the	  pathogenesis	  of	  
diabetic	   microvascular	   dysfunction	   are	   activated	   by	   hyperglycemia-­‐mediated	  
superoxide	   generation	   by	   the	   mitochondria	   (4).	   Hyperglycemia	   results	   in	   the	  
increased	  availability	  of	  reducing	  equivalents	  NADH	  and	  FADH2,	  which	  in	  turn	  lead	  
to	   increased	  electron	   transfer	   through	   the	  mitochondrial	   electron	   transport	   chain.	  
The	  overall	  rate	  of	  this	  electron	  transport	  is	  governed	  by	  mitochondrial	  respiratory	  
control,	  which	  ultimately	   is	   the	   amplitude	  of	   the	   electrochemical	   trans-­‐membrane	  
proton	   gradient.	   In	   our	   studies,	   we	   believe	   that	   the	   high	   glucose	   environment	  
generates	   a	   high	   trans-­‐membrane	   proton	   gradient	   and	   high	   ΔΨm,	   thereby	  
prolonging	   the	   presence	   of	   the	   superoxide	   generating	   intermediate	   –	   ubiquinone	  
(28,	  45).	  This	  is	  in	  agreement	  with	  the	  findings	  of	  others	  demonstrating	  changes	  in	  
ΔΨm	   in	   high	   glucose-­‐exposed	   cells(24,	   38).	   We	   also	   showed	   that	   C-­‐peptide	  
treatment	   prevented	   both	   the	   hyperpolarization,	   and	   the	   subsequent	  
depolarization,	  in	  high	  glucose-­‐exposed	  renal	  MECs.	  We	  propose	  that	  the	  increases	  
in	   ΔΨm,	   described	   as	   hyperpolarization,	   may	   result	   in	   the	   partial	   inhibition	   of	  
electron	  transport	  chain	  complexes	   leading	  to	  a	   large	  stimulation	  of	  mitochondrial	  
superoxide	  generation.	  Our	   studies	   also	   show	   increased	   superoxide	  generation	  by	  
the	   mitochondria	   in	   high	   glucose-­‐exposed	   renal	   MECs,	   which	   was	   abrogated	   by	  
treatment	   with	   C-­‐peptide.	   A	   similar	   increase	   in	   mitochondrial	   superoxide	  
generation	  upon	  exposure	  to	  high	  glucose	  has	  also	  been	  reported	   in	  various	  other	  
cell	  types	  (8,	  14,	  24,	  38,	  44).	  	  	  
Although	  all	  of	  the	  complexes	  of	  the	  mitochondrial	  electron	  transport	  chain	  
contribute	   to	   total	   mitochondrial	   superoxide	   generation,	   growing	   evidence	   now	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suggests	   that	   complex	   I	   produces	  most	   of	   the	   superoxide	   generated	  within	   intact	  
mammalian	  mitochondria	  (3).	  It	  is	  well	  known	  that	  complex	  II	  also	  has	  the	  capacity	  
to	   produce	   superoxide,	   but	   this	   only	   occurs	   while	   in	   the	   presence	   of	   specific	  
inhibitors	  and	  is	  not	  a	  physiologically	  relevant	  site	  of	  generation	  (15).	  Complex	  III,	  
on	  the	  other	  hand,	  has	  been	  shown	  to	  produce	  large	  amounts	  of	  superoxide,	  at	  least	  
in	   the	   presence	   of	   antimycin	   (15).	   	   To	   characterize	   the	   role	   of	   each	   individual	  
complex	  in	  the	  generation	  of	  excessive	  mitochondrial	  superoxide	  in	  our	  high	  glucose	  
model,	  we	  assessed	   the	  activities	  of	   complex	   I,	   III	   and	   IV.	  As	  expected	   in	  our	  high	  
glucose	  exposed	  renal	  MECs,	  we	  found	  a	  significant	  reduction	  in	  complex	  I	  activity,	  
with	   no	   apparent	   changes	   to	   the	   activities	   of	   complex	   III	   and	   IV.	   This	   is	   in	  
accordance	   with	   the	   observations	   of	   others	   (3,	   7,	   15,	   24).	   Further,	   Lambert	   and	  
Brand	   (29)	   have	   shown	   that	   high	   superoxide	   generation	   by	   the	   mitochondria	  
requires	   inhibition	   of	   complex	   I	   activity.	   Surprisingly,	   C-­‐peptide	   prevented	   the	  
reduction	  in	  complex	  I	  activity	  caused	  by	  the	  high	  glucose	  exposure,	  in	  the	  absence	  
of	   any	   effect	   on	   basal	   complex	   III	   and	   IV	   activities.	   Moreover,	   increased	  
mitochondrial	   superoxide	   generation	   exacerbates	   mitochondrial	   oxidative	   stress	  
further	  and	  leads	  to	  conversion	  of	  the	  mitochondrial	  glutathione	  pool	  to	  glutathione	  
disulfide	   (21).	   Glutathionylation	   of	   complex	   I	   has	   been	   shown	   to	   contribute	   to	  
oxidative	  damage	  to	  its	  subunits	  and	  loss	  of	  activity	  (2,	  20).	  	  
C-­‐peptide	  has	  been	  shown	  to	  be	  a	  potent	  stimulant	  of	  MAPKs	  (25-­‐27).	  Activation	  of	  
ERK	   by	   C-­‐peptide	   has	   been	   shown	   in	   numerous	   cell	   types	   (16,	   31,	   55,	   57).	   Our	  
experiments	   to	   study	   the	   effect	   of	   C-­‐peptide	   on	   MAPKs	   yielded	   similar	   results	  
demonstrating	   the	   activation	   of	   ERK1/2.	   This	   is	   especially	   important	   because	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several	  recent	  studies	  indicate	  that	  ERK	  1/2	  may	  affect	  the	  mitochondrial	  activities	  
by	  regulating	  the	  expression	  of	  mitochondrial	  proteins	  in	  the	  nucleus	  in	  addition	  to	  
having	  intrinsic	  mitochondrial	  activities	  (48).	  Specifically,	  ERK1/2	  has	  been	  shown	  
to	   localize	   to	   mitochondria	   in	   human	   alveolar	   macrophages	   and	   control	  
mitochondrial	  membrane	   potential	   as	  well	   as	   ATP	   production	   (36).	   However,	   the	  
exact	   mechanisms	   by	   which	   ERK1/2	   are	   translocated	   and	   regulated	   in	   the	  
mitochondria	  are	  still	  obscure	  and	  are	  beyond	  the	  scope	  of	  our	  study.	  
In	  this	  work,	  we	  have	  shown	  that	  C-­‐peptide	  protects	  renal	  MECs	  exposed	  to	  a	  
high	   glucose	   environment	   from	   mitochondrial	   dysfunction	   via	   improvements	   to	  
mitochondrial	  electrochemical	  coupling	  and	  reductions	  in	  mitochondrial	  superoxide	  
generation	   through	   restoration	   of	   mitochondrial	   respiratory	   complex	   I	   activity.	  
Together,	   these	   data	   not	   only	   support	   the	   continued	   thought	   that	   C-­‐peptide	  
treatment	  affords	  protection	  against	  high	  glucose	  environments,	  but	  that	  its	  unique	  
impact	  on	  the	  mitochondria	  should	  be	  a	  mechanism	  pursued	  in	  more	  detail.	  
Conclusions:	  Our	  work	  demonstrates	  that	  C-­‐peptide	  curtailed	  high	  glucose-­‐induced	  
mitochondrial	   functional	   impairments	   in	   renal	   MECs.	   Although	   interest	   in	   the	  
physiologic	   benefits	   of	   C-­‐peptide	   has	   persisted	   for	   more	   than	   two	   decades,	   C-­‐
peptide	   has	   yet	   to	   make	   its	   way	   into	   standard	   treatment	   regimens	   for	   various	  
diabetic	  complications.	  The	  findings	  from	  our	  work	  have	  to	  be	  confirmed	  in	  vivo,	  but	  
provides	  proof-­‐of-­‐principle	  evidence	  in	  support	  of	  the	  inclusion	  of	  C-­‐peptide	  to	  the	  
existing	   therapeutic	   regimen	   for	   treatment	   of	   diabetic	   complications,	   specifically	  
those	  related	  to	  diabetes-­‐induced	  renal	  impairment.	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Figure	  5B.	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FIGURE	  LEGENDS:	  
Figure	  1:	  A)	  State	  3	  respiration	  is	  the	  slope	  of	  measured	  O2	  consumption	  in	  the	  
presence	  of	  glutamate-­‐malate	  and	  ADP.	  ,	  significantly	  different	  than	  low-­‐glucose	  
and	  high-­‐glucose	  +	  C-­‐peptide	  (p	  <	  0.02).	  B)	  State	  4	  respiration	  is	  the	  slope	  of	  
measured	  O2	  consumption	  after	  ADP	  depletion.	  C)	  RCR	  is	  the	  ratio	  of	  state	  3	  to	  state	  
4	  respiration.	  ,	  significantly	  less	  than	  low-­‐glucose	  and	  high-­‐glucose	  +	  C-­‐peptide	  
(p	  <	  0.0001).	  n=	  8	  experiments.	  Data	  represent	  mean±	  SEM.	  
Figure	  2:	  A)	  At	  24-­‐hours,	  high	  glucose	  resulted	  in	  significant	  mitochondrial	  
membrane	  hyperpolarization.	  Subsequently,	  endothelial	  mitochondria	  were	  
depolarized	  (after	  48-­‐hours).	  Treatment	  with	  C-­‐peptide	  resulted	  in	  restoration	  of	  
ΔΨm	  at	  both	  24-­‐	  and	  48-­‐hours	  of	  exposure	  to	  a	  high	  glucose	  stress.	  	  ,	  significantly	  
greater	  than	  low-­‐glucose	  and	  high-­‐glucose	  +	  C-­‐peptide	  (p<0.009);	  # ,	  significantly	  
less	  than	  low-­‐glucose	  and	  high-­‐glucose	  +	  C-­‐peptide	  (p<0.002).	  Data	  represent	  
means±SEM	  and	  n=6	  experiments.	  B)	  Representative	  fluorescence	  micrographs	  of	  
renal	  MECs	  treated	  with	  JC-­‐1.	  
Figure	  3:	  A)	  Representative	  histograms	  of	  MitoSOX	  Red	  flow	  cytometry	  data	  at	  24	  
hrs.	  Y-­‐axes	  represent	  the	  number	  of	  counts	  of	  cells	  that	  emit	  fluorescence.	  X-­‐axes	  
represent	  the	  average	  fluorescence	  intensity	  of	  cells.	  A1	  represents	  treatment	  
conditions;	  A2	  represent	  vehicle	  control	  and	  positive	  control.	  B)	  Fold-­‐change	  of	  
mean	  fluorescence	  intensity	  of	  cells,	  including	  the	  control	  of	  low-­‐glucose	  +	  
antimycin.	  ,	  significantly	  different	  than	  low-­‐glucose	  and	  high-­‐glucose	  +	  C=-­‐peptide	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(p	  <	  0.0001).	  # ,	  significantly	  different	  than	  high-­‐glucose	  and	  low-­‐glucose	  +	  
antimycin	  (p	  <	  0.0001).	  
Figure	  4:	  Mitochondrial	  complex	  activity,	  as	  measured	  by	  spectrophotometry.	  A)	  
There	  is	  	  a	  significant	  decrease	  in	  complex	  I	  activity	  in	  high-­‐glucose	  exposed	  renal	  
MECs	  compared	  to	  low-­‐glucose	  and	  high-­‐glucose	  +	  C-­‐peptide	  at	  both	  24-­‐	  and	  48-­‐
hours.	  ,	  significantly	  less	  than	  low-­‐glucose	  and	  high-­‐glucose	  +	  C-­‐peptide	  (p<0.002	  
at	  24	  hr	  and	  p<0.0009	  at	  48	  hr).	  # ,	  significantly	  greater	  than	  high	  glucose	  at	  48	  hr	  (p	  
<	  0.05).	  B)	  and	  C)	  Both	  complex	  III	  and	  IV	  activities	  are	  not	  different	  among	  the	  
treatment	  conditions.	  Data	  represent	  mean±SEM;	  n=16	  experiments.	  
Figure	  5:	  	  Cell	  supernatants	  obtained	  after	  24	  hr	  treatments	  were	  subjected	  to	  
western	  blotting	  analysis	  for	  detection	  of	  	  phosphorylated	  ERK	  isoforms	  (p44	  
kDa/pERK1	  and	  p42	  kDa/pERK2)	  and	  Phosphorylated	  p38	  MAPK	  isoforms.	  A)	  
Phosphorylated	  MAPK	  band	  intensities	  were	  normalized	  to	  total	  MAPK	  levels.	  Data	  
are	  expressed	  as	  percentage	  change	  relative	  to	  control	  low	  glucose	  treatment.	  Data	  
represent	  mean±SEM,	  n=6.	  B)	  Representative	  western	  blot	  images	  
	  
REFERENCES:	  
1.	   Al-­Rasheed	  NM,	  Meakin	  F,	  Royal	  EL,	  Lewington	  AJ,	  Brown	  J,	  Willars	  GB,	  
and	  Brunskill	  NJ.	  Potent	  activation	  of	  multiple	  signalling	  pathways	  by	  C-­‐peptide	  in	  
opossum	  kidney	  proximal	  tubular	  cells.	  Diabetologia	  47:	  987-­‐997,	  2004.	  
2.	   Beer	   SM,	   Taylor	   ER,	   Brown	   SE,	   Dahm	   CC,	   Costa	   NJ,	   Runswick	  MJ,	   and	  
Murphy	   MP.	   Glutaredoxin	   2	   catalyzes	   the	   reversible	   oxidation	   and	  
	   103	  
glutathionylation	   of	   mitochondrial	   membrane	   thiol	   proteins:	   implications	   for	  
mitochondrial	   redox	   regulation	   and	   antioxidant	   defense.	   J	   Biol	   Chem	  279:	   47939-­‐
47951,	  2004.	  
3.	   Brand	  MD,	  Affourtit	  C,	  Esteves	  TC,	  Green	  K,	  Lambert	  AJ,	  Miwa	  S,	  Pakay	  
JL,	   and	   Parker	   N.	   Mitochondrial	   superoxide:	   production,	   biological	   effects,	   and	  
activation	   of	   uncoupling	   proteins.	  Free	   Radical	   Biology	   and	  Medicine	  37:	   755-­‐767,	  
2004.	  
4.	   Brownlee	   M.	   Biochemistry	   and	   molecular	   cell	   biology	   of	   diabetic	  
complications.	  Nature	  414:	  813-­‐820,	  2001.	  
5.	   Brownlee	   M.	   The	   pathobiology	   of	   diabetic	   complications:	   a	   unifying	  
mechanism.	  Diabetes	  54:	  1615-­‐1625,	  2005.	  
6.	   Bugger	   H,	   Boudina	   S,	   Hu	   XX,	   Tuinei	   J,	   Zaha	   VG,	   Theobald	   HA,	   Yun	   UJ,	  
McQueen	  AP,	  Wayment	  B,	  Litwin	  SE,	  and	  Abel	  ED.	  Type	  1	  Diabetic	  Akita	  Mouse	  
Hearts	  are	   Insulin	  Sensitive	  but	  Manifest	  Structurally	  Abnormal	  Mitochondria	   that	  
Remain	  Coupled	  Despite	  Increased	  Uncoupling	  Protein	  3.	  Diabetes	  08-­‐0079,	  2008.	  
7.	   Dabkowski	   ER,	  Williamson	   CL,	   and	  Hollander	   JM.	   Mitochondria-­‐specific	  
transgenic	   overexpression	   of	   phospholipid	   hydroperoxide	   glutathione	   peroxidase	  
(GPx4)	   attenuates	   ischemia/reperfusion-­‐associated	   cardiac	   dysfunction.	   Free	  
Radical	  Biology	  &	  Medicine	  45:	  855-­‐865,	  2008.	  
8.	   Du	   Y,	   Miller	   CM,	   and	   Kern	   TS.	   Hyperglycemia	   increases	   mitochondrial	  
superoxide	   in	   retina	   and	   retinal	   cells.	   Free	   Radical	   Biology	   &	   Medicine	   35:	   1491-­‐
1499,	  2003.	  
	   104	  
9.	   Esterhazy	   D,	   King	   MS,	   Yakovlev	   G,	   and	   Hirst	   J.	   Production	   of	   reactive	  
oxygen	  species	  by	  complex	   I	   (NADH:ubiquinone	  oxidoreductase)	   from	  Escherichia	  
coli	  and	  comparison	  to	  the	  enzyme	  from	  mitochondria.	  Biochemistry	  47:	  3964-­‐3971,	  
2008.	  
10.	   Fink	  BD,	  Reszka	  KJ,	  Herlein	  JA,	  Mathahs	  MM,	  and	  Sivitz	  WI.	  Respiratory	  
uncoupling	   by	   UCP1	   and	   UCP2	   and	   superoxide	   generation	   in	   endothelial	   cell	  
mitochondria.	  Am	  J	  Physiol	  Endocrinol	  Metab	  288:	  E71-­‐79,	  2005.	  
11.	   Friederich	  M,	  Hansell	  P,	  and	  Palm	  F.	  Diabetes,	  oxidative	  stress,	  nitric	  oxide	  
and	  mitochondria	  function.	  Curr	  Diabetes	  Rev	  5:	  120-­‐144,	  2009.	  
12.	   Genova	   ML,	   Pich	   MM,	   Bernacchia	   A,	   Bianchi	   C,	   Biondi	   A,	   Bovina	   C,	  
Falasca	  AI,	  Formiggini	  G,	  Castelli	  GP,	  and	  Lenaz	  G.	  The	  mitochondrial	  production	  
of	  reactive	  oxygen	  species	  in	  relation	  to	  aging	  and	  pathology.	  Ann	  N	  Y	  Acad	  Sci	  1011:	  
86-­‐100,	  2004.	  
13.	   Genova	   ML,	   Ventura	   B,	   Giuliano	   G,	   Bovina	   C,	   Formiggini	   G,	   Parenti	  
Castelli	   G,	   and	   Lenaz	   G.	   The	   site	   of	   production	   of	   superoxide	   radical	   in	  
mitochondrial	  Complex	  I	  is	  not	  a	  bound	  ubisemiquinone	  but	  presumably	  iron-­‐sulfur	  
cluster	  N2.	  FEBS	  Lett	  505:	  364-­‐368,	  2001.	  
14.	   Graier	   WF,	   Posch	   K,	   Fleischhacker	   E,	   Wascher	   TC,	   and	   Kostner	   GM.	  
Increased	  superoxide	  anion	  formation	  in	  endothelial	  cells	  during	  hyperglycemia:	  an	  
adaptive	   response	   or	   initial	   step	   of	   vascular	   dysfunction?	   Diabetes	   Research	   and	  
Clinical	  Practice	  45:	  153-­‐160,	  1999.	  
	   105	  
15.	   Green	   K,	   Brand	   MD,	   and	   Murphy	   MP.	   Prevention	   of	   mitochondrial	  
oxidative	  damage	  as	  a	  therapeutic	  strategy	  in	  diabetes.	  Diabetes	  53	  Suppl	  1:	  S110-­‐
118,	  2004.	  
16.	   Grunberger	   G,	   Qiang	   X,	   Li	   Z,	   Mathews	   ST,	   Sbrissa	   D,	   Shisheva	   A,	   and	  
Sima	  AAF.	  Molecular	  basis	  for	  the	  insulinomimetic	  effects	  of	  C-­‐peptide.	  Diabetologia	  
44:	  1247-­‐1257,	  2001.	  
17.	   Herlein	  JA,	  Fink	  BD,	  O'Malley	  Y,	  and	  Sivitz	  WI.	  Superoxide	  and	  Respiratory	  
Coupling	  in	  Mitochondria	  of	  Insulin-­‐Deficient	  Diabetic	  Rats.	  Endocrinology	  150:	  46-­‐
55,	  2009.	  
18.	   Horwitz	   DL,	   Starr	   JI,	   Mako	   ME,	   Blackard	   WG,	   and	   Rubenstein	   AH.	  
Proinsulin,	   insulin,	   and	   C-­‐peptide	   concentrations	   in	   human	   portal	   and	   peripheral	  
blood.	  J	  Clin	  Invest	  55:	  1278-­‐1283,	  1975.	  
19.	   Huang	   DY,	   Richter	   K,	   Breidenbach	   A,	   and	   Vallon	   V.	   Human	   C-­‐peptide	  
acutely	   lowers	  glomerular	  hyperfiltration	  and	  proteinuria	   in	  diabetic	   rats:	   a	  dose-­‐
response	  study.	  Naunyn	  Schmiedebergs	  Arch	  Pharmacol	  365:	  67-­‐73,	  2002.	  
20.	   Hurd	   TR,	   Costa	   NJ,	   Dahm	   CC,	   Beer	   SM,	   Brown	   SE,	   Filipovska	   A,	   and	  
Murphy	  MP.	  Glutathionylation	  of	  mitochondrial	  proteins.	  Antioxid	  Redox	  Signal	  7:	  
999-­‐1010,	  2005.	  
21.	   Hurd	   TR,	   Requejo	   R,	   Filipovska	   A,	   Brown	   S,	   Prime	   TA,	   Robinson	   AJ,	  
Fearnley	  IM,	  and	  Murphy	  MP.	  Complex	  I	  within	  Oxidatively	  Stressed	  Bovine	  Heart	  
Mitochondria	  Is	  Glutathionylated	  on	  Cys-­‐531	  and	  Cys-­‐704	  of	   the	  75-­‐kDa	  Subunit.	   J	  
Biol	  Chem	  283:	  24801-­‐24815,	  2008.	  
	   106	  
22.	   Johansson	  BL,	   Borg	  K,	   Fernqvist-­Forbes	   E,	   Kernell	   A,	   Odergren	  T,	   and	  
Wahren	  J.	  Beneficial	  effects	  of	  C-­‐peptide	  on	  incipient	  nephropathy	  and	  neuropathy	  
in	  patients	  with	  Type	  1	  diabetes	  mellitus.	  Diabetic	  medicine	  17:	  181-­‐189,	  2000.	  
23.	   Johansson	  BL,	  Sjoberg	  S,	  and	  Wahren	  J.	  The	  influence	  of	  human	  C-­‐peptide	  
on	   renal	   function	   and	   glucose	   utilization	   in	   type	   1	   (insulin-­‐dependent)	   diabetic	  
patients.	  Diabetologia	  35:	  121-­‐128,	  1992.	  
24.	   Kanwar	  M,	  Chan	  P-­S,	  Kern	  TS,	  and	  Kowluru	  RA.	  Oxidative	  Damage	  in	  the	  
Retinal	   Mitochondria	   of	   Diabetic	   Mice:	   Possible	   Protection	   by	   Superoxide	  
Dismutase.	  Invest	  Ophthalmol	  Vis	  Sci	  48:	  3805-­‐3811,	  2007.	  
25.	   Kitamura	   T,	   Kimura	   K,	   Jung	   BD,	   Makondo	   K,	   Okamoto	   S,	   Ca√±as	   X,	  
Sakane	   N,	   Yoshida	   T,	   and	   Saito	   M.	   Proinsulin	   C-­‐peptide	   rapidly	   stimulates	  
mitogen-­‐activated	  protein	  kinases	  in	  Swiss	  3T3	  fibroblasts:	  requirement	  of	  protein	  
kinase	   C,	   phosphoinositide	   3-­‐kinase	   and	   pertussis	   toxin-­‐sensitive	   G-­‐protein.	  
Biochem	  J	  355:	  123-­‐129,	  2001.	  
26.	   Kitamura	  T,	  Kimura	  K,	   Jung	  BD,	  Makondo	  K,	  Sakane	  N,	  Yoshida	  T,	  and	  
Saito	   M.	   Proinsulin	   C-­‐peptide	   activates	   cAMP	   response	   element-­‐binding	   proteins	  
through	  the	  p38	  mitogen-­‐activated	  protein	  kinase	  pathway	  in	  mouse	  lung	  capillary	  
endothelial	  cells.	  Biochem	  J	  366:	  737-­‐744,	  2002.	  
27.	   Kitamura	  T,	  Kimura	  K,	  Makondo	  K,	  Furuya	  DT,	  Suzuki	  M,	  Yoshida	  T,	  and	  
Saito	   M.	   Proinsulin	   C-­‐peptide	   increases	   nitric	   oxide	   production	   by	   enhancing	  
mitogen-­‐activated	   protein-­‐kinase-­‐dependent	   transcription	   of	   endothelial	   nitric	  
oxide	  synthase	  in	  aortic	  endothelial	  cells	  of	  Wistar	  rats.	  Diabetologia	  46:	  1698-­‐1705,	  
2003.	  
	   107	  
28.	   Korshunov	   SS,	   Skulachev	   VP,	   and	   Starkov	   AA.	   High	   protonic	   potential	  
actuates	   a	   mechanism	   of	   production	   of	   reactive	   oxygen	   species	   in	   mitochondria.	  
FEBS	  Letters	  416:	  15-­‐18,	  1997.	  
29.	   Lambert	   AJ,	   and	   Brand	   MD.	   Inhibitors	   of	   the	   quinone-­‐binding	   site	   allow	  
rapid	  superoxide	  production	  from	  mitochondrial	  NADH:ubiquinone	  oxidoreductase	  
(complex	  I).	  J	  Biol	  Chem	  279:	  39414-­‐39420,	  2004.	  
30.	   Langley	  RR,	  Ramirez	  KM,	  Tsan	  RZ,	  Van	  Arsdall	  M,	  Nilsson	  MB,	  and	  Fidler	  
IJ.	  Tissue-­‐specific	  microvascular	  endothelial	  cell	  lines	  from	  H-­‐2K(b)-­‐tsA58	  mice	  for	  
studies	  of	  angiogenesis	  and	  metastasis.	  Cancer	  Res	  63:	  2971-­‐2976,	  2003.	  
31.	   Li	  ZG,	  Qiang	  X,	  Sima	  AA,	  and	  Grunberger	  G.	  C-­‐peptide	  attenuates	  protein	  
tyrosine	   phosphatase	   activity	   and	   enhances	   glycogen	   synthesis	   in	   L6	   myoblasts.	  
Biochem	  Biophys	  Res	  Commun	  280:	  615-­‐619,	  2001.	  
32.	   McCullough	  PA,	  Bakris	  GL,	  Owen	  WF,	  Klassen	  PS,	  and	  Califf	  RM.	  Slowing	  
the	   progression	   of	   diabetic	   nephropathy	   and	   its	   cardiovascular	   consequences.	  
American	  Heart	  Journal	  148:	  243-­‐251,	  2004.	  
33.	   McGill	   JB.	   Improving	   microvascular	   outcomes	   in	   patients	   with	   diabetes	  
through	  management	  of	  hypertension.	  Postgrad	  Med	  121:	  89-­‐101,	  2009.	  
34.	   Mogensen	   CE.	   Preventing	   end-­‐stage	   renal	   disease.	  Diabet	  Med	  15	   Suppl	   4:	  
S51-­‐56,	  1998.	  
35.	   Mogensen	   CE.	   The	   kidney	   in	   diabetes:	   how	   to	   control	   renal	   and	   related	  
cardiovascular	  complications.	  Am	  J	  Kidney	  Dis	  37:	  S2-­‐6,	  2001.	  
36.	   Monick	  MM,	  Powers	  LS,	  Barrett	  CW,	  Hinde	  S,	  Ashare	  A,	  Groskreutz	  DJ,	  
Nyunoya	  T,	  Coleman	  M,	  Spitz	  DR,	  and	  Hunninghake	  GW.	  Constitutive	  ERK	  MAPK	  
	   108	  
Activity	   Regulates	   Macrophage	   ATP	   Production	   and	   Mitochondrial	   Integrity.	   The	  
Journal	  of	  Immunology	  180:	  7485-­‐7496,	  2008.	  
37.	   Mukhopadhyay	  P,	  Rajesh	  M,	  Yoshihiro	  K,	  Hasko	  G,	  and	  Pacher	  P.	  Simple	  
quantitative	   detection	   of	   mitochondrial	   superoxide	   production	   in	   live	   cells.	  
Biochemical	  and	  biophysical	  research	  communications	  358:	  203-­‐208,	  2007.	  
38.	   Munusamy	   S,	   and	  MacMillan-­Crow	   LA.	  Mitochondrial	   superoxide	   plays	   a	  
crucial	   role	   in	   the	   development	   of	  mitochondrial	   dysfunction	   during	   high	   glucose	  
exposure	   in	   rat	   renal	   proximal	   tubular	   cells.	   Free	   Radical	   Biology	   &	   Medicine	   46:	  
1149-­‐1157,	  2009.	  
39.	   Murphy	  MP.	  How	  mitochondria	  produce	  reactive	  oxygen	  species.	  J	  Biol	  Chem	  
417:	  1-­‐13,	  2009.	  
40.	   Nordquist	  L,	  Brown	  R,	  Fasching	  A,	  Persson	  P,	  and	  Palm	  F.	  Proinsulin	  C-­‐
peptide	   reduces	   diabetes-­‐induced	   glomerular	   hyperfiltration	   via	   efferent	   arteriole	  
dilation	   and	   inhibition	   of	   tubular	   sodium	   reabsorption.	  Am	   J	   Physiol	   Renal	   Physiol	  
297:	  F1265-­‐1272,	  2009.	  
41.	   Nordquist	  L,	  Lai	  EY,	  Sjoquist	  M,	  Patzak	  A,	  and	  Persson	  AE.	  Proinsulin	  C-­‐
peptide	   constricts	   glomerular	   afferent	   arterioles	   in	   diabetic	   mice.	   A	   potential	  
renoprotective	  mechanism.	  Am	  J	  Physiol	  Regul	   Integr	  Comp	  Physiol	  294:	  R836-­‐841,	  
2008.	  
42.	   Nugent	  RA,	   Fathima	  SF,	   Feigl	  AB,	   and	  Chyung	  D.	   The	  Burden	   of	   Chronic	  
Kidney	  Disease	  on	  Developing	  Nations:	  A	  21st	  Century	  Challenge	   in	  Global	  Health.	  
Nephron	  Clin	  Pract	  118:	  c269-­‐c277.	  
	   109	  
43.	   Palmeira	   CM,	   Rolo	   AP,	   Berthiaume	   J,	   Bjork	   JA,	   and	   Wallace	   KB.	  
Hyperglycemia	   decreases	   mitochondrial	   function:	   The	   regulatory	   role	   of	  
mitochondrial	   biogenesis.	   Toxicology	   and	   Applied	   Pharmacology	   225:	   214-­‐220,	  
2007.	  
44.	   Quijano	   C,	   Castro	   L,	   Peluffo	   G,	   Valez	   V,	   and	   Radi	   R.	   Enhanced	  
mitochondrial	  superoxide	   in	  hyperglycemic	  endothelial	  cells:	  direct	  measurements	  
and	   formation	   of	   hydrogen	   peroxide	   and	   peroxynitrite.	   Am	   J	   Physiol	   Heart	   Circ	  
Physiol	  293:	  H3404-­‐3414,	  2007.	  
45.	   Rolo	   AP,	   and	   Palmeira	   CM.	   Diabetes	   and	  mitochondrial	   function:	   Role	   of	  
hyperglycemia	  and	  oxidative	  stress.	  Toxicology	  and	  Applied	  Pharmacology	  212:	  167-­‐
178,	  2006.	  
46.	   Samnegard	  B,	   Jacobson	  SH,	   Jaremko	  G,	   Johansson	  B-­L,	   and	  Sjoquist	  M.	  
Effects	  of	  C-­‐peptide	  on	  glomerular	  and	  renal	  size	  and	  renal	  function	  in	  diabetic	  rats.	  
Kidney	  Int	  60:	  1258-­‐1265,	  2001.	  
47.	   Samnegard	   B,	   Jacobson	   SH,	   Jaremko	   G,	   Johansson	   BL,	   Ekberg	   K,	  
Isaksson	  B,	  Eriksson	  L,	  Wahren	  J,	  and	  Sjoquist	  M.	  C-­‐peptide	  prevents	  glomerular	  
hypertrophy	   and	   mesangial	   matrix	   expansion	   in	   diabetic	   rats.	   Nephrol	   Dial	  
Transplant	  20:	  532-­‐538,	  2005.	  
48.	   Seger	  R,	  Hanoch	  T,	  Rosenberg	  R,	  Dantes	  A,	  Merz	  WE,	  Strauss	  JF,	  3rd,	  and	  
Amsterdam	   A.	   The	   ERK	   signaling	   cascade	   inhibits	   gonadotropin-­‐stimulated	  
steroidogenesis.	  J	  Biol	  Chem	  276:	  13957-­‐13964,	  2001.	  
49.	   Shafqat	  J,	  Juntti-­Berggren	  L,	  Zhong	  Z,	  Ekberg	  K,	  Köhler	  M,	  Berggren	  PO,	  
Johansson	   J,	   Wahren	   J,	   and	   Jörnvall	   H.	   Proinsulin	   C-­‐peptide	   and	   its	   analogues	  
	   110	  
induce	   intracellular	   Ca2+	   increases	   in	   human	   renal	   tubular	   cells.	   Cellular	   and	  
Molecular	  Life	  Sciences	  (CMLS)	  59:	  1185-­‐1189,	  2002.	  
50.	   Shen	  X,	  Zheng	  S,	  Thongboonkerd	  V,	  Xu	  M,	  Pierce	  WM,	  Jr.,	  Klein	  JB,	  and	  
Epstein	   PN.	   Cardiac	  mitochondrial	   damage	   and	   biogenesis	   in	   a	   chronic	  model	   of	  
type	  1	  diabetes.	  Am	  J	  Physiol	  Endocrinol	  Metab	  287:	  E896-­‐905,	  2004.	  
51.	   Sivitz	   WI,	   and	   Yorek	   MA.	   Mitochondrial	   dysfunction	   in	   diabetes:	   from	  
molecular	   mechanisms	   to	   functional	   significance	   and	   therapeutic	   opportunities.	  
Antioxid	  Redox	  Signal	  12:	  537-­‐577.	  
52.	   Steiner	  DF.	  On	  the	  role	  of	  the	  proinsulin	  C-­‐peptide.	  Diabetes	  27	  Suppl	  1:	  145-­‐
148,	  1978.	  
53.	   Trounce	  IA,	  Kim	  YL,	  Jun	  AS,	  and	  Wallace	  DC.	  Assessment	  of	  mitochondrial	  
oxidative	   phosphorylation	   in	   patient	   muscle	   biopsies,	   lymphoblasts,	   and	  
transmitochondrial	  cell	  lines.	  Methods	  in	  Enzymology	  264:	  484-­‐509,	  1996.	  
54.	   Wallerath	  T,	  Kunt	  T,	   Forst	  T,	   Closs	  EI,	   Lehmann	  R,	   Flohr	  T,	  Gabriel	  M,	  
Schafer	   D,	   Gopfert	   A,	   Pfutzner	   A,	   Beyer	   J,	   and	   Forstermann	   U.	   Stimulation	   of	  
endothelial	   nitric	   oxide	   synthase	   by	   proinsulin	   C-­‐peptide.	  Nitric	   Oxide	   9:	   95-­‐102,	  
2003.	  
55.	   Zhong	   Z,	   Davidescu	   A,	   Ehren	   I,	   Ekberg	   K,	   Jornvall	   H,	   Wahren	   J,	   and	  
Chibalin	  AV.	   C-­‐peptide	   stimulates	  ERK1/2	   and	   JNK	  MAP	  kinases	   via	   activation	  of	  
protein	  kinase	  C	  in	  human	  renal	  tubular	  cells.	  Diabetologia	  48:	  187-­‐197,	  2005.	  
56.	   Zhong	   Z,	   Davidescu	   A,	   Ehrén	   I,	   Ekberg	   K,	   Jörnvall	   H,	   Wahren	   J,	   and	  
Chibalin	  AV.	   C-­‐peptide	   stimulates	  ERK1/2	   and	   JNK	  MAP	  kinases	   via	   activation	  of	  
protein	  kinase	  C	  in	  human	  renal	  tubular	  cells.	  Diabetologia	  48:	  187-­‐197,	  2005.	  
	   111	  
57.	   Zhong	  Z,	  Kotova	  O,	  Davidescu	  A,	  Ehren	  I,	  Ekberg	  K,	  Jornvall	  H,	  Wahren	  J,	  
and	   Chibalin	   AV.	   C-­‐peptide	   stimulates	   Na+,	   K+-­‐ATPase	   via	   activation	   of	   ERK1/2	  





























	   113	  
It	  had	  long	  been	  accepted	  that	  the	  peptide	  that	  connects	  the	  A-­‐	  and	  B-­‐chains	  
of	   insulin,	   termed	   C-­‐peptide,	   was	   biologically	   inert.	   However,	   many	   studies	   have	  
demonstrated	  that	  replacement	  doses	  of	  C-­‐peptide	  can	  ameliorate	  diabetes-­‐induced	  
renal	  dysfunction	  (35,	  40-­‐42,	  61,	  69,	  70,	  89,	  90,	  92).	  Yet,	  the	  mechanisms	  underlying	  
the	  benefits	  of	  C-­‐peptide	  during	  DM	  are	  still	  unclear.	  DM	  has	  been	  widely	  recognized	  
as	  a	  state	  of	  imbalance	  between	  oxidants	  and	  antioxidant	  protective	  systems	  (7,	  26,	  
29).	   Moreover,	   the	   chronic	   hyperglycemia	   associated	   with	   DM	   causes	   elevated	  
oxidative	   stress	   in	   the	   renal	   microcirculation	   (87,	   99),	   directly	   damaging	   the	  
microvessels	   leading	   to	   dysfunction	   (64),	   and	   ultimately	   manifesting	   as	   kidney	  
damage	   and	   dysfunction(29,	   79).	   Our	   central	   hypothesis	   is	   that	   C-­peptide	  
prevents	   diabetes-­induced	   renal	   dysfunction	   by	   ameliorating	   oxidative	  
imbalance	   within	   the	   microcirculation,	   and	   specifically	   renal	   microvascular	  
endothelial	  cells.	  	  
STZ-­‐induced	   type	   I	   DM	   has	   been	   widely	   used	   as	   model	   for	   DN,	   however	  
interpreting	  results	  in	  this	  model	  can	  be	  confounded	  by	  the	  non-­‐specific	  toxicity	  of	  
STZ	   (10,	  100).	  To	  mitigate	   this	  non-­‐specific	   cytotoxicity,	  we	  employed	   the	  AMDCC	  
model	  of	  multiple	  low-­‐dose	  STZ	  injections	  –	  daily	  i.p.	  injections	  of	  50mg/kg	  STZ	  for	  
five	  days	  (10,	  11).	  This	  protocol	  has	  been	  shown	  to	  cause	  repetitive	  low-­‐grade	  ß-­‐cell	  
damage	  accompanied	  by	  lymphocytic	  infiltration	  of	  the	  pancreatic	  islets	  (57,	  88).	  In	  
our	   hands,	   the	   AMDCC	   multiple	   low-­‐dose	   STZ	   protocol	   provided	   a	   mouse	   model	  
with	  high	  fasting	  blood	  glucose	   levels	   that	   lacks	  the	  catabolic	  state	  that	  commonly	  
accompanies	  the	  single	  high-­‐dose	  STZ	  protocol	  (10).	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Our	  evaluation	  of	  the	  short-­‐term	  effects	  (24-­‐hours)	  of	  C-­‐peptide	  were	  based	  
on	  three	  factors/previous	  findings:	  1)	  the	  half-­‐life	  of	  C-­‐peptide	  is	  30-­‐minutes	  (63);	  
2)	  its	  mechanism	  of	  action,	  at	  least	  in	  part,	  is	  mediated	  by	  rapid	  G-­‐protein–coupled	  
receptor	  signaling	  and	  changes	  to	  protein	  activation/expression	  (31,	  80,	  85),	  and	  3)	  
the	   replacement	   of	   physiological	   levels	   of	   C-­‐peptide	   on	   a	   short-­‐term	   basis	   (1–3	  
hours)	   in	   diabetic	   patients	   lacking	   C-­‐peptide	   has	   provided	   significant	   protection	  
against	  diabetic	  complications	  (39,	  42).	  Moreover,	  the	  treatment	  with	  C-­‐peptide	  did	  
not	  alter	  fasting	  blood	  glucose	  or	  bodyweight	  (refer	  to	  table	  1	  in	  chapter	  2).	  As	  such,	  
we	  believe	   that	   these	  variables	  did	  not	  confound	  our	  evaluations	  of	  C-­‐peptide	  and	  
its	  effects	  on	  the	  renal	  microcirculation.	  
Our	  studies	  to	  examine	  the	  effect	  of	  C-­‐peptide	  on	  early	  renal	  dysfunction	  in	  
mice	  due	  to	  type	  I	  DM	  demonstrate	  that	  short-­‐term	  infusion	  of	  C-­‐peptide	  improved	  
renal	  function.	  Our	  results	  are	  in	  good	  agreement	  with	  other	  studies	  that	  examined	  
the	   benefits	   of	   short-­‐term	   administration	   of	   C-­‐peptide	   in	   experimental	   animal	  
models	   of	   diabetes	   (91,	   98).	   Several	   studies	   reported	   that	   C-­‐peptide	   reduces	  
diabetes-­‐induced	   glomerular	   hyperfiltration	   via	   constriction	   of	   renal	   afferent	  
arterioles	   (35,	   41,	   42).	   However,	   renal	   vasoconstrictive	   effect	   of	   C-­‐peptide	   takes	  
considerably	   longer	   time	  to	  develop	  compared	  to	  well-­‐known	  constrictors	  such	  as	  
angiotensin	  II	  or	  norepinephrine	  (70).	  An	  explanation	  of	  this	  could	  be	  a	  sequential	  
cascade	  of	  intracellular	  events	  leading	  to	  vasoconstriction.	  	  
It	   has	   been	   suggested	   that	   alterations	   in	   renal	   proximal	   Na+/K+-­‐ATPase	  
activity	   may	   in	   itself	   regulate	   GFR	   (106).	   Indeed,	   Na+/K+-­‐ATPase	   activity	   in	   the	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kidney	  is	  elevated	  during	  the	  early	  onset	  of	  diabetes,	  probably	  due	  to	  the	  increased	  
tubular	  electrolyte	  load	  resulting	  from	  the	  elevated	  GFR	  (106).	  Recently,	  C-­‐peptide	  
has	  been	  recently	  shown	  to	  alter	  renal	  proximal	   tubular	  Na+	   load	  by	   inhibiting	  Na	  
reabsorption,	   thereby	   suggesting	   that	   C-­‐peptide	   may	   decrease	   diabetic	  
hyperfiltration	  through	  inhibition	  of	  Na+/K+-­‐ATPase	  activity	  (69).	  In	  this	  study,	  the	  
diabetic	   rats	  displayed	  reduced	  proximal	   tubular	  Na+	   reabsorption	  after	  C-­‐peptide	  
administration,	  and	  it	  is	  possible	  that	  the	  reduced	  GFR	  observed	  in	  these	  animals	  is	  
caused	  by	  TGF	  activation.	  	  
Although	   C-­‐peptide	   clearly	   possesses	   a	   reducing	   effect	   on	   diabetic	  
hyperfiltration,	  by	  constricting	  afferent	  arteriole	  and	  dilating	  efferent	  arteriole	  there	  
is	  still	  no	  effector,	  no	  receptor,	  and	  no	  downstream	  signalling	  cascade	  reported	  for	  
this	   phenomena.	   Thus,	   regulation	   of	   GFR,	   tubular	   electrolyte	   handling	   and	   renal	  
blood	   flow	   are	   interconnected	   via	   several	   mechanisms	   which	   need	   to	   be	  
investigated	  separately	  in	  order	  to	  fully	  understand	  how	  C-­‐peptide	  might	  influence	  
kidney	   function.	   Even	   though	   our	   studies	   did	   not	   include	   GFR	  measurements,	  we	  
measured	  urinary	  albumin	  creatinine	  ratio,	  an	  indicator	  for	  microalbuminuria	  (95),	  
which	   in	   turn	   is	   a	   sign	   of	   generalized	   microvascular	   dysfunction.	   C-­‐peptide	  
administration	   for	  24	  hours	  decreased	  albumin	  creatinine	  ratios	   in	   type	   I	  diabetic	  
mice,	   suggesting	   that	   C-­‐peptide	   has	   a	   salutary	   effect	   on	   renal	  microvasculature	   at	  
initial	  stages	  of	  DN.	  	  
Although	   numerous	   reports	   suggest	   that	   C-­‐peptide	   prevents	   diabetes-­‐
induced	  changes	  in	  the	  perfusion	  of	  peripheral	  vascular	  beds	  (18,	  42),	  opposing	  or	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no	   effects	   have	   been	   reported	   in	   the	   kidney	   (6,	   48,	   107).	   	   With	   diabetic	   kidney	  
disease,	   despite	   important	   structural	   changes	   within	   the	   glomerulus,	   tubular	   and	  
interstitial	   lesions	   are	   ultimately	   an	   outcome	   that	   occurs	  with	   the	   progression	   of	  
type	  I	  DM	  (21,	  86,	  101).	   In	   fact,	   tubulointerstitial	   injury,	  as	  opposed	  to	  glomerular	  
injury,	   is	   the	   predominant	   form	   of	   renal	   damage/dysfunction	   that	   occurs,	   and	  
develops	   independently	   in	   type	   I	   diabetic	   patients	   (67).	   Human	   tubulointerstitial	  
injury	   is	   associated	   with	   decreases	   in	   the	   number	   and	   area	   of	   post-­‐glomerular	  
capillaries	  as	   the	   fibrosis	  of	   the	   renal	   cortical	   interstitium	   increases	   (113).	  During	  
the	  early	  stages	  of	   injury,	  the	  peritubular	  vasculature	  is	  damaged	  by	  pro-­‐apoptotic	  
stimuli,	   particularly	   transient	   ischemia	   (86).	   Consequently,	   rarefaction	   of	   the	  
peritubular	  microvasculature	  with	  ensuing	  chronic	  hypoxia	  is	  a	  hallmark	  of	  tubulo-­‐
interstitial	  fibrosis	  (101).	  Concomitantly,	  work	  has	  also	  shown	  that	  there	  is	  a	  loss	  of	  
endothelial	   cell	   staining	   correlated	   to	   areas	   of	   tubulointerstitial	   injury,	   further	  
suggesting	  a	  loss	  of	  peritubular	  capillaries	  (21).	  Our	  results	  clearly	  indicate	  that	  C-­‐
peptide	   improves	   peritubular	   perfusion	   in	   the	   kidney	   cortices	   of	   type	   I	   diabetic	  
mice.	   C-­‐peptide	   treatment	   not	   only	   improved	   perfusion,	   but	   also	   improved	   renal	  
function,	   as	   indicated	   by	   improved	   albumin	   creatinine	   ratios,	   similar	   to	   other	  
reports	  in	  diabetic	  animal	  models	  (61,	  68,	  70).	  	  
Hyperglycemia	   preceding	   DM	   alters	   microvascular	   perfusion	   in	   different	  
vascular	   beds	   and	   can	   result	   in	   heterogeneous	   flow	  patterns	   (43,	   44,	   49,	   74).	  We	  
examined	   the	  effect	  of	  C-­‐peptide	  on	   type	   I	  diabetes-­‐induced	  heterogeneity	   in	   flow	  
pattern	  within	  renal	  peritubular	  capillaries.	  For	  the	  purposes	  of	  our	  study,	  we	  focus	  
on	   one	   aspect	   of	   Ht	   in	   peripheral	   vasculature:	   flow	   heterogeneity	   (Ht).	   Flow	   Ht	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simply	   means	   that	   total	   inflow	   is	   not	   distributed	   identically	   among	   the	   perfused	  
vessels	   (17).	   Flow	  Ht	   is	   controlled	  within	  microcirculation	   and	   is	   essential	   to	   our	  
understanding	  of	  tissue	  function	  and	  vascular	  perfusion.	  .	  One	  of	  the	  caveats	  in	  our	  
discussion	  of	   flow	  Ht	   is	   that	  some	  of	   the	  key	  measurements,	   such	  as	  RBC	   flux	  and	  
velocity,	   are	   lacking	   and	   is	  mainly	   based	   on	   perfusion	   times	   obtained	   from	  visual	  
observation	  of	  flow	  patterns.	  A	  quotient	  of	  mean	  flow	  (an	  index	  of	  central	  tendency	  
of	   the	   flow)	   and	   standard	   deviation	   (an	   index	   of	   dispersion)	   is	   the	   coefficient	   of	  
variation,	   is	   a	   convenient	   measure	   of	   the	   relative	   dispersion	   or	   the	   true	  
heterogeneity	   of	   the	   flow.	   At	   a	   constant	   level	   of	   mean	   flow,	   redistributing	   flow	  
among	   vessels	   might	   alter	   fractional	   flow	   distribution,	   and	   the	   coefficient	   of	  
variation	  will	  show	  the	  change	  in	  relative	  dispersion	  (17).	  
Important	  information	  regarding	  flow	  dispersion	  may	  be	  gained	  through	  an	  
analysis	  of	  histograms	  describing	  the	  sample	  distribution	  (34,	  60,	  93).	  A	  change	  in	  
the	  shape	  of	  sample	  distribution	  is	  indicative	  of	  a	  redistribution	  of	  flow.	  This	  is	  often	  
manifested	   as	   a	   change	   in	   the	   shape	   of	   histograms	   (34,	   60,	   93).	   Our	   analysis	   of	  
frequency	  distribution	  histograms,	  as	  shown	  in	  Figure	  4.1,	  depicts	  a	  left	  shift	  in	  the	  
flow	   pattern	   and	   shorter	   perfusion	   times	   in	   intermittently	   perfused	   capillaries	   of	  
diabetic	   kidney,	   indicating	   a	   heterogeneous	   flow	   pattern.	   Similar	   heterogeneous	  
flow	  patterns	  were	  described	  for	  other	  vascular	  beds	   in	  diabetic	  animal	  models	  as	  
well	  as	  DM	  patients	  (43,	  44,	  49,	  74).	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Figure	   4.1	   :	   Frequency	   distribution	   histogram	   depicting	   blood	   flow	   in	   individual	   renal	   peritubular	  
capillaries.	  Capillary	  perfusion	  was	  determined	  using	  stereological	  point-­‐counting	  grid	  (see	  Methods	  
section	  under	  Chapter	  2	  for	  detailed	  description	  of	  analysis).	  A	  capillary	  was	  counted	  if	  a	  point	  landed	  
within	  its	  dimensions.	  10-­‐15	  fields	  of	  view	  per	  animal	  were	  used	  for	  analysis.	  	  	  X-­‐	  axis	  represents	  the	  
perfusion	   times	   binned	   as	   3	   second	   groups,	   with	   ticks	   representing	   center	   of	   each	   bin.	   Y-­‐	   axis	  
represents	  percentage	  of	  capillaries.	  A	  continuously	  perfused	  capillary	  (open	  bars)	  was	  defined	  as	  one	  
which	   possessed	   continuous	   red	   blood	   cell	   flow	   (RBC)	   for	   the	   20	   sec	   video	   period.	   If	   a	   perfused	  
capillary	  demonstrated	  RBC	  flow	  that	  stopped	  at	   least	  once	  during	  the	  20	  sec	  period,	   it	  was	  deemed	  
intermittently	   perfused	   capillary	   (hatch	   bars).	   Non-­‐perfused	   capillaries	   (filled	   bars)	   were	   any	  
capillaries	  that	  did	  not	  have	  RBC	  flow	  through	  out	  the	  entire	  20	  sec	  observation	  period.	  Both	  Diabetic	  
and	  Diabetic	  +	  C-­‐pep	  mice	  have	  higher	  number	  of	  non-­‐perfused	  and	  intermittent	  capillaries	  compared	  
to	  the	  Non-­‐diabetic	  mice.	  There	  is	  a	  right	  shift	  in	  the	  distribution	  of	  perfusion	  times	  of	  intermittently-­‐
perfused	  capillaries	  in	  Diabetic	  +	  C-­‐pep	  mice	  compared	  to	  that	  of	  Diabetic	  mice.	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  Even	  though	  C-­‐peptide	  treatment	  for	  24	  hours	  did	  not	  alter	  the	  percentage	  
of	  non-­‐perfused	  and	  continuously	  perfused	  capillaries	  compared	  to	  that	  in	  diabetic	  
mice,	   it	   caused	   a	   right	   shift	   in	   the	   distribution	   histogram	   indicating	   that	   more	  
intermittent	   vessels	  were	   perfused	   for	   longer	   periods	   of	   time.	   This	  was	   expected	  
with	   a	   shorter	   treatment	   period	   and	  we	   believe	   that	   the	   24-­‐	   hour	   duration	   of	   C-­‐
peptide	   treatment	   utilized	   in	   our	   study	   is	   not	   long	   enough	   to	   cause	   structural	  
changes.	  As	  such,	  our	  study	  focuses	  on	  early	  renal	  functional	  abnormalities	  caused	  
by	   DN	   at	   around	   6-­‐7	   weeks,	   where	   in	   structural	   abnormalities	   are	   still	   evolving	  
within	   the	   diabetic	   kidney.	  Moreover	   our	   frequency	   distribution	   analysis	   includes	  
perfusion	  data	  collected	  from	  only	  one	  animal	  per	  group.	  Further	  analysis	  utilizing	  a	  
larger	   sample	   size	   is	   needed	   to	   understand	   the	   effect	   of	   C-­‐peptide	   on	   flow	   Ht	  
observed	  in	  peritubular	  capillaries	  of	  type	  I	  diabetic	  kidney.	  	  
	   In	  small	  capillaries,	  microvascular	  blood	  flow	  is	   increasingly	  determined	  by	  
rheological	  properties	  of	  RBC	  (78).	  Studies	  of	  the	  rheological	  behavior	  of	  RBCs	  in	  the	  
capillary	  network	  clearly	  demonstrated	  that	  capillary	  flux	  and	  velocity	  are	  strongly	  
dependent	  on	  the	  ability	  of	  RBCs	  to	  deform	  on	  entry	  into	  the	  capillaries	  (78).	  Thus	  
reductions	   in	   RBC	   deformability	   may	   adversely	   affect	   capillary	   perfusion	   and	  
reduces	   flow	   in	   microcirculation,	   if	   the	   capillary	   diameter	   and	   blood	   pressure	  
remain	   constant	   (16).	   Microvascular	   network	   may	   passively	   compensate	   for	  
increasing	   RBC	   stiffness	   by	   shunting	   RBC	   within	   the	   capillary	   network	   through	  
pathways	   of	   lesser	   resistance	   (58).	   However,	   such	   ability	   to	   recruit	   additional	  
capillaries	  by	  normal	  compensatory	  mechanisms	  may	  be	  compromised	  in	  disorders	  
manifest	  by	  diminished	  RBC	  deformability,	  notably	  DM	  (78).	  Na+/K+-­‐ATPase	  activity	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was	   found	   to	   be	   decreased	   in	   many	   tissues,	   especially	   RBC	   membrane,	   of	   type	   I	  
diabetic	   patients	   as	  well	   as	   animal	  models	   (1,	   104).	   This	   impairment	   could	   be	   at	  
least	   partly	   responsible	   for	   development	   of	   diabetic	   complications.	   It	   has	   been	  
shown	  that	  early	  type	  I	  DM	  is	  characterized	  not	  only	  by	  functional	  disturbances	  such	  
as	   increased	   shear	   stress	   and	   tangential	   pressure	   on	   the	   microvascular	  
endothelium,	  increased	  leukocyte-­‐endothelial	  interactions	  but	  also	  hemorheological	  
disturbances	   such	   as	   increased	   blood	   viscosity,	   increased	   RBC	   aggregation	   and	  
changes	  in	  the	  hemodynamic	  properties	  of	  the	  RBCs	  (24).	  These	  disturbances	  affect	  
microvascular	  blood	  flow	  and	  precede	  structural	  alterations.	  	  
	  
Figure	  4.2:	  Schematic	  presentation	  of	  the	  molecular	  mechanism	  of	  C-­‐peptide	  activity	  
on	  endothelial	  cells	  and	  microvascular	  blood	  flow.	  Adapted	  from	  Forst	  et	  al.,	  2008	  
(24)	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C-­‐peptide	   supplementation	   has	   been	   shown	   to	   restore	   Na+/K+-­‐ATPase	  
activity	   in	  different	  cell	   types	  during	   in	  vitro	  and	   in	  vivo	   investigations	  (22,	  23,	  30,	  
51,	   71,	   73,	   117).	   	   C-­‐peptide	   has	   also	   been	   shown	   to	   stimulate	   endothelial	   NO	  
secretion	  by	  activation	  of	  eNOS	  via	  Ca2+	  calmodulin	  regulation.	  Thus,	  there	  is	  strong	  
evidence	  that	  C-­‐peptide	  improves	  RBC	  deformability	  and	  microvascular	  blood	  flow	  
in	  type	  I	  DM.	  As	  illustrated	  in	  Figure	  4.2,	  the	  underlying	  mechanisms	  involve	  at	  least	  
the	  activation	  of	  eNOS	  and	  Na+/K+-­‐ATPase.	  	  
The	  endothelial	  dysfunction	   that	  occurred	   in	  STZ-­‐induced	  diabetic	   rats	  was	  
reported	   to	   elicit	   an	   inflammatory	   tubulointerstitial	   response	   and	   plasma	   leak	  
through	   injured	  peritubular	  capillaries	  (97).	  Moreover,	  diabetic	  mice	   lacking	  eNOS	  
were	  also	   shown	   to	  develop	   tubulointerstitial	   injury	   (66).	  Type	   I	  diabetic	  patients	  
exhibit	  a	  strong	  correlation	  between	  the	  ratio	  of	  asymmetric	  dimethyl	  arginine	  to	  L-­‐
arginine	   (a	   marker	   of	   endothelial	   dysfunction)	   and	   tubulointerstitial	   injury	   (5).	  
Based	   on	   these	   reports	   and	   our	   studies,	  wherein	   C-­‐peptide	   improved	   peritubular	  
perfusion,	  we	  chose	  to	   investigate	  the	  molecular	  mechanisms	  of	  C-­‐peptide	  in	  RCEs	  
isolated	  from	  kidneys	  of	  type	  I	  diabetic	  mice.	  	  
Disturbances	  in	  the	  antioxidant	  capacity	  of	  endothelial	  cells	  contribute	  to	  the	  
redox	   imbalance	   that	   exists	   during	  DM	   (26).	   Important	   to	   this	   redox	   status	   is	   the	  
bioavailability	   of	   NADPH,	   an	   essential	   cofactor	   for	   the	   proper	   function	   of	   many	  
antioxidant	  enzyme	  systems	  (e.g.,	  GR,	  GPx,	  glutathione-­‐s-­‐transferase,	  CAT	  (108))	  as	  
well	  as	  the	  vasoprotective	  systems	  (including	  heme	  oxygenase	  and	  NOS).	  DM	  results	  
in	   a	   net	   depletion	   of	   NADPH	  mainly	   due	   to	   the	   increased	   flux	   through	   the	   polyol	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pathway	  (33,	  81),	   in	  addition	  to	  increased	  NOX	  activity	  (7,	  14).	  NOX	  could	  act	  as	  a	  
double-­‐edged	   sword,	   with	   transient	   activation	   providing	   a	   feedback	   antioxidant	  
response	   to	   ROS	   via	   receptor	   tyrosine	   kinases	   and	   redox-­‐sensitive	   transcription	  
factors	   (25).	   Prolonged	   activation,	   on	   the	   other	   hand	   may	   lead	   to	   depletion	   of	  
intracellular	  NADPH	  and	  impaired	  ROS	  scavenging	  associated	  with	  eNOS	  uncoupling	  
and	  mitochondrial	  dysfunction	  (25).	  	  
Previous	   studies	   have	   shown	   DM	   decreased	   NADPH	   levels	   in	   rat	   kidney	  
cortices	  and	  in	  bovine	  aortic	  endothelial	  cells	  (3,	  111,	  115).	  As	  such,	  loss	  of	  NADPH	  
is	   likely	  an	  important	  factor	  by	  which	  endothelial	  dysfunction,	  and	  the	  subsequent	  
impairment	   in	   vasoprotection,	   might	   occur.	   Although	   others	   have	   demonstrated	  
similar	  reductions	  in	  NADPH	  within	  the	  diabetic	  kidney	  (111),	  these	  studies	  were	  of	  
the	  whole	  organ.	  We	  have	  shown,	  for	  the	  first	  time,	  that	  there	  is	  a	  net	  loss	  of	  NADPH	  
in	   renal	   cortical	   endothelial	   cells	   of	   type	   I	   diabetic	   mice.	   	   C-­‐peptide	   treatment	  
restored	   the	   diabetic	   endothelial	   NADPH	   levels	   to	   more	   than	   basal	   levels.	   This	  
suggests	   that	   type	   I	  DM	   leads	   to	   a	   loss	   in	   endothelial	  NADPH	   in	  mouse	  RCEs,	   and	  
provides	   the	   first	   indication	   that	   treatment	   of	   diabetic	   mice	   with	   C-­‐peptide	  
enhances	   endothelial	   NADPH.	  We	   demonstrate	   that	   C-­‐peptide	   confers	   antioxidant	  
benefit	  by	  preventing	  the	  loss	  of	  NADPH	  during	  type	  I	  DM.	  Notably,	  with	  C-­‐peptide	  
treatment,	  there	  is	  a	  significant	  increase	  in	  diabetic	  endothelial	  NADPH	  above	  non-­‐
diabetic	  levels.	  This	  interesting	  and	  unexpected	  finding	  suggests	  that	  C-­‐peptide	  may	  
act	  by	  enhancing	   the	  synthesis	  of	  NADPH	  and/or	  decreasing	   its	  consumption.	   It	   is	  
generally	  accepted	  that	  improvements	  to	  NADPH	  bioavailability	  in	  a	  diabetic	  setting	  
is	   related	   to	   its	   diminished	   consumption.	   However,	   information	   on	   the	   impact	   of	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treatments	   on	   its	   synthesis	   is	   limited.	   	   To	   explore	   the	   role	   of	   C-­‐peptide	   in	   the	  
augmentation	   of	   NADPH	   synthesis,	   we	   examined	   its	   effect(s)	   on	   the	   rate-­‐limiting	  
enzyme	  of	  NADPH	  synthesis,	  G6PD.	  	  
G6PD	   is	   a	   critical	   participant	   in	   cellular	   antioxidant	   protection	   because	   it	  
produces	  NADPH,	   the	   essential	   intracellular	   reductant	   (102).	   Among	   the	   enzymes	  
that	  generate	  NADPH,	  only	  G6PD	  was	  found	  to	  be	  activated	  during	  oxidative	  stress	  
(20).	   It	   has	   also	   been	   shown	   that	   a	   deficiency	   in	   G6PD	   activity	   increases	   the	  
susceptibility	   of	   endothelial	   cells	   to	   oxidants	   (54,	   55).	   Superoxide	   production	   by	  
neutrophil	   NOX	   is	   decreased	   in	   granulocytes	   suggesting	   that	   NOX	   dependent	  
superoxide	   production	   may	   be	   regulated	   by	   NADPH	   derived	   from	   G6PD	   driven	  
pentose	   phosphate	   pathway	   (103).	   Interestingly,	   a	   recent	   observation	   indicates	  
G6PD	   can	   localize	   to	   mitochondria	   and	   serve	   as	   an	   important	   source	   of	  
mitochondrial	  NADPH	  (62).	  They	  have	  shown	   that,	  under	  high	  glucose	  conditions,	  
muscle	  cells	  relied	  heavily	  on	  matrix	  associated	  G6PD	  as	  a	  source	  of	  NADPH.	  
	  PKA	  mediated	  phosphorylation	  of	  G6PD,	  and	  consequently	  diminished	  G6PD	  
activity,	   during	  exposure	   to	   in	   vitro	   and	   in	   vivo	   hyperglycemia	  has	  been	   shown	   to	  
reduce	  NADPH	   biovailabilty	   (111,	   112,	   114).	   Previously,	   G6PD	  was	   thought	   to	   be	  
minimally	   affected	   by	   PTMs,	   and	   only	   regulated	   by	   specific	   signal	   transduction	  
molecules	   (76,	   99,	   102,	   111,	   112).	   	   Recent	  work	   from	  Stanton’s	   group	   (111,	   114)	  
demonstrated	   that,	   in	   rat	   kidney	   cortices	   and	   bovine	   aortic	   endothelial	   cells,	  
hyperglycemia	   caused	   inhibition	   of	   G6PD	   activity	   (by	   activating	   PKA	   via	   c-­‐AMP)	  
with	   concomitant	   decreases	   in	   G6PD	   expression	   and	   NADPH	   bioavailability.	   The	  
	   124	  
diminished	   endothelial	   G6PD	   activity	   we	   show	   in	   our	   studies	   reinforces	   these	  
reports.	  Using	  antibodies	  against	  phosphoserine,	  Stanton’s	  group	  reported	  that	  the	  
inhibition	  of	  G6PD	  activity	  is	  by	  PTMs,	  via	  phosphorylation	  of	  key	  serine	  residue/s	  
on	   G6PD	   (111,	   114).	   Our	   attempt	   to	   identify	   phosphorylation	   of	   G6PD	   using	  
phosphoserine	  specific	  antibodies	  (data	  not	  shown)	  produced	  ambiguous	  results.	  In	  
spite	  of	  advances	  in	  detecting	  phospho-­‐proteins	  by	  Western	  blotting	  using	  phospho-­‐
specific	   antibodies,	   phospho-­‐serine	   and	   phospho-­‐threonine	   antibodies	   lack	  
considerable	   specificity	   (84).	   	   Moreover	   our	   focus	   on	   mouse	   renal	   cortical	  
endothelial	  cells,	  as	  opposed	  to	  Stanton	  group’s	  study	  in	  diabetic	  rat	  kidney	  cortex,	  
may	  have	  contributed	  to	  differences	  in	  identification	  of	  G6PD	  phosphorylation	  using	  
phospho-­‐serine	  specific	  antibodies	  (111,	  114).	  Moreover,	  a	  recent	  report	  by	  Pan	  et	  
al.,	   demonstrates	   that	  G6PD	   translocates	   to	   the	  plasma	  membrane	  and	   is	   tyrosine	  
phosphorylated	  by	  c-­‐Src,	  a	  non-­‐receptor	  tyrosine	  kinase	  (76).	  Using	  G6PD	  tyrosine	  
mutants	  and	  protein	  phosphate	  inhibitors,	  they	  show	  that	  tyrosine	  phosphorylation	  
of	  G6PD	  plays	  a	  key	  role	  in	  vascular	  endothelial	  growth	  factor	  mediated	  endothelial	  
cell	   responses,	   mainly	   angiogenesis.	   	   One	   more	   recent	   report	   highlights	   that	  
activation	   of	   G6PD	   in	   diabetic	   livers	  may	   involve	   phosphorylation	   via	   a	   signaling	  
cascade	  that	   involves	  PI-­‐3	  kinase	  and/or	  Src	  kinase	  (28).	  Given	  such	  contradicting	  
reports,	   it	   is	   obvious	   that	   G6PD	   is	   subject	   to	   differential	   regulation	   based	   on	   the	  
tissue	   observed	   and	   disease	   condition.	   More	   importantly,	   these	   reports	   also	  
highlight	   the	   existence	   of	   a	   post-­‐translational	   mechanism	   regulating	   G6PD	   at	   the	  
tissue	   level,	   countering	   the	   popular	   notion	   of	   G6PD	   as	   a	   “house-­‐keeping”	   enzyme	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(59,	  77).	  Hence	  further	  work	  is	  warranted	  to	  delineate	  mechanisms	  by	  which	  G6PD	  
is	  regulated	  under	  normal	  as	  well	  as	  pathophysiological	  conditions.	  
Our	  work	   relied	  on	  more	   sophisticated	  detection	   technique	   for	  pinpointing	  
post-­‐translational	   modifications,	   using	   two-­‐dimensional	   (2D)	   gel	   electrophoresis.	  
Our	  2D-­‐gel	  electrophoresis	  data	  indicates	  that	  G6PD	  is	  post-­‐translationally	  modified	  
in	   diabetic	   RCEs.	   Unique	   resolving	   power	   of	   2D-­‐gel	   electrophoresis	   allows	   for	  
separation	  of	  different	  modified	  forms	  of	  the	  same	  protein	  into	  distinct	  spots	  on	  the	  
gel	   (2).	   Heterogeneous	   phosphorylation	   of	   a	   protein	   yields	   a	   series	   of	   spots	  with	  
same	   molecular	   weight	   but	   different	   pI	   values	   (83).	   The	   shift	   of	   G6PD	   immuno-­‐
reactive	  spots	  towards	  cathodic	  end	  denotes	  a	  change	  of	  the	  pI	  towards	  more	  acidic	  
values	   and	  may	   be	   an	   indication	   of	   the	   predominant	   PTM	   i.e.	   phosphorylation.	   In	  
addition	   to	   2D-­‐gel	   electrophoresis,	   further	   studies	   using	   mass-­‐spectrometry	   are	  
needed	  for	  confirming	  the	  phosphorylation	  of	  G6PD.	  
Treatment	   with	   C-­‐peptide	   ameliorated	   the	   diabetes-­‐induced	   reductions	   in	  
G6PD	   activity	   by	   preventing	   its	   PTM,	   potentially	   phosphorylation,	   in	   RCEs.	   We	  
believe	   that	   preventing	   the	   PTMs	   of	   G6PD,	   thereby	   enhancing	   the	   synthesis	   of	  
NADPH,	   may	   be	   a	   major	   mechanism	   by	   which	   C-­‐peptide	   improves	   endogenous	  
vasoprotection.	  In	  fact,	  C-­‐peptide	  has	  been	  shown	  to	  interact	  (38)	  and	  attenuate	  the	  
activity	   of	   protein	   tyrosine	   phosphatase	   (56).	   Similar	   interactions	   with	   other	  
phosphatases,	   specifically	   serine/threonine	   phosphatases,	   may	   be	   occurring	  
physiologically.	  One	  such	  serine/threonine	  phosphatase	  is	  protein	  phosphatase	  2A	  
(PP2A)	  and	  has	  been	  widely	  implicated	  in	  regulating	  the	  activity	  of	  several	  protein	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kinases.	   Specifically,	   PP2A	   has	   been	   shown	   to	   dictate	   the	   functional	   status	   of	   a	  
calcium	  channel	  protein	  in	  β-­‐cell	  by	  fine-­‐tuning	  the	  balance	  between	  PKA	  mediated	  
phosphorylation	   (thereby	   cAMP	   activation)	   and	   serine/threonine	  
dephosphorylation	  (50).	  The	  exact	  role	  of	  C-­‐peptide	   in	  modulating	  PP2A	  mediated	  
dephosphorylation,	   and	   possibly	   PKA	   mediated	   phosphorylation,	   needs	   to	   be	  
examined	  further.	  	  	  
	  Mitochondrial	   superoxide	   generation	   has	   been	   widely	   implicated	   in	   the	  
pathogenesis	   of	   diabetic	   microvascular	   complications	   (12,	   64).	   Further,	   reports	  
using	  the	  mitochondria	  isolated	  from	  diabetic	  animals	  demonstrated	  compromised	  
mitochondrial	   respiration	   (13,	   32,	   96).	   Recently,	   Palmeira	   et	   al.(75)	   reported	  
impairment	   of	   mitochondrial	   respiration	   rates	   under	   high-­‐glucose	   conditions	   in	  
HepG2	   cells.	   Clearly,	   there	   is	   a	  need	   to	  delineate	   the	  mechanisms	  underlying	  high	  
glucose-­‐mediated	   damage	   to	   microvascular	   endothelial	   cells,	   the	   main	   cell	   type	  
associated	  with	  diabetic	  end-­‐organ	  complications.	  More	  importantly,	  microvascular	  
endothelial	   cells	  play	  an	   important	   role	   in	   the	  overt	  hyperglycemic	  damage	   to	   the	  
kidney	  due	  to	  their	  deficiency	  in	  glucose	  transport.	  The	  murine	  renal	  microvascular	  
endothelial	   cells	  utilized	   in	   this	   study	  are	  an	   ideal	   cell	   type	   to	   study	   the	  effects	  of	  
high	   glucose-­‐induced	   mitochondrial	   impairments	   that	   ultimately	   lead	   to	   renal	  
microvascular	  dysfunction.	  
	  In	  our	  study,	  we	  attempted	  to	  fill	  the	  dearth	  of	  knowledge	  regarding	  the	  impact	  
of	   C-­‐peptide	   on	   diabetes-­‐induced	   mitochondrial	   dysfunction.	   We	   examined	   the	  
influence	   of	   C-­‐peptide	   on	   mitochondrial	   function	   in	   high	   glucose-­‐exposed	   renal	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microvascular	  endothelial	  cells.	  We	  show	  that	  C-­‐peptide	  inhibits	  high	  glucose-­‐induced	  
changes	  to	  mitochondrial	  respiration,	  membrane	  potential,	  superoxide	  generation	  and	  
complex	   I	   activity.	   Our	   investigation	   is	   the	   first	   study	   to	   demonstrate	   that	   the	  
protection	  rendered	  by	  C-­‐peptide	  during	  diabetes	  likely	  involves	  the	  mitochondria.	  
Although	   all	   of	   the	   complexes	   of	   the	   mitochondrial	   electron	   transport	   chain	  
contribute	   to	   total	   mitochondrial	   superoxide	   generation,	   growing	   evidence	   now	  
suggests	   that	   complex	   I	   produces	   most	   of	   the	   superoxide	   generated	   within	   intact	  
mammalian	   mitochondria	   (9).	   Further,	   Lambert	   and	   Brand	   (52)	   have	   shown	   that	  
elevated	  superoxide	  generation	  by	   the	  mitochondria	  requires	   inhibition	  of	   complex	   I	  
activity.	   Increased	   mitochondrial	   superoxide	   generation	   exacerbates	   mitochondrial	  
oxidative	   stress	   and	   leads	   to	   conversion	   of	   the	   mitochondrial	   glutathione	   pool	   to	  
glutathione	  disulfide	  (37).	  As	  a	  consequence,	  glutathione	  depletion	  has	  been	  shown	  to	  
cause	   mitochondrial	   dysfunction	   and	   inhibition	   of	   complex	   I	   activity.	   Moreover,	  
glutathionylation	   of	   complex	   leads	   to	   contribute	   to	   oxidative	   damage	   to	   its	   subunits	  
and	   loss	   of	   activity	   (8,	   36)	   as	  well	   as	   increased	  mitochondrial	   superoxide	   formation	  
(8).	  	  As	  discussed	  previously,	  NADPH	  acts	  as	  a	  backbone	  for	  regeneration	  of	  GSH	  from	  
oxidized	   glutathione	   and	   can	   serve	   as	   an	   important	   contributor	   in	   maintaining	  
mitochondrial	  glutathione	  pool	  as	  well.	  Figure	  4.3	  illustrates	  the	  proposed	  mechanism	  
by	   which	   C-­‐peptide	   may	   ameliorate	   mitochondrial	   dysfunction	   through	   an	   indirect	  
effect	  on	  mitochondrial	  GSH	  via	  increasing	  cellular	  NAPDH	  bioavailability.	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Figure	   4.3:	   Schematic	   illustrating	   the	   speculated	   mechanism	   by	   which	   C-­‐peptide	   affords	  
protection	   to	   hyperglycemia	   exposed	   endothelial	   cells.	   C-­‐peptide	   binds	   and	   acts	   through	   a	  
putative	  G-­‐protein	  coupled	  receptor	  (GPCR),	  followed	  by	  subsequent	  activation	  of	  adenyl	  cyclase,	  
PKA	  via	  release	  of	  cAMP	  and	  Phosphoinositide-­‐3	  Kinase	  (PI-­‐3K).	  This	  leads	  to	  increase	  in	  G6PD	  
activity	   and	  NADPH.	  NAPDH	  plays	   a	   pivotal	   role	   by	   acting	   as	   a	   backbone	   for	   action	  of	   cellular	  
antioxidative	  enzymes	   (such	  as	  eNOS,	  heme	  oxygenase)	  and	  by	  enhancing	  GSH	   levels.	  GSH	  has	  
been	   shown	   to	   regulate	  mitochondrial	  Complex	   I	   activity	   through	   reversible	   	   glutathionylation	  
(via	  action	  of	  glutataredoxin),	  and	  thereby	  acts	  to	  reduce	  mitochondrial	  superoxide.	  Additionally	  
cAMP	  released	  by	  C-­‐peptide’s	  binding	  to	  membrane	  GPCR	  can	  act	  as	  substrate	  for	  activation	  PGC-­‐
1a	  via	  its	  binding	  to	  cAMP	  response	  binding	  element	  (CREB).	  As	  a	  result	  there	  may	  be	  an	  increase	  
in	   expression	   of	   mitochondrial	   antioxidative	   enzymes	   such	   as	   SOD	   and	   UCP-­‐2,	   that	   can	  
counteract	  mitochondrial	  superoxide.	  Combined,	  C-­‐peptide	  can	  act	  through	  the	  above	  mentioned	  
pathways	  and	  prevent	  endothelial	  damage	  by	  decreasing	  cellular	  ROS	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.	  
C-­‐peptide	   has	   been	   shown	   to	   be	   a	   potent	   stimulant	   of	   MAPKs	   (45-­‐47).	  
Activation	  of	  ERK	  by	  C-­‐peptide	  has	  been	  demonstrated	  in	  numerous	  cell	  types	  (27,	  56,	  
116,	   117).	   Our	   experiments	   evaluating	   the	   effect(s)	   of	   C-­‐peptide	   on	   the	   renal	  
microcirculation	  yielded	  similar	  results,	  demonstrating	  the	  activation	  of	  ERK1/2.	  This	  
is	  especially	  important	  because	  several	  recent	  studies	  indicate	  that	  ERK1/2	  may	  affect	  
several	  mitochondrial	  functions	  by	  regulating	  the	  expression	  of	  mitochondrial	  proteins	  
in	   the	   nucleus	   (94).	   ERK1/2	   may	   also	   have	   intrinsic	   mitochondrial	   activities.	  
Specifically,	  ERK1/2	  has	  been	  shown	  to	  localize	  to	  the	  mitochondria	  of	  human	  alveolar	  
macrophages	   and	   control	   mitochondrial	   membrane	   potential	   as	   well	   as	   ATP	  
production(65).	  However,	  the	  exact	  mechanisms	  by	  which	  ERK1/2	  translocates	  to	  and	  
is	  regulated	  in	  the	  mitochondria	  are	  still	  obscure.	  	  	  
In	   conclusion,	   our	   study	   demonstrates	   that	   C-­‐peptide	   improves	   anti-­‐oxidant	  
status	  of	   the	  diabetic	   renal	   cortical	   endothelial	   cells	  by	  preventing	   the	  PTMs	  of	   anti-­‐
oxidative	   enzyme	   G6PD,	   and	   thereby	   enhancing	   the	   synthesis	   of	   NADPH.	   This	   anti-­‐
oxidant	   benefit	   can	   complement	   the	   beneficial	   effects	   of	   C-­‐peptide	   on	  mitochondrial	  
function	   in	   high	   glucose	   exposed	   endothelial	   cells.	   Briefly,	   C-­‐peptide	   ameliorates	  
hyperglycemia-­‐induced	  endothelial	  oxidative	  stress	  by	  improving	  antioxidant	  defenses	  
and	   by	   preventing	   mitochondrial	   dysfunction.	   This	   study	   adds	   more	   substantial	  
evidence	   to	   include	   C-­‐peptide	   in	   the	   therapeutic	   regimen	   for	   treatment	   of	   type	   I	  
diabetes-­‐associated	  microvascular	  complications	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4.1	  Future	  Directions	  	  
Interactions	  of	  C-­‐peptide	  with	  protein	   tyrosine	  phosphatases	  has	  been	   shown	  
previously	   (38,	   (56).	   There	   is	   a	   potential	   for	   physiological	   interactions	   with	   other	  
phosphatases	  such	  as	  serine/threonine	  phosphatases.	  Thus	  C-­‐peptide	  could	  be	  playing	  
an	   important	  role	   in	  modulating	  the	  phosphorylation	  status	  of	   intracellular	  effectors.	  	  
A	   serine/threonine	   phosphatase,	   protein	   phosphatase	   2A	   (PP2A),	   has	   been	   widely	  
implicated	  in	  the	  regulation	  of	  the	  activity	  of	  several	  protein	  kinases	  (50),	  specifically	  
PKA	  (50).	  Future	  work	  to	  examine	  the	  influence	  of	  C-­‐peptide	  on	  protein	  phosphatases	  
may	  help	  to	  shed	  light	  on	  the	  intracellular	  mechanisms	  by	  which	  C-­‐peptide	  alters	  the	  
phosphorylation	  status	  of	  G6PD	  and	  other	  potential	  effectors.	  	  
Further	   studies	   are	   needed	   to	   investigate	   in	   more	   detail	   how	   C-­‐peptide	  
signalling	   is	  manifested	  within	   the	  mitochondria,	   and	   specifically	  with	   complex	   I.	   To	  
that,	   recent	   reports	   suggest	   that	  C-­‐peptide	  activates	  cAMP	  response	  element	  binding	  
(CREB)	  protein	  through	  the	  p38	  mitogen-­‐activated	  protein	  kinase	  pathway	  (82).	  CREB	  
functions	   as	   an	   upstream	   regulator	   of	   ND6	   (4,	   109),	   a	   mitochondrial-­‐encoded	   gene	  
product	   and	   well-­‐characterized	   subunit	   of	   complex	   I.	   ND6	   is	   essential	   for	   proper	  
complex	   I	   assembly	   and	   function	   (15,	   19).	   CREB	   also	   regulates	   the	   expression	   and	  
function	   of	   peroxisome	   proliferator-­‐activated	   receptor	   gamma	   coactivator-­‐1α	   (PGC-­‐
1α)(53).	   PGC-­‐1α,	   in	   turn,	   regulates	   the	   expression	   of	   several	  mitochondrial	   proteins	  
involved	   in	   oxidative	   phosphorylation	   (72,	   110),	   as	   well	   as	   several	   mitochondrial	  
antioxidant	  enzymes	  (105)	   (i.e.,	  manganese	  superoxide	  dismutase,	  peroxiredoxins	   III	  
and	   V,	  mitochondrial	   thioredoxin	   and	   thioredoxin	   reductase,	   glutathione	   peroxidase	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and	  the	  mitochondrial	  uncoupling	  protein	  2).	  Of	  these,	  several	  groups	  have	  shown	  that	  
increased	   mitochondrial	   uncoupling	   protein	   2	   expression	   and	   activation	   results	   in	  
significantly	   reduced	   superoxide	   production.	  We	   believe	   that	   C-­‐peptide	   has	   salutary	  
effects	   on	   endothelial	   redox	   balance	   by	   preventing	   mitochondrial	   superoxide	  
generation	  and	  enhancing	  antioxidant	  defenses	  mentioned	  above.	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